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Abstract
The dynamic properties of biological systems are the result of the underlying dynamic in-
teractions of their individual components. The mitogen-activated protein kinase (MAPK)
network is a conserved signalling module that regulates cellular fate such as growth and
differentiation. The activity of extracellular signal-regulated kinase 2 (ERK2) is regu-
lated by complex spatio-temporal dynamics that play an important role for specific
downstream signalling effects. One of the main challenges to understand MAPK sig-
nalling and the mechanisms enabling signal propagation inside cells is the lack of means
to detect kinase activity with high spatio-temporal resolution in living cells. While tra-
ditional biochemical techniques are limited to population averages with poor temporal
and practically no spatial resolution, previously published FRET-based biosensors for
ERK2 activity suffer from several serious disadvantages, including the indirect detec-
tion of ERK2 activity via substrate phosphorylation or conformational change, a low
dynamic range and insufficient spatial resolution (Fujioka et al., 2006; Sato et al., 2007;
Harvey et al., 2008a). Therefore, a method to visualise and quantify ERK2 activity on
a single cell level with high spatio-temporal resolution and a wide dynamic range was
developed.
The most direct approach to measure kinase activity in living cells is the visualisa-
tion of transient enzyme-substrate (ES) interactions. The formation of ES complexes
can be detected by measuring Fo¨rster resonance energy transfer/fluorescent donor life-
times (FRET/FLIM) between a donor-tagged kinase and an acceptor-labeled substrate
peptide (Yudushkin et al., 2007). However, FLIM approaches rely on a high fraction of
donor molecules undergoing FRET (i.e. a high fraction of enzyme in complex with its
substrate) and KM-values for short peptides of known ERK2 substrates are in a range
of 100 µM - 1 mM. It is thus difficult to get sufficiently high substrate concentrations
inside cells.
In an attempt to increase local substrate concentrations the substrate peptide was
fused to ERK2 via a flexible peptide linker. This sensor design of ERK2 Activity Sensor
4 (EAS4) is generic and should in principle be applicable to all kinases. It is based on
the reversible binding and phosphorylation of a short substrate peptide by the kinase
of interest. Binding of the substrate peptide to the active site of the kinase induces a
global conformational change of EAS4 that can be measured by a change in the FRET
signal obtained from an attached FRET pair of fluorescent proteins. Thus, this newly
developed FRET-based fluorescent ERK2 biosensor approach is the first that directly
reports spatio-temporal kinase activity by visualising transient ES interactions and dis-
plays a dynamic range and spatial resolution superior to previously published ERK2
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biosensors. In addition, EAS4 revealed that heregulin (HRG)-induced sustained ERK
activity in MCF-7 cells is primarily cytosolic, while HRG-induced nuclear and epidermal
growth factor (EGF)-induced ERK activity is transient, demonstrating the potential of
EAS4.
Die dynamischen Eigenschaften von biologischen Systemen sind das Ergebnis der zu-
grundliegenden dynamischen Wechselbeziehungen der individuellen Komponenten. Die
Mitogen-activated Protein Kinase (MAPK)-Kaskade ist ein evolutiona¨r konserviertes
Signalweiterleitungsmodul, das das Schicksal von Zellen wie Wachstum oder Differen-
zierung reguliert. Die Aktivierung von Extracellular Signal-regulated Kinase 2 (ERK2)
folgt einer komplexen zeitlichen und ra¨umlichen Dynamik, die eine wichtige Rolle fu¨r
bestimmte nachgeordnete Signaleffekte spielt. Eine der Hauptherausforderungen fu¨r das
Versta¨ndnis von MAPK Signalweiterleitung und der Mechanismen, die Signalweiter-
leitung innerhalb der Zelle ermo¨glichen, ist der Mangel an Methoden um Kinase-Aktivita¨t
mit hoher zeitlicher und ra¨umlicher Auflo¨sung in lebenden Zellen zu erfassen. Wa¨hrend
traditionelle, biochemische Methoden auf Messungen von Durchschnittswerten aus einer
Vielzahl von Zellen begrenzt sind, haben bereits vero¨ffentlichte, auf FRET basierende
Biosensoren fu¨r ERK2-Aktivita¨t mehrere schwere Nachteile wie die nur indirekte Er-
mittlung von ERK2-Aktivita¨t u¨ber die Phosphorylierung eines Substrats oder u¨ber eine
Konformationsa¨nderung, einen niedrigen, dynamischen Messbereich und ungenu¨gende
ra¨umliche Auflo¨sung (Fujioka et al., 2006; Sato et al., 2007; Harvey et al., 2008a).
Deshalb wurde in der vorliegenden Arbeit eine Methode entwickelt, um ERK2-Aktivita¨t
in einzelnen Zellen mit hoher zeitlicher und ra¨umlicher Auflo¨sung und einem grossen
dynamischen Messbereich sichtbar zu machen und zu quantifizieren.
Der direkteste Ansatz um Kinase-Aktivita¨t in lebenden Zellen zu messen ist die Sicht-
barmachung von kurzlebigen Enzym-Substrat (ES) Wechselwirkungen. Die Bildung eines
ES-Komplexes kann u¨ber die Messung von Fo¨rster Resonanzenergietransfer/Fluoreszenz-
lebenszeiten (FRET/FLIM) zwischen einer Donor-markierten Kinase und einem Akzep-
tor-markierten Substratpeptid nachgewiesen werden (Yudushkin et al., 2007). Allerdings
sind FLIM-Methoden auf ein grossen Anteil an Donormoleku¨len angewiesen, die FRET
eingehen (d.h. einen hohen Anteil an Enzym im Komplex mit seinem Substrat) und kurze
Peptide aus bekannten ERK2-Substraten haben KM-Werte in einem Bereich von 100 µM
- 1 mM. Es ist deshalb schwierig, ausreichend hohe Substratkonzentration innerhalb von
Zellen zu erreichen.
In einem Versuch, die lokale Substratkonzentration zu erho¨hen, wurde das Substratpep-
tid u¨ber einen flexiblen Peptidlinker mit ERK2 verbunden. Der Aufbau von ERK2 Activ-
ity Sensor 4 (EAS4) sollte prinzipiell auf alle Kinasen anwendbar sein. Er basiert auf der
reversiblen Bindung und Phosphorylierung eines kurzen Substratpeptids durch die unter-
suchte Kinase. Die Bindung des Substratpeptids im aktiven Zentrum der Kinase verur-
sacht eine umfassende Konformationsa¨nderung von EAS4, die u¨ber eine A¨nderung des
FRET-Signals erfasst werden kann, das durch Anha¨ngen eines FRET-Paares fluoreszie-
render Protein erzielt wird. Deshalb ist dieser neu entwickelte, auf FRET basierende, flu-
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oreszierende ERK2-Biosensor der Erste, der direkte Kinase-Aktivita¨t in Raum und Zeit
anzeigt, indem kurzlebige ES-Wechselwirkungen sichtbar gemacht werden. EAS4 zeich-
net sich ausserdem durch einen dynamischen Messbereich und eine ra¨umliche Auflo¨sung
aus, die zuvor vero¨ffentlichten ERK2 Biosensoren u¨berlegen ist. Zusa¨tzlich konnte mit
Hilfe von EAS4 gezeigt werden, dass Heregulin (HRG)-vermittelte, anhaltende ERK Ak-
tivita¨t in MCF-7 Zellen vornehmlich im Zytosol zu finden ist, wa¨hrend HRG-vermittelte
ERK2-Aktivita¨t im Zellkern sowie EGF-vermittelte ERK2-Aktivita¨t transient ist. Dies
zeigt das Potential von EAS4 fu¨r die weitere Untersuchung von biologischen Fragestel-
lungen.
3

1 Introduction
Complex systems like whole organisms or even living cells cannot be fully described by
counting the involved molecules (assuming that all of these are known). Further informa-
tion about the location, mobility and time frame of appearance of each molecule would
be required (Schultz, 2007).
Dynamic networks of interacting proteins are the core machinery of living cells. Protein
interacting networks build and degrade the cell’s DNA, RNA, lipids, carbohydrates and
proteins, form the cell’s structure and allow its movement, provide energy and convert
chemicals as well as sense, integrate and process information (Gru¨nberg and Serrano,
2010). Essentially, the dynamic properties of biological systems are a result of the under-
lying dynamic interactions of their individual components (Schultz, 2007; Verveer and
Bastiaens, 2008; Dehmelt and Bastiaens, 2010; Grecco and Verveer, 2011).
One example for protein interaction networks are signalling networks. Signal propa-
gation events are tightly controlled in both space and time. One challenge, however, is
that a limited number of signalling components, capable of a relatively small repertoire
of biochemical reactions, is used in a combinatorial fashion to generate different, specific
biological fates (Kolch, 2005). This raises the question as to how signalling specificity is
achieved. A complete understanding of signal transduction systems requires information
about the spatio-temporal dynamics of intracellular signalling (Miyawaki, 2003; Schultz,
2007; Verveer and Bastiaens, 2008; Grecco and Verveer, 2011).
Traditional, biochemical methods to analyse protein networks and activities in general
or signalling networks in particular using immunoblots and radioactive labeling, DNA
microarrays, and mass spectrometry are restricted to population averages and there-
fore provide very little or no spatio-temporal information. Immunofluorescence provides
only poor temporal information about protein activities due to the fixation process.
Modern fluorescence microscopy techniques, such as Fo¨rster resonance energy transfer
(FRET), fluorescence recovery after photobleaching (FRAP) or fluorescence correlation
spectroscopy (FCS) now provide sufficient spatial and temporal resolution to study quan-
titative protein interactions (Miyawaki, 2003; Yasuda, 2006; Schultz, 2007; Grecco and
Verveer, 2011).
Fluorescence imaging of biosensors enables direct visualisation of biological functions,
e.g. signalling activities and measurements of molecular activity patterns in cells. In ad-
dition, information from different biosensors can help to gain information about causal
connectivities and offers the possibility to determine cell-to-cell variability (Wouters
5
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et al., 2001; Miyawaki, 2003; Dehmelt and Bastiaens, 2010).
To understand the organising principles of protein-protein interactions that underlie
spatio-temporal dynamics of cell biology in general or signal transduction in particular,
information from quantitative imaging has to be integrated with computational models
of signal transduction networks (such as described in Schoeberl et al., 2002). These
models can then serve to formulate new hypotheses that can be tested experimentally
(Dehmelt and Bastiaens, 2010).
1.1 Signalling by Extracellular Signal-Regulated Kinase
(ERK)
A fundamental property of living cells is the ability to sense and respond appropri-
ately to changing environmental conditions and various other stimuli. Transmission of
extracellular signals to their intracellular targets is mediated by a network of interacting
proteins that regulate a large number of cellular processes (Seger and Krebs, 1995). In-
tracellular events following growth factor stimulation are of particular interest because
malfunctioning/defective regulation of growth factor regulated processes often leads to
altered proliferation or cellular transformation (Seger and Krebs, 1995; Wolf and Seger,
2002; Dhillon et al., 2007).
Growth factor signalling is mediated by membrane-bound growth factor receptors.
These ususally contain a protein tyrosine kinase either as an integral part or as an asso-
ciated protein in or at their intracellular domain. In response to growth factor stimulation
receptor tyrosine kinase are activated and tyrosyl phosphorylation is rapidly translated
into changes of the phosphorylation levels of cytosolic and nuclear proteins on serine
and threonine residues, which in turn leads to a change in the properties of the target
protein (reviewed in Seger and Krebs, 1995.
1.1.1 Signalling via the Mitogen-Activated Protein Kinase (MAPK)
Network
Many of these phosphorylation signals are propagated by activation of evolutionary con-
served mitogen-activated protein kinases (MAPKs) within the cell. MAPK-mediated
signalling is critical for the regulation of proliferation, differentiation and survival in
mammalian cells (Chang and Karin, 2001).
Six distinct MAPK modules are currently distinguished in mammalian cells and are
usually named after the last kinase of the series (Fig. 1.1) (reviewed in Chen et al., 2001;
Chang and Karin, 2001; Dhillon et al., 2007):
1. the extracellular signal-regulated kinase (ERK1/2).
2. the ERK3/4 module, activated by serum and stress.
6
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3. the Jun N-terminal kinase (JNK) module, also known as stress-activated protein
kinases (SAPK1). It is activated in reponse to various types of stress, e.g. inflam-
matory cytokines, tumor necrosis factor-alpha, interleukin-1, and osmolar stress,
but also by hormones and growth factors.
4. the p38 MAPK module, also known as SAPK2-4.
5. the ERK5 module, activated by oxidative stress, hyperosmolarity and mitogens,
such as serum or certain growth factors.
6. the ERK7/8 module.
Figure 1.1: Schematic overview of MAPK pathways (adapted from Chen et al., 2001).
The Raf/MEK/ERK module can be activated by a large number of different growth
factors, hormones or neurotransmitters (e.g. epidermal growth factor (EGF), platelet-
derived growth factor, fibroblast growth factor, neurite growth factor, angiotensin II,
endothelin, thrombin, or norepinephrine). While hormones and cytokines activate the
ERK1/2 module via G-protein-coupled receptors, growth factors usually activate the
ERK1/2 module through receptor tyrosine kinases (Wolf and Seger, 2002).
The Raf/MEK/ERK module is activated by Ras-family GTPases (Fig. 1.2) that cou-
ple signals from the activated receptor to Raf-family serine/threonine kinases by a yet
not fully understood mechanism. Raf kinases in turn phosphorylate and activate the
dual-specificity kinases MEK1 and MEK2 (Seger et al., 1992; Page`s et al., 1994), the
only known substrate of which are ERK1/2. Phosphorylated MEK1/2 subsequently ac-
tivate ERK1/2 by phosphorylation of Thr183 and Tyr185 in their activation loop (Ahn
et al., 1991; Payne et al., 1991; Robbins et al., 1993). In resting cells, ERK1/2 are pri-
7
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Figure 1.2: The Raf-MEK-ERK cascade. In the classical model, the Raf/MEK/ERK
cascade is activated via Ras and consecutively each kinase layer phosphorylates and activates the
downstream layer. Phosphorylated ERK1/2 then either translocates to the nucleus to activate
its targets or phosphorylates its targets in the cytosol (adapted from Casar et al., 2009).
marily located in the cytosol, mediated by interactions with cytosolic anchors (Chen
et al., 2001; Yoon and Seger, 2006; Yao and Seger, 2009). Phosphorylation of ERK1/2
leads to its dissociation from these anchors and rapid translocation to the nucleus (Chen
et al., 1992; Gonzalez et al., 1993; Lenormand et al., 1993; Fukuda et al., 1997; Adachi
et al., 1999).
Computational analysis of MAPK signalling has proposed a number of theoretical
mechanisms that are involved in signal propagation from membrane receptors to the site
of action by MAPK, including spatial gradients of phospho-proteins (Brown and Kholo-
denko, 1999; Kholodenko, 2006), travelling waves of phospho-proteins (Markevich et al.,
2006), oscillations in the MAPK cascade (Kholodenko, 2000, 2006) or the signalling en-
dosome hypothesis (Howe and Mobley, 2004; Howe, 2005; Kholodenko, 2006).
The formation of spatial gradients of phospho-proteins in living cells is based on a
membrane bound kinase that phosphorylates (signalling) proteins, which then diffuse
into the cytosol, where they become dephosphorylated by evenly distributed, opposing
8
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Figure 1.3: Spatial gradients of phospho-proteins inside living cells. Spatial segregation
of a kinase and the opposing phosphatase in a protein-phosphorylation-dephosphorylation cycle
generates intracellular gradients of phospho-proteins. The kinase (Kin) is localised to the cell
membrane, whereas the phosphatase (Phos) is homogeneously distributed in the cytoplasm. The
concentration gradient is shown by colour intensity. vkin = kinase rate; vp = phosphatase rate
(adapted from Kholodenko, 2006).
phosphatases (Fig. 1.3). System analysis of the MAPK cascade considering measured
values for kinase and phosphatase activities as well as protein diffusion proposes the
existence of steep phospho-/signalling protein gradients inside cells that could even lead
to subthreshold levels at their site of action (e.g. the nucleus). Indeed, such phospho-
protein gradients have been observed (Niethammer et al., 2004; Maeder et al., 2007;
Yudushkin et al., 2007).
Several mechanisms to overcome the proposed gradients have been suggested. These
include spatio-temporal regulation of protein phosphatase activity and travelling waves
of phosphoproteins (Markevich et al., 2006; Kholodenko, 2006). Regulating phosphatases
in a spatial and signal-dependent manner (e.g. inhibiting phosphatase activity upon in-
coming signals, subsequently resulting in less steep phospho-protein gradients) might be
one way to enable signal propagation. Travelling waves of phospho-proteins arise from
bistability in the two-step phosphorylation and dephosphorylation cycle of ERK and may
extend the phospho-protein signal from the membrane to the cell interior (Fig. 1.4). For
a kinase cascade in which a kinase at each level subsequently activates the downstream
kinase, phospho-protein gradients become shallower down the cascade and may spread
even further upon signalling (Fig. 1.4). Introduction of an additional positive feedback
by which a downstream kinase also phosphorylates its upstream activator, allows the
propagation of phosphorylation waves with high velocities over potentially very large
distances, e.g. during retrograde survival signalling in neurons (Markevich et al., 2006).
9
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Figure 1.4: Travelling waves of phospho-proteins. Propagation of a travelling wave of
phospho-proteins through a three-tiered kinase cascade in response to a transient, 30-second
pulse of activity by the input = membrane bound kinase. Additional positive feedback in the
cytosol may enable phosphorylation waves to propagate with high velocity over exceedingly long
distances, potentially aiding in retrograde survival signalling in neurons. M1P = phosphorylated
kinase of the first level level, activated by the membrane-bound kinase; M2P = phosphorylated
second level kinase, activated by M1P; M3P = M2P-activated kinase (adapted from Kholodenko,
2006).
Another mechanism to overcome spatial gradients of phospho-proteins inside living
cells has been proposed with the signalling endosome hypothesis (Howe and Mobley,
2004; Howe, 2005). The signalling endosome hypothesis suggests that signalling com-
plexes associated with endosomal membranes can be specifically transported in direction
of the nucleus rather than randomly spread their signal into the cell by diffusion (Fig.
1.5). Association with endosomal membranes may also protect signalling proteins from
deactivation.
Although spatial gradients of phospho-MAPKs have been shown to occur in yeasts
(Maeder et al., 2007), these data only provide poor temporal resolution. Moreover, no
proof of phospho-MAPK gradients in mammalian cells exists until today. In addition,
while spatio-temporal regulation of protein phosphatase activity has been shown to oc-
cur (Yudushkin et al., 2007), the travelling waves of phospho-proteins and the signalling
endosome hypothesis as mechanisms to overcome phospho-proteins gradients remain un-
proven. Traditional biochemical techniques do not allow the exploration of these features
and previously published ERK biosensors suffer from serious disadvantages, such as a
low dynamic range, indirect measurements of ERK activity and the requirement to fuse
them to subcellular localisation sequences to obtain spatial information. Thus, a new
10
Introduction
Figure 1.5: The signalling endosome hypothesis. Only “directed” transport of signalling
molecules with endosomes allows signals to reach the nucleus. Representative trajectories of si-
mulated diffusion and dephopshorylation of STAT-3 in response to Interleukin-6 signalling in 22
single events (red and blue), compared to the movement of a signalling endosome. Time frame
in both cases was 1 second at 37 ◦C (adapted from Howe, 2005).
fluorescent ERK biosensor directly reporting MAPK activity may prove useful in the
elucidation of the MAPK signalling features.
There is a plethora of data showing the importance of endosomal trafficking for MAPK
signalling (Di Guglielmo et al., 1994; Vieira et al., 1996; Kranenburg et al., 1999; Pierce
et al., 2000; Jiang and Sorkin, 2002; Taub et al., 2007; Uhles et al., 2007). For example,
ERK could not be fully activated in response to EGF when receptor-mediated endocy-
tosis was blocked by dominant negative dynamin (Vieira et al., 1996). Also, appropriate
trafficking of the activated EGF receptor is a prerequisite for correct spatio-temporal
regulation of MAPK signalling (Taub et al., 2007). A functional ERK2 biosensor may
also provide new insights into the relationship of endocytosis and MAPK signalling.
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1.1.2 The Extracellular Signal-Regulated Kinase (ERK)
ERK1 and ERK2 are two 44 and 42 kDa serine/threonine kinases, respectively. Like
other protein kinases, ERK 1/2 are composed of a small and a big lobe (Fig. 1.6) (Chen
et al., 2001; Yao and Seger, 2009). The active site is formed at the interface of N- and C-
terminal domains and in unphosphorylated ERK2, it is masked by the activation loop.
The conformational change of the activation loop is induced by Thr183 and Tyr185
phosphorylation and coordinated by the amino acids between Asp173 and His176 of the
activation loop and by the amino acids of the so-called L16 lip (Canagarajah et al., 1997).
Figure 1.6: The three-dimensional structure of ERK2. The active site of ERK2 is formed
at the interface of two folding domains. Phosphorylation sites (Thr183 and Tyr185) in the activa-
tion loop, the MAP kinase insert, the common docking (CD) motif, α helix C, and the C-terminal
extension L16 are shown (adapted from Chen et al., 2001).
ERK1/2 execute their functions through a large number of downstream target pro-
teins, depending on the condition, cell type and cellular compartment (reviewed in Yoon
and Seger, 2006). To be fully active, ERK2 has to be phosphorylated on a conserved
Thr-Xxx-Tyr motif in the activation loop (Ahn et al., 1991; Payne et al., 1991; Robbins
et al., 1993). Phosphorylation is non-processive (it requires two separate phosphorylation
events) (Ferrell and Bhatt, 1997) and induces a global conformational change (Cana-
garajah et al., 1997) of the kinase that exposes the substrate-binding pocket in order to
position the Ser/Thr to be phosphorylated in close proximity towards the γ-phosphate
of prebound ATP. These changes induce full activity of ERK1/2, which is approximately
five orders of magnitude higher than their basal activity.
The consensus phosphorylation site of ERK is Pro-Xxx-Ser/Thr-Pro, with the first
proline residue being not as conserved (Gonzalez et al., 1991) and Xxx as any amino
12
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acid except proline. However, the interaction between the phospho-acceptor motif of
the ERK substrate and the active site of ERK does not provide sufficient affinity and
specificity (Yoon and Seger, 2006). Two additional docking motifs are being used for
improved substrate recognition. One motif found in many ERK interaction partners
is the D domain, a basic and hydrophobic region that interacts with ERK1/2’s cyto-
solic retention sequence (CRS), also called common docking (CD) motif (Tanoue et al.,
2000). Binding of the D domain to the CRS/CD motif is independent of ERK’s activi-
ty/phosphorylation state and thus can be responsible for a pre-existing ERK-substrate
association. That would facilitate the phosphorylation reaction as described for scaffold
proteins (see Section 5.3) (Chen et al., 2001; Yoon and Seger, 2006).
The other docking motif is called the DEF (docking site for ERK) domain, which
usually occurs in the form Phe-Xxx-Phe-Pro (Jacobs et al., 1999; Fantz et al., 2001).
This motif cannot be found in all ERK substrates and is therefore believed to increase
target specificity of some ERK substrates. The hydrophobic pocket that is the DEF-
binding site is located in close proximity of ERK’s active site (Lee et al., 2004) and is
only accessible for ERK substrates when the activation loop is phosphorylated. Thus,
only active ERK molecules can bind to the DEF domain (Yoon and Seger, 2006).
Signalling of the Raf/MEK/ERK module is regulated by dynamic subcellular loca-
lisation (Yao and Seger, 2009). This spatial and temporal regulation is achieved by
translocation of some components between subcellular compartments, the association
with anchoring of scaffold proteins and a distinct set of MAPK phosphatases in each
compartment (Fig. 1.7). ERK1/2 activation and localisation is dynamically controlled
by continuous phosphorylation and dephosphorylation which can be differentially regu-
lated upon stimulation (Costa et al., 2006).
MEK functions as the cytoplasmic anchor of ERK1/2 in resting cells. Co-expression of
MEK1 with ERK1/2 is able to retain ERK in the cytosol of unstimulated cells (Fukuda
et al., 1997; Rubinfeld et al., 1999; Adachi et al., 2000; Burack and Shaw, 2005) and
this cytoplasmic retention of ERK is mediated by direct interaction with the nuclear
export sequence (NES) of MEK (Fukuda et al., 1997) and its D domain. Since only de-
phosphorylated, inactive ERK1/2 binds to MEK1/2 (Canagarajah et al., 1997; Adachi
et al., 1999), this mechanism is thought to restore an activatable cytoplasmic pool of
ERK1/2 probably ensuring and enabling sustained, continuous or oscillating ERK1/2
activation (Adachi et al., 2000). In resting cells, ERK1/2 are primarily located in the
cytosol, mediated by interactions with cytosolic anchors such as the MEK1/2, certain
phosphatases, KSR, β-arrestin, MP1, PEA15 and some cytoskeletal proteins (Reszka
et al., 1995; Fukuda et al., 1997; Adachi et al., 1999; Blanco-Aparicio et al., 1999; Morri-
son, 2001; Formstecher et al., 2001; Gaumont-Leclerc et al., 2004; Casar et al., 2009; Yao
and Seger, 2009). In addition, ERK dimerisation (Khokhlatchev et al., 1998) is involved
in binding to scaffold proteins and activation of cytosolic substrates (Casar et al., 2008).
Activation of MEK leads to the dissociation of the ERK1/2 from their cytosolic an-
chors and is required for translocation of ERK1/2 to the nucleus (Fukuda et al., 1997;
13
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Figure 1.7: Intracellular localisation of different components of Raf/MEK/ERK sig-
nalling. Dynamic subcellular localisation of ERK is achieved by shuttling to subcellular com-
partments and controlled by various anchoring and scaffold proteins as well as a distinct set of
MKPs in each compartment (adapted from Yao and Seger, 2009).
Adachi et al., 1999). Translocation of ERK1/2 is phosphorylation-dependent and kinase
activity is not required as e.g. kinase-dead mutants of ERK2 accumulate in the nucleus
as well (Khokhlatchev et al., 1998). Nuclear accumulation is rapid with a peak at around
5 - 15 min (Chen et al., 1992; Lenormand et al., 1993; Fukuda et al., 1997; Adachi et al.,
1999; Ando et al., 2004; Burack and Shaw, 2005; Costa et al., 2006; Cohen-Saidon et al.,
2009), but is also reported to persist for hours (Volmat et al., 2001). Phosphorylated
ERK1/2 (ppERK1/2) translocates via passive and active transport mechanisms (Adachi
et al., 1999; Ando et al., 2004; Burack and Shaw, 2005). A novel nuclear translocation
signal (NTS) seems to mediate nuclear translocation of ERK1/2 (Chuderland et al.,
2008).
Nuclear export of ERK1/2 is mediated by the interaction of ERK with MEK1/2 via
MEK’s NES and the MEK-ERK complex is actively transported into the cytosol (Adachi
et al., 2000).
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Since the activation of ERK requires phosphorylation on both threonine and tyrosine
residues, it can be inactivated by serine/threonine phosphatases, tyrosine phosphatases
or dual specificity phosphatases. A certain subgroup of dual specificity phosphatases
known as MAP kinase phosphatases (MKPs) specifically dephosphorylates members of
the MAPK family (extensively reviewed in Camps et al., 2000). Stimulation of MAPK
induces rapid MKP transcription. MKPs then translocate to specific subcellular com-
partments to inactivate MAPKs and prevent their anew activation by direct interactions.
More than 180 distinct substrates of ERK1/2 have been identified so far (Yoon and
Seger, 2006; Yao and Seger, 2009). Despite the vast interest of the research community in
nuclear ERK signalling and the resulting negligence for cytosolic ERK targets, approxi-
mately 50 % of the ERK substrates can be found in the cytosol (Fig. 1.2). ERK substrates
can be classified into several functional groups including: a) transcription factors, b)
protein kinases and phosphatases, c) cytoskeletal and scaffold proteins, d) receptors and
signalling molecules, e) apoptosis-related proteins and f) others.
1.2 Visualisation of Spatio-Temporal Dynamics of
Intracellular MAPK Signalling
Protein-protein interactions, as e.g. in MAPK signalling, have traditionally been ana-
lysed by biochemical and biophysical methods including affinity chromatography, co-
immunoprecipitation, yeast two-hybrid screens, immunoblots and radioactive labeling
(Chen et al., 2003). However, while - without doubt - these techniques have generated
invaluable information for the elucidation of e.g. the components of signalling pathways,
they are restricted to measurements of the average activation status of a given MAPK in
a population of cells (Pertz, 2010) and therefore provide very little or no spatio-temporal
information. Immunofluorescence in principle offers good spatial resolution but provides
only poor temporal information about protein activities due to the fixation process and
is therefore unsuitable to study fast dynamic processes. As far as known, only dynamic,
live cell imaging approaches using fluorescent biosensors offer sufficient spatio-temporal
resolution to probe enzyme or specifically MAPK activity (Bastiaens and Pepperkok,
2000; Wouters et al., 2001; Miyawaki, 2003; Yasuda, 2006; Schultz, 2007; Grecco and
Verveer, 2011).
In a simple version of a fluorescent biosensor, the protein of interest is fused to a fluo-
rescent protein (FP) and its translocation followed upon stimulation and/or activation
(Wouters et al., 2001). Indeed, fluorescently labeled ERK1/2 has been widely used to
study dynamics of ERK activation (Ando et al., 2004; Costa et al., 2006; Cohen-Saidon
et al., 2009; Shankaran et al., 2009) as its phosphorylation and thus activation induces
nuclear translocation (Lenormand et al., 1993; Khokhlatchev et al., 1998; Lenormand
et al., 1998; Adachi et al., 1999). Nuclear translocation of ERK2 has also been used
in this study to assess growth factor stimulation in living cells (e.g. see Section 3.1).
However, the phosphorylation state of ERK1/2 does not necessarily reflect its activity
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as demonstrated by the finding that total ERK1/2 phosphorylation levels are unaltered
when disruption of ERK dimerisation blocks cytoplasmic ERK signaling (Casar et al.,
2008). Here, total ERK1/2 phosphorylation levels suggest that ERK is fully active, com-
pletely ignoring that the cytoplasmic pool is blocked (Casar et al., 2009). Analogously,
overexpression of PEA15 prevents nuclear entry of ppERK1/2, inhibiting nuclear while
concurrently enhancing cytoplasmic ERK signalling (Formstecher et al., 2001; Casar
et al., 2009). Furthermore, ERK1/2 expressed on endogenous levels has been found to
reside in the nucleus for hours after stimulation while being quickly dephosphorylated
(Volmat et al., 2001). And even more convincing, while nuclear translocation of ERK1/2
is phosphorylation dependent, kinase activity is not required as e.g. kinase-dead mutants
of ERK2 also accumulate in the nucleus (Khokhlatchev et al., 1998). Thus, the promi-
nent nuclear translocation of ERK1/2 has caused a striking negligence for cytoplasmic
ERK1/2 signalling (Casar et al., 2009) for obvious reasons - it does not provide any
information of cytoplasmic ERK1/2 activity.
ERK2 activation has been analysed by intermolecular FRET studies proving the di-
rect cytoplasmic interaction of MEK1 and ERK2 in resting cells. Stimulation with EGF
led to the loss of FRET and its slow recovery when ERK returned to the cytoplasm
(Burack and Shaw, 2005; Fujioka et al., 2006) in agreement with biochemical evidence
for the MEK-ERK interaction (Fukuda et al., 1997; Adachi et al., 1999, 2000). But this
assay also only resolves known dynamics for ERK activation since the dissociation and
reassociation of the MEK-ERK complex is simply another approach to probe for ERK
phosphorylation. Therefore, it does not provide information about spatio-temporal acti-
vity of ERK2. To date, as far as known, only one study reports FRET between ERK2
and a downstream substrate but it does not present time-resolved information (Debata
et al., 2010).
Genetically encoded, intramolecular FRET-based biosensor that report protein activi-
ties have been developed for many signalling kinases (as reviewed in Zhang et al., 2002;
Miyawaki, 2003; Giepmans et al., 2006; Li et al., 2006; Aoki et al., 2008). Advantages of
those FRET sensors are: they can be modularly constructed by simple genetic manipu-
lations (Li et al., 2006) according to in-principle generic design strategies (Sato et al.,
2002; Sato and Umezawa, 2004; Aoki et al., 2008). They can be easily delivered into
cells by transient or stable transfection and expression. They can be targeted to specific
organelles, cells or tissues, allowing imaging of kinase activities from subcellular levels
to whole organisms (Li et al., 2006). There is a relatively low chance of interaction of
individual parts of the sensor molecule with endogenous proteins. Additionally, due to
their fixed donor-acceptor stoichiometry, they are in principle suitable for ratiometric
FRET imaging, reducing instrumental costs and increasing signal-to-noise ratio, and
simplifying data acquisition and analysis (Miyawaki, 2003; Yasuda, 2006; Aoki et al.,
2008; Grecco and Verveer, 2011).
Drawbacks of those type of FRET probes is the relatively large size of the two FPs
that have to be introduced increasing sensor protein size by at least 50 kDa. Problems
may also arise from sensor protein overexpression as binding of endogenous proteins
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to the biosensor required for sensor action may perturb normal signalling. Differential
susceptibility to photobleaching of the two fluorophores may cause artifacts in the ana-
lysis when not handled properly. Maturation of FPs is relatively slow and it should be
kept in mind that efficiency of the sensor protein folding, maturation and degradation
or proteolysis may effect the measurements (Miyawaki, 2003; Li et al., 2006). Additional
problems with data analysis or interpretation (e.g. imprecise spatial or temporal resolu-
tion) may arise due to the specific design of the FRET sensor being used.
A number of FRET-based intramolecular fluorescent biosensors for ERK2 have been
described in the literature. However, they all suffer from several serious disadvantages.
Figure 1.8: Miu2 - a FRET-based probe for monitoring ERK2 activation in living
cells. A) Schematic representation of the Miu2 design. ERK2 is sandwiched by CFP and YFP.
Dissociation of ERK2 from the MEK-ERK complex upon phosphorylation results in a decrease
of FRET. B) ERK2 activation dynamics as measured with Miu2 in HeLa cells (adapted from
Fujioka et al., 2006).
Miu2 comprises of ERK2 and the FRET pair CFP-YFP fused to ERK2’s N- and C-
terminus (Fujioka et al., 2006). The N- and C-termini of ERK2 are in close proximity.
Phosphorylation of the kinase by MEK1 induces a global conformational change that
alters the distance and orientation between the fluorophore pair, thereby changing the
FRET signal (Fig. 1.8A). Miu2 therefore only reports the dynamics of a phosphorylation-
induced conformational change of ERK2 (or the presence of phosphorylated versus non-
phorphorylated ERK2) rather than localised ERK2 activity. In addition, the dynamic
range of Miu2 with an approximately 6 % change is rather low (Fujioka et al., 2006).
However, while confirming earlier findings about ERK activation and MEK-ERK in-
teractions, Miu2 has not yet been proven to contribute to new findings of spatio-temporal
ERK dynamics.
Another fluorescent reporter for ERK2 activity, termed ERK Activity Sensor 3 (EAS-
3) is based on the conformational change of a substrate peptide for ERK2 (Green and
Alberola-Ila, 2005). Amino acids 375-404 of the human transcription factor Elk1, in-
cluding two minimal consensus ERK1/2 phosphorylation sites, were used as a peptide
linker to fuse ECFP and EYFP. Phosphorylation of the hElk1(375-404) sequence results
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Figure 1.9: EAS-3 - a substrate-based FRET sensor for ERK2 activity. A) Schematic
representation of the EAS-3 probe. A short substrate peptide of ERK2 (hElk1(375-404)) is
sandwiched by ECFP and EYFP. Phosphorylation of hElk1(375-404) alters the FRET signal
from the two fluorophores. The red part in the substrate peptide indicates the relative position
of the DEF domain. B) Change in FRET efficiency of EAS-3 in the presence of activated kinases
showing the specificity of EAS-3 for ERK2 (adapted from Green and Alberola-Ila, 2005).
in a change of secondary structure of the peptide, altering the FRET efficiency of the
sensor protein (Fig. 1.9A). While the relatively small size of the sensor constructs makes
it theoretically very interesting, the presented approach suffers serious flaws. For once,
the sensor can only report ERK2 activity indirectly since a change in FRET efficiency
requires binding of and phosphorylation by ppERK2, as well as the change of secondary
structure of the peptide. Therefore, detecting localisation of ERK2 activity will be im-
precise if not impossible due to rapid diffusion from active ERK. However, the study
does not provide any in-vivo data. It is well known, that ERK activity increases dramat-
ically shortly after cell stimulation (Lenormand et al., 1993; Ando et al., 2004; Burack
and Shaw, 2005; Costa et al., 2006; Cohen-Saidon et al., 2009; Shankaran et al., 2009).
In contrast, data presented by Green and Alberola-Ila (2005) show a relatively slow con-
tinuous change of the FRET signal. While this maybe due to the specific conditions in
the used in-vitro assay, it does not suggest a great potential for the detection of ERK2
activation dynamics in living cells. Finally, FRET efficiency changes are presented with
arbitrary units (Fig. 1.9B), making it impossible to judge the dynamic range of EAS-3
(Green and Alberola-Ila, 2005).
Two other FRET-based ERK2 biosensor, named “Erkus” (Sato et al., 2007) and
“EKAR” (Extracellular signal regulated K inase Activity Reporter, Harvey et al., 2008a)
have been developed, based on a generic design for FRET-based kinase activity reporters
(Sato et al., 2002; Zhang et al., 2002). Essentially, a substrate peptide for ERK2 was fused
to a phospho-peptide binding domain via a flexible peptide linker and then sandwiched
by a FRET pair of fluorescent proteins (Fig. 1.10). Addition of an ERK2 docking motif
is crucial for sensor specificity.
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Figure 1.10: FRET-based probes for ERK2 activity based a generic design for FRET-
based kinase activity reporters. A) Schematic representation of EKAR. A short substrate
peptide of ERK2 and a phospho-peptide binding domain linked by a flexible peptide linker are
sandwiched by a FRET pair of FPs. ERK2 phosphorylation of EKAR triggers its conformational
change and the concomitant FRET signal (adapted from Harvey et al., 2008a). B) and C) Dy-
namics of ERK2 activation as measured by Erkus and EKAR. B) (left): FLIM and ratio-images
of HEK293 transfected with EKARcyto before and after EGF treatment. (right): Graphs repre-
senting fluorescent lifetime (red) and FRET ratio (blue) changes from the respective images on
the left (adapted from Harvey et al., 2008a). C) Graphs representing the average FRET ratio
change of Erkus and a dominant negative mutant expressed in MCF-7 cells upon EGF treatment
(adapted from Sato et al., 2007).
The dynamic range of Erkus and EKAR is not very high, as known for intramolecular
FRET sensors (Li et al., 2006; Aoki et al., 2008). Similar to EAS-3, Erkus and EKAR
also provide only indirect information about ERK2 activition and activity. Rapid dif-
fusion of the phosphorylated sensor from active ERK will result in at best imprecise
localisation of subcellular ERK2 activity. Additionally, to report dynamics of ERK2 ac-
tivity rather than simple ERK2 activation kinetics, the sensor protein has to become
dephosphorylated in a similar fashion as endogenous ERK2. But if the phosphatase
inactivating ERK2 and dephosphorylating Erkus and/or EKAR are two different pro-
teins, time-resolved ERK2 activity measured with those biosensors at least does not
reflect true ERK2 inactivation dynamics. In fact, fusion of Erkus and EKAR to nuclear
or cytoplasmic localisation sequences was necessary to discriminate at least compart-
mentalised ERK2 activity and resolve known ERK2 activity profiles (Sato et al., 2007;
Harvey et al., 2008a). Taken together, the usefulness of Erkus and EKAR in detection
of spatio-temporal ERK2 activity is questionable.
In addition to the general functionality of the respective sensor construct neither of the
two studies introducing Erkus and EKAR has presented new findings concerning ERK
signalling (Sato et al., 2007; Harvey et al., 2008a). Also, only one further publication
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has been published until today using EKAR to investigate the effect of the A-kinase-
anchoring protein AKAP-Lbc and kinase suppressor of Ras (KSR1) on MAPK signalling
in HEK293 cells (Smith et al., 2010).
The most direct approach to visualise spatio-temporal ERK activity would be imag-
ing of transient enzyme-substrate interactions of ERK2. Enzymatic modification of a
substrate necessarily requires its binding to the active site of the enzyme forming a tran-
sient ES complex before being released. The formation of ES complexes can be detected
by measuring FRET/FLIM between a donor-tagged enzyme and an acceptor-labeled
substrate peptide (Fig. 1.11) (Yudushkin et al., 2007). Since the donor fluorophore is
exclusively attached to the enzyme of interest, substrate-bound enzyme can be de-
tected with almost exclusive specificity (Schultz, 2007). Using global analysis, fluorescent
lifetimes can be converted into fractions of unbound and bound enzyme populations,
with the latter representing the amount of ES complex (Verveer et al., 2000; Lakowicz,
2006; Yudushkin et al., 2007; Schultz, 2007; Grecco et al., 2009). In cells, regions with
high amounts of ES complexes denote regions with low enzyme activity and vice versa
(Schultz, 2007). This technique can potentially provide information about binding affini-
ties and kinetics of protein interactions as well as enzymatic activities both in-vitro and
in-vivo (Yudushkin et al., 2007; Gru¨nberg and Serrano, 2010) and has been successfully
employed to reveal spatio-temporal regulation of PTP1B upon growth factor stimulation
(Yudushkin et al., 2007).
Figure 1.11: Principle of imaging enzyme-substrate interactions with FRET. Only
after uncaging, the phosphorylated, synthetic substrate peptide binds to the active site of PTP1B
and FRET occurs. After dephosphorylation, the substrate dissociates from the enzyme, resulting
in a loss of FRET. FRET can be measured by FLIM or intensity-based methods (adapted from
Yudushkin et al., 2007).
No attempts to establish ES complex imaging for kinases have been published until to-
day, though. Imaging of transient kinase-substrate and more specifically ERK2-substrate
interactions follows a similar principle as visualising phosphatase-substrate interactions:
the occurence and loss of FRET upon binding, phosphorylation (instead of dephospho-
rylation) and release of an acceptor-labeled substrate peptide to its donor-tagged kinase
is recorded in spatio-temporal manner.
The ability to visualise ERK2 activity with high spatio-temporal dynamics would al-
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low the investigation of a wide variety of MAPK signalling mechanisms such as growth
factor signalling from endosomes (Howe and Mobley, 2004; Howe, 2005; Kholodenko,
2006), spatial gradients and travelling waves of phospho-proteins (Brown and Kholo-
denko, 1999; Markevich et al., 2006; Kholodenko, 2006; Yudushkin et al., 2007; Maeder
et al., 2007), oscillations in the MAPK cascade (Kholodenko, 2000, 2006), compartmen-
tal and differential MAPK signalling upon growth factor stimulation (Santos et al., 2007;
Nakakuki et al., 2010), and the investigation of feedback loops in the MAPK module
(Kholodenko, 2006; Santos et al., 2007; Lin et al., 2009; Smith et al., 2010). However,
none of the previously published FRET-based biosensor approaches developed to follow
spatial and time-resolved ERK2 activity is good enough to resolve these features.
1.3 Fo¨rster Resonance Energy Transfer (FRET)
1.3.1 Principles of Fo¨rster Resonance Energy Transfer (FRET)
A molecule in an electronically excited state can relax into its ground state by emission
of a photon from singlet excited states (= fluorescence) or via several non-radiative
processes. One form of non-radiative relaxation into the ground state is migration of the
excited state energy between the excited donor (D*) and the acceptor (A) molecule in
its ground state (Fig. 1.12) (Lakowicz, 2006):
D* + A → D + A* (1.1)
Fo¨rster resonance energy transfer (FRET), describes the non-radiative transfer of
energy from an excited donor molecule to a (fluorescent) acceptor molecule located in
close proximity by resonance coupling of donor and acceptor dipoles (Li et al., 2006).
FRET is accompanied by a decrease (“quenching”) in donor quantum yield, since fewer
photons are emitted directly, and excited state lifetime τD of the donor as the efficiency
of excited state relaxation is enhanced. Simultaneously, FRET leads to enhanced (sen-
sitised) acceptor emission because the acceptor is excited by FRET (Lakowicz, 2006;
Grecco and Verveer, 2011).
The rate of energy transfer, kT is described by (Lakowicz, 2006; Li et al., 2006):
kT =
1
τD
x
9000lnk2QDA J
128pi5 n4NA
x
1
R6
=
1
τD
(
R0
R
)6
(1.2)
with R as the distance between the donor and acceptor. The Fo¨rster radius (R0) is
defined as the distance between the donor and acceptor where FRET efficiency is 50 %
(Lakowicz, 2006; Li et al., 2006):
R0 =
(
9000lnk2QDA J
128pi5 n4NA
)1/6
(1.3)
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Figure 1.12: Energy transitions between electronic states during Fo¨rster Resonance
Energy Transfer. Jablonski diagram illustrating the non-radiative transfer of excited state
energy from the donor to the acceptor molecule. A donor molecule can be excited by the ab-
sorption of a photon from the ground state S0 to one of the vibrational level S1, S2, ... (excited
state of the molecule). The excited molecule returns to the ground state via several processes,
e.g. the emission of photons = fluorescence. In the presence of a suitable acceptor, excited state
energy can be transferred from the donor to the acceptor fluorophore without the emission of a
photon. Resulting sensitised emission spectrum is similar to the acceptor emission spectrum. kT
describes the rate of energy transfer as formulated in equation 1.2.
with QDA as the quantum yield of the donor in the presence of the acceptor, n as
the refractive index of the medium, NA as Avogadro’s number, τD as the lifetime of
the donor in absence of the acceptor, k2 as the relative orientation factor and J as the
spectral overlap integral, defined by:
J =
∫ ∞
0
FD(λ) A(λ)λ
4 dλ (1.4)
with FD(λ) as the donor emission profile and A(λ) as the acceptor’s molar extinction
coefficient.
The FRET efficiency (E ) is defined as the probability of energy transfer per donor
excitation event and can be described by (Lakowicz, 2006; Li et al., 2006; Yasuda, 2006):
E =
kT
kT + τ
−1
D
=
R60
R60 +R
6
(1.5)
The energy transfer efficiency mainly depends on three factors: the overlap of donor
emission and acceptor excitation spectra (Fig. 1.13A), the orientation of donor and
acceptor dipoles and the distance between the donor and acceptor fluorophore (Fig.
1.13B)(Bastiaens and Pepperkok, 2000; Chen et al., 2003; Lakowicz, 2006; Li et al.,
2006; Grecco and Verveer, 2011).
For optimal FRET efficiencies, spectral overlap should exceed 30 % and dipole orien-
tation of the donor acceptor pair should not be perpendicular (Chen et al., 2003; Suhling
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Figure 1.13: Factors influencing the FRET efficiency. A) FRET efficiency is dependent
on the overlap of donor emission and acceptor excitation spectra (adapted from Bastiaens and
Pepperkok, 2000). B) FRET efficiency as a function of fluorophore distance. The Fo¨rster radius
(R0) is defined as the distance between the donor and acceptor where FRET efficiency is 50 %.
FRET efficiencies between 10 % and 90 % correspond to fluorophore distances of 1.4 - 0.7 R0
(adapted from Li et al., 2006).
et al., 2005). The orientation factor k2 characterises the statistical average of relative fluo-
rophore orientation and determines coupling of fluorophore dipoles and energy transfer
efficiency. It is usually assumed to be 2/3, the value for randomised rotational diffusion
of the donor and acceptor prior to FRET (Lakowicz, 2006; Li et al., 2006). Preferably,
the distance between the fluorophores is in a range from 0.7-1.4 R0 (usually 4-7 nm),
corresponding to 90 - 10 % FRET efficiency (Fig. 1.13B)(Li et al., 2006). Since these va-
lues correspond well to the size of biomolecules or distances of protein complexes, FRET
can be used as a direct proof of protein-protein interactions (Bastiaens and Pepperkok,
2000; Chen et al., 2003; Lakowicz, 2006; Grecco and Verveer, 2011).
1.3.2 Intensity-Based Fo¨rster Resonance Energy Transfer (FRET)
Approaches
The energy transfer efficiency is often measured using relative fluorescent intensities
of the donor (and acceptor) in the prescence (IDA) and absence (ID) of the acceptor
(Lakowicz, 2006; Yasuda, 2006):
E = 1 − IDA
ID
(1.6)
In FRET, the direct excitation of a donor molecule in close proximity to an appro-
priate acceptor results in sensitised emission of the acceptor fluorophore and quenching
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Figure 1.14: Effects of FRET on donor and acceptor fluorescence. FRET is accompanied
by quenching of donor and sensitised emission of acceptor fluoroscence (adapted from Yudushkin
et al., 2007).
of donor fluorescence (Fig. 1.14) (Bastiaens and Pepperkok, 2000).
Several methods to assess FRET efficiency via intensity-based approaches exist, e.g.
ratiometric FRET imaging, acceptor sensitised emission FRET measurements and ac-
ceptor photobleaching.
Ratiometric FRET Imaging
In ratiometric FRET imaging, the ratio of donor (ID) and acceptor (IA) fluorescence
when excited with the donor wavelength, ID/IA is calculated for each pixel as a mea-
sure of relative FRET efficiencies (Yasuda, 2006). If only donor fluorophores are excited,
ID/IA does not depend on the relative concentrations of donor and acceptor molecules.
In practice, donor intensity images are divided by donor excitation/acceptor emission
images, or vice versa. Comparison of ratio-images taken at different time points or from
different conditions allows a qualitative statement about the state of FRET between
two molecules. Due to the simplicity of the approach (essentially only two images are
required), it can be implemented on nearly any fluorescent microscope and provides
high temporal resolution limited only by the speed of the instrument. However, as rela-
tive donor and acceptor concentrations affect the FRET ratio, ratiometric imaging can
only be used for fixed stoichiometries of donor and acceptor molecules (Bastiaens and
Pepperkok, 2000; Zhang et al., 2002; Yasuda, 2006).
Ratiometric FRET approaches are ideal to observe conformational changes of proteins
and has been widely used to study signalling activities (Miyawaki et al., 1997; Ting et al.,
2001; Itoh et al., 2002; Vilardaga et al., 2003; Sato and Umezawa, 2004; Fujioka et al.,
2006; Pertz et al., 2006).
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Acceptor Sensitised Emission FRET Measurements
Ratiometric FRET measurements are invalid without fixed stoichiometries of donor and
acceptor molecules because fluorescent intensity is dependent on fluorophore concentra-
tion and local concentrations of donor- and acceptor-labelled proteins may vary during
the course of the experiment. Alternatively, acceptor-sensitised emission can be detected
as a measure of FRET. Spectral bleed through arising from the spectral overlap of
the donor and acceptor molecule can contaminate the FRET signal. Several methods
to avoid, minimise or correct for spectral bleed through contaminations have been de-
veloped, requiring the sequential acquisition of three (Gordon et al., 1998) to seven
(Elangovan et al., 2003) images. Elaborate image-processing procedures are necessary
to remove spectral bleedthrough and to separate direct donor and acceptor fluorescence
from sensitised emission (Bastiaens and Pepperkok, 2000). Additionally, similar to ra-
tiometric FRET imaging, the method is sensitive to differential photobleaching of donor
and acceptor fluorophores.
Acceptor Photobleaching
FRET can be measured quantitatively by measuring donor fluorescence before (IAD)
and after acceptor (ID) photobleaching (Bastiaens et al., 1996; Kenworthy, 2001). Pho-
tobleaching of the acceptor results in an increase in donor fluorescence (dequenching).
Quantitative measurements are possible when the acceptor can be bleached selectively
and bleedthrough of the acceptor into the donor channel is negligible. Quantitative FRET
efficiencies can be calculated by computing the ratio of donor fluorescence before and
after photobleaching according to equation 1.6 (Bastiaens et al., 1996; Yasuda, 2006).
Unlike sensitised emission measurements, acceptor photobleaching can be done highly
specific because absorption spectra steeply drop at their red edge (Bastiaens and Pep-
perkok, 2000). Additionally, it requires only a single sample and FRET efficiencies can
thus be directly correlated with donor and acceptor intensities. A major disadvantage of
the technique is the irreversible bleaching of the acceptor fluorophore which eliminates
its use for live cell and time-lapse imaging (Kenworthy, 2001).
Donor Photobleaching
Photobleaching of fluorophores occurs in electronically excited states (Lakowicz, 2006).
Since FRET shortens the excited state lifetime, it protects a fluorescent molecule from
photobleaching. Therefore donor photobleaching in the presence and absence of the
acceptor can be used to measure FRET by comparing donor photobleaching curves.
This, however, requires fitting (multi-component) time constants (Jovin and Arndt-
Jovin, 1989; Kenworthy, 2001).
1.3.3 Principles of Fluorescent Lifetime Imaging Microscopy (FLIM)
One major disadvantage of intensity-based FRET approaches is their sensitivity to lo-
cal fluctuations of fluorophore concentration which cannot be controlled experimentally.
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Different sensitivities of donor and acceptor fluorophores to photobleaching may also
lead to artifacts. Additionally, quantification of FRET efficiencies obtained by intensity-
based methods often requires elaborate multiparameter calibration procedures (Elango-
van et al., 2003).
The fluorescence lifetime is an intrinsic property of a fluorophore that is independent of
light path length and probe concentration but dependent on processes that influence the
efficiency excited state relaxation such as FRET. It is also affected by the local environ-
ment, e.g. ion and/or oxygen concentration, pH, polarity, and viscosity (Suhling et al.,
2005; Lakowicz, 2006). Fluorescent (excited state) lifetime based FRET approaches only
measure donor fluorescent lifetime and therefore do not require absolute specificity of the
acceptor-labeled probe. Global analysis of FLIM data allows the quantitative estimation
of FRET efficiencies as well as of fractions of interacting molecules (Verveer et al., 2000;
Grecco et al., 2009).
The fluorescent lifetime τ is defined as the average time a fluorophore remains in the
excited state following excitation and can be described by (Suhling et al., 2005; Lakowicz,
2006):
τ =
1
kSr + k
S
nr
(1.7)
with k r as the rate constant for radiative deactivation and knr as the rate constant for
non-radiative deactivation, while the latter is the sum of the rate constant for internal
conversion k ic and the rate constant for intersystem crossing k isc: knr = k ic +k isc. It is
mainly the influence of environmental factors on the non-radiative rate constant knr that
is measured with FLIM (Festy et al., 2007).
It is important to note that the lifetime is a statistical value, meaning the excited
fluorophores emit their photons randomly after excitation into the excited state by ab-
sorption of a photon. Thus, when excited with an infinitesimal short pulse of light the
excited state population and consequently the fluorescent intensity decay exponentially
according to (van Munster and Gadella, 2005; Lakowicz, 2006):
I(t) = I0 exp (−t/τ) (1.8)
with I(t) as the fluorescent intensity as a function of time, I0 as the intensity at time
0, and t as time. It should be noted that equation 1.8 is only valid for fluorophores with
mono-exponential decay rates.
Fluorescent lifetime measurements are often used to measure quantitatively the occu-
rence of FRET in biological samples. FRET leads to a decrease in donor fluorescence
lifetime because it provides an additional decay process for the donor molecule by faci-
litating the relaxation of the donor-excited state (Breusegem et al., 2006). The energy
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transfer efficiency can also be calculated from the fluorescent lifetimes (τDA and τD)
(Lakowicz, 2006):
E = 1 − τDA
τD
(1.9)
Figure 1.15: The effect of FRET on the donor fluorescence decay. A) FRET can occur
when a donor (GFP)-and acceptor-tagged protein (red and blue) are within a distance of less
than 10 nm. Thus, FRET can be used to show protein-protein interactions far beyond the usual
resolution limit of conventional light microscopes (adapted from Wouters et al., 2001). B) FRET
leads to a shortened excited-state lifetime of the donor fluorophore (adapted from Suhling et al.,
2005).
1.3.4 Fluorescent Lifetime-Based FRET Approaches
Mainly, two different principles are used to determine fluorescent lifetimes, frequency-
domain and time-domain fluorescent lifetime measurements.
Frequency-Domain Fluorescent Lifetime Measurements
For frequency-domain fluorescent lifetime measurements, the intensity of the excitation
light is sinusoidally modulated with a frequency reciprocal to the fluorescent lifetime
of interest. Due to the non-instant fluorescent decay (the lifetime of the fluorophore
causes the emission light to be delayed in time relative to the excitation light), the
fluorescence emission will be sinusoidally modulated but display a reduction in relative
modulation depth and a phase shift (Fig. 1.16) (Bastiaens and Squire, 1999; van Munster
and Gadella, 2005; Lakowicz, 2006). Phase shift (∆Φ) and relative modulation depth (M)
can be used to calculate phase (τΦ) and modulation lifetimes (τM) according to:
τΦ = ω
−1 tan(∆Φ) (1.10)
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τM = ω
−1√(M)−2 − 1 (1.11)
with ω as the modulation frequency.
Figure 1.16: Principle of frequency-domain fluorescence lifetime measurements. In
frequency-domain fluorescent lifetime measurements, the excitation light is sinusoidally modu-
lated. From the resulting phase shift and demodulation of the emitted fluorescence, the lifetime
of the fluorophore can be determined according to equations 1.10 and 1.11 with ∆Φ as the phase
shift, M the demodulation factor or modulation, E0 as the peak-to-peak height, F0 as the average
intensity of the excitation light, and E1 as the peak-to-peak height and F1 as the average inten-
sity of the emission light. The x-axis and y-axis denots time and intensity, respectively (adapted
from Bastiaens and Squire, 1999).
Phase and modulation lifetimes are equal (τΦ = τM) in samples that contain only a
single species of mono-exponentially decaying fluorophore molecules. For fluorophores
with multi-exponential decay lifetimes or in samples containing more than one species
of fluorophores, the phase lifetime may be smaller than the modulation lifetime (τΦ <
τM) and the lifetime composition can be obtained by measuring phase and modulation
lifetimes using multiple modulated excitation frequencies (Bastiaens and Squire, 1999;
Suhling et al., 2005; van Munster and Gadella, 2005).
Time-Domain Fluorescent Lifetime Measurements
In time-domain lifetime measurements, the sample is excited with a very short (relative
to the lifetime to be measured) pulse of light, resulting in an exponential decrease of
fluorescence emission intensity over time. The fluorescent lifetime τ can be calculated
from the decay curve as the time at which the intensity decreases to 1/exp of the inten-
sity at t = 0 (Bastiaens and Squire, 1999; van Munster and Gadella, 2005; Lakowicz,
2006).
Time correlated single photon counting (TCSPC) was used to determine fluorescent
lifetimes. In TCSPC, the arrival time of the first photon after the excitation pulse is
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recorded at high time resolution. These arrival times can be stored in a histogram with
the x-axis denoting the arrival time and the y-axis the number of photons per time
difference. Recording photon arrival time after the excitation pulse for a large number
of photons yields a representation of a decay curve as exemplified in Fig. 1.17.
Figure 1.17: Exemplified TCSPC histogram of a fluorophore with a mono-expo-
nential decay rate. The TCSPC histogram was recorded from living HeLa cells expres-
sing mCitrine-ERK2 using an Olympus FluoView FV1000 laser scanning confocal microscope
equipped with PicoQuant’s compact lifetime and FCS upgrade kit, and displayed and analysed
with PicoQuant’s SymPhoTime v5.12 software. The number of photons (counts) collected for
the whole 256x256 pixel image is plotted against the arrival time interval (blue lines, top). The
residuals (bottom) evaluate the error in the fit. Tail-fitting (black line) for the fluorescence decay
yields a lifetime of 3.04 ns and a χ2 of 1.047.
After acquisition of the photon-counting histogram, time-domain fluorescent lifetime
data are analysed by fitting fluorescence decay models to the decay curves (Fig. 1.17).
For the fitting, the initial part of the decay curve including the peak is excluded as the
decay curve here is influenced by the instrument response function (IRF). The corres-
ponding analysis is called a “tailfit”. When it is assumed that the decay follows a single-
exponential decay model, equation 1.8 may be employed for fitting. In case more than
one lifetime is to be expected in the sample, e.g. for FRET analysis, a multi-exponential
fluorescence decay can be fitted according to the following model (Lakowicz, 2006):
I(t) =
n∑
i=1
Ai exp(−t/τi) +B (1.12)
with B as the background, n as the number of decay times present, the pre-exponential
factor Ai as the amplitudes of the components and τi as the fluorescent lifetimes.
The pre-exponential factors Ai have different meanings for the case of one fluorophore
displaying a complex decay or a mixture of fluorophores. While for the latter Ai values
depend on concentrations, absorption, quantum yield and intensities of each fluorophore,
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for fluorophores with a complex decay, the Ai values yield information about the fraction
of molecules in each conformation (Lakowicz, 2006). During the analysis of FRET mea-
surements using a mono-exponentially decaying fluorophore, equation 2.1 can be used
with A2 and A1 approximating the population of fluorophores undergoing FRET versus
the population of fluorophore molecules that do not FRET, and τ1 and τ2 correspon-
ding to the quenched and unquenched lifetime. The amplitudes, however, do not exactly
correspond to actual fractions (= numbers of molecules) of quenched versus unquenched
fluorophores as they denote intensity amplitudes and are therefore influenced by the
quantum yield of the fluorophore.
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2.1 Material
2.1.1 Chemicals
Adenosin-5’-triphosphate (ATP) Sigma-Aldrich R©
Ammonium persulfate (APS) SERVA Electrophoresis GmbH
Ampicillin sodium salt SERVA Electrophoresis GmbH
Bromphenolblue Sigma-Aldrich R©
2’-deoxyadenosine-5’-triphosphate (dATP) InvitrogenTM Life Technologies
2’-deoxycytidine-5’-triphosphate (dCTP) InvitrogenTM Life Technologies
2’-deoxyguanosine-5’-triphosphate (dGTP) InvitrogenTM Life Technologies
2’-deoxythymidine-5’-triphosphate (dTTP) InvitrogenTM Life Technologies
Dimethyl sulfoxide (DMSO) SERVA Electrophoresis GmbH
Disodium hydrogen phosphate (Na2HPO4) Merck KG
Dithiothreitol (DTT) Fluka R© Analytical
Ethanol J.T.Baker
Ethidium bromide (10 mg/ml) Fisher Scientific
Ethylenediaminetetraacetic acid (EDTA) Fluka R© Analytical
Glycerol GERBU Biotechnik GmbH
Glycine Carl Roth GmbH
Hoechst 33342, trihydrochloride, trihydrate Molecular ProbesTM
N-(2-Hydroxyethyl)Piperazine-N’-ethane-2-
sulfonic acid (HEPES)
GERBU Biotechnik GmbH
Imidazole Merck KG
Isopropanol J.T.Baker
Isopropyl β-D-thiogalactopyranoside (IPTG) AppliChem GmbH
Kanamycine sulfate GERBU Biotechnik GmbH
Lissamine rhodamine B sulfonyl chloride AnaSpec, Inc.
Magnesium chloride (MgCl2) Merck KG/J.T.Baker
Methanol AppliChem GmbH
2-Mercapto-ethanol SERVA Electrophoresis GmbH
Monopotassium phosphate (KH2PO4) J.T. Baker
Pefabloc Fluka R© Analytical
Phosphatase Inhibitor Cocktail 1 Sigma-Aldrich R©
Phosphatase Inhibitor Cocktail 2 Sigma-Aldrich R©
Phorbol-12-myristat-13-acetat (PMA) AppliChem GmbH
Potassium chloride (KCl) J.T.Baker
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Sodium acetate (NaOAc) Merck KG
Sodium chloride (NaCl) Fluka R© Analytical
Sodium dodecyl sulfate (SDS) SERVA Electrophoresis GmbH
Sucrose USB Corporation
N,N,N’,N’-Tetramethylene-diamine
(TEMED)
Sigma-Aldrich R©
Tris-base Carl Roth GmbH
Tris-HCl J.T. Baker
Triton X-100 SERVA Electrophoresis GmbH
Tween 20 SERVA Electrophoresis GmbH
U0126 (MEK1/2 Inhibitor) Cell Signaling Technology R©
UltraPureTM Agarose InvitrogenTM Life Technologies
Yeast extract Fluka R© Analytical
2.1.2 Enzymes, Hormones and Antibodies
active MEK1 (250,000 U/mg) Merck KG
AgeI (5,000 U/ml) New England Biolabs Inc.
alpha-Tubulin (mouse, A11126) InvitrogenTM Life Technologies
BamH I (20,000 U/ml) New England Biolabs Inc.
BspE I (10,000 U/ml) New England Biolabs Inc.
BsrGI (10,000 U/ml) New England Biolabs Inc.
Elk1 (I-20) (rabbit, sc-355) Santa Cruz Biotechnology, Inc.
Epidermal Growth Factor (Human EGF) Cell Signaling Technology R©
Heregulin (HRG) MilliporeTM
HindIII (20,000 U/ml) New England Biolabs Inc.
Insulin from bovine pancreas Sigma-Aldrich R©
IRDye R© 680 goat anti-rabbit IgG LI-COR R© Biosciences
IRDye R© 800CW goat anti-mouse IgG LI-COR R© Biosciences
NcoI (10,000 U/ml) New England Biolabs Inc.
p44/42 MAPK (rabbit, #9102) Cell Signaling Technology R©
PfuUltra High-Fidelity DNA polymerase AD Stratagene
phospho-Elk1 (B-4) (mouse, sc-8406) Santa Cruz Biotechnology, Inc.
phospho-p44/42 MAPK (Thr202/Tyr204) (E10)
(monoclonal, mouse, #9106)
Cell Signaling Technology R©
Platinum R© Pfx DNA polymerase InvitrogenTM Life Technologies
SalI (20,000 U/ml) New England Biolabs Inc.
shrimp alkaline phosphatase (SAP) (10,000 U/ml) New England Biolabs Inc.
XhoI (20,000 U/ml) New England Biolabs Inc.
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2.1.3 Oligonucleotides
All oligonucleotides were purchased from Sigma-Aldrich Chemie GmbH in HPLC purified
form. Primer sequences are detailed in S.6 .
2.1.4 Plasmids
mCherry-C1 Clontech Laboratories Inc.
mCitrine-C1 Clontech Laboratories Inc.
mCitrine-N1 Clontech Laboratories Inc.
MEK1-mCherry kind gift by Piet Lommerse, Max-Planck-Institute of
Molecular Physiology, Dortmund, Germany
pcDNA3.1(+) InvitrogenTM Life Technologies
pEGFP-C1 Clontech Laboratories Inc.
pEGFP-hElk1 kind gift by Robert A. Hipskind, Institut de Genetique
Moleculaire de Montpellier, Montpellier, France
pET-ERK2 kind gift by Piet Lommerse, Max-Planck-Institute of
Molecular Physiology, Dortmund, Germany
pEYFP-MEK1 kind gift by Piet Lommerse, Max-Planck-Institute of
Molecular Physiology, Dortmund, Germany
pProEx HTB kind gift by Alfred Wittinghofer, Max-Planck-Institute of
Molecular Physiology, Dortmund, Germany
2.1.5 Buffers and Solutions
ERK2 elution buffer 20 mM Tris (pH 7.5), 250 mM NaCl, 200 mM imidazole, 1
mM DTT, 0.1 % Triton X-100, 0.1 mM Pefabloc, protease
inhibitors
ERK2 lysis buffer 20 mM Tris (pH 7.5), 200 mM NaCl, 1 mM DTT, 0.1 %
Triton X-100, 0.1 mM Pefabloc, protease inhibitors
ERK2 storage buffer 20 mM Tris (pH 7.5), 100 mM NaCl, 1 mM DTT, 0.1 %
Triton X-100, 10 % glycerol, 0.1 mM Pefabloc, protease
inhibitors
ERK2 wash buffer 20 mM Tris (pH 7.5), 250 mM NaCl, 5 mM imidazole, 1
mM DTT, 0.1 % Triton X-100, 0.1 mM Pefabloc, protease
inhibitors
LB agar plates add 15 g agar per litre LB medium, pour plates when the
autoclaved medium has approx. 55 ◦C, if desired add ap-
propriate concentration of the desired antibiotic
LB medium 10 g/l Bacto-Trypton, 5 g/l bacto-yeast extract, 10 g/l
NaCl, autoclave
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1x PBS (pH 7.4) 137 mM NaCl, 10 mM Na2HPO4, 2.6 mM KCl, 1.8 mM
KH2PO4
5x SDS sample buffer 60 mM Tris-HCl (pH 6.8), 25 % glycerol, 2 % SDS, 14.4
mM 2-mercapto-ethanol, 0.1 % brom-phenolblue
SDS running buffer 25 mM Tris-base, 192 mM glycine, 0.1 % SDS
separating gel buffer 1.5 M Tris-HCl (pH 8.8)
SOC medium 20 g/l Bacto-Trypton, 5 g/l bacto-yeast extract, 0.5 g/l
NaCl, 2.5 mM KCl, 10 mM MgCl2 (SOB medium), auto-
clave, before use add 20 mM glucose to obtain SOC medium
stacking gel buffer 0.5 M Tris-HCl (pH 6.8)
1x TAE buffer 40 mM Tris/Acetate (pH 7.5), 20 mM NaOAc, 1 mM EDTA
1x TBST 100 mM Tris-HCl (pH 7.4), 150 mM NaCl, 0.1 % Tween 20
transfer buffer 25 mM Tris-base, 192 mM glycine, 0.1 % SDS, 20 %
methanol
2.1.6 Kits and Purchased Solutions
Kits and Purchased Solutions for Working with DNA
BigDye R© Terminator v3.1 cycle sequencing kit Applied Biosystems
100x BSA New England Biolabs Inc.
6x DNA gel loading buffer Novagen
2-log DNA ladder New England Biolabs Inc.
100 mM dNTP mix InvitrogenTM Life Technologies
DyeEx R© 2.0 Spin kit QIAGEN
GelPilot loading dye, 5x QIAGEN
50 mM Magnesium Sulfate InvitrogenTM Life Technologies
NucleoBond R© Xtra Maxi EF kit Macherey-Nagel GmbH & Co.
KG.
10x Pfx amplification buffer InvitrogenTM Life Technologies
10x PCRx Enhancer solution Invitrogen
TM Life Technologies
QIAprep R© Spin Miniprep kit QIAGEN
QIAquick R© Gel Extraction kit QIAGEN
QIAquick R© PCR Purification kit QIAGEN
Quick LigationTM Kit New England Biolabs Inc.
QuikChange XL Site-Directed Mutagenesis kit Stratagene
10x Restriction Enzme Buffer 1 New England Biolabs Inc.
10x Restriction Enzme Buffer 2 New England Biolabs Inc.
10x Restriction Enzme Buffer 3 New England Biolabs Inc.
10x Restriction Enzme Buffer 4 New England Biolabs Inc.
Zero Blunt R© TOPO R© PCR cloning kit InvitrogenTM Life Technologies
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Kits and Purchased Solutions for Working with Proteins
30 % Acrylamide/Bis solution Bio-Rad Laboratories, Inc.
Blocking buffer for near infra-red fluorescent west-
ern blotting
Rockland Inc.
Bradford reagent Sigma-Aldrich R©
10x Cell lysis buffer Cell Signaling Technology R©
Complete Mini EDTA-free protease inhibitor
tablets
Roche Applied Science
Micro BCATM Protein Assay reagent kit Pierce Biotechnology Inc.
Ni-NTA His•Bind R© Resins Novagen
Odyssey Infrared Imaging System blocking buffer Li-Cor R© Biosciences
Precision Plus ProteinTM standards Bio-Rad Laboratories, Inc.
1x TBS Sigma-Aldrich R©
TC-FlAsHTM TC-ReAsHTM II In-Cell Tetracys-
teine Tag Detection Kit
InvitrogenTM Life Technologies
Kits and Purchased Solutions for Working with Cells
DPBS PANTM Biotech GmbH
Dulbecco’s Modified Eagle’s Medium (DMEM) PANTM Biotech GmbH
Fetal calf serum (FCS) PANTM Biotech GmbH
Fugene R© 6 transfection reagent Roche Applied Science
L-Glutamine GIBCO R©/InvitrogenTM Life Tech-
nologies
Trypsin/EDTA PANTM Biotech GmbH
2.1.7 Bacterial Strains
One Shot R© TOP10 Competent Cells InvitrogenTM Life Technologies
RosettaTM2(DE3) SinglesTM Competent Cells Novagen
XL10 Gold
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2.1.8 Mammalian Cell Lines
Cell line Origin Supplier Reference
COS-7 african green monkey kidney fi-
broblast
ATCC (Gluzman, 1981)
HeLa human cervical adenocarcinoma ATCC (Gey et al., 1952)
MCF-7 human mammary gland adenocar-
cinoma
ATCC (Brooks et al., 1973; Soule
et al., 1973)
MDA-MB-
231
human mammary gland adenocar-
cinoma
ATCC (Cailleau et al., 1974)
2.1.9 Material and Equipment
Centrifuges & Rotors
Centrifuge “5415R” Eppendorf
Centrifuge “5810R” Eppendorf
Centrifuge “RC 26 Plus” Sorvall R©
Rotor “SH-3000” Sorvall R©
Rotor “FA-45-24-11” Eppendorf
Rotor “FL 064-04053” Eppendorf
Vacuum centrifuge “Concentrator 5301” Eppendorf
Material and Equipment for Working with DNA
Gel Imaging Station Bio-Rad Laboratories
Gene PulserTM Bio-Rad Laboratories
PCR-Cycler “Mastercycler epgradient” Eppendorf
Power PacTM 1000 Bio-Rad Laboratories
Pulse controller Bio-Rad Laboratories
Material and Equipment for Working with Proteins
A-1010BTM arc lamp PTI R© - Photon Technology International
Amicon Ultra-15 centrifugal filter unit
(NMWL 30K)
MilliporeTM
BryteBox PTI R© - Photon Technology International
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1.0 mm cassettes for western blots InvitrogenTM Life Technologies
1.0 mm 10-well combs InvitrogenTM Life Technologies
Econo-Pac R© 10 DG disposable chroma-
tography columns
Bio-Rad Laboratories, Inc.
Fluorescence cuvettes (30 µl, 45 µl, 100
µl)
Hellma GmbH & Co. KG
Incubation box for western blots Li-Cor R© Biosciences
Incubator Shaker Series I26 New Brunswick Scientific
LPS-220B lamp power supply PTI R© - Photon Technology International
MD 5020 motor driver PTI R© - Photon Technology International
Nitrocellulose membrane Bio-Rad Laboratories, Inc.
Odyssey Infrared Imager Li-Cor R© Biosciences
Plate reader “Multiskan Askent” Thermo Scientific
814 photomultiplier detection system PTI R© - Photon Technology International
Power PacTM HC Bio-Rad Laboratories, Inc.
QuantaMasterTM fluorescent spectrome-
ter
PTI R© - Photon Technology International
Sonicator needle (MS 73) Bandelin Electronic GmbH & Co. KG
Sonicator
TCM-1000 control module PTI R© - Photon Technology International
Test tube rotator “34528” Snijders
UV-Cuvettes (1 ml) Sarstedt Aktiengesellschaft & Co.
96-well ELISA microplates Greiner Bio-One GmbH
XCell SureLockTM Mini-Cell InvitrogenTM Life Technologies
XCell IITM blot module InvitrogenTM Life Technologies
Material and Equipment for Working with Cells
Cell scraper BD FalconTM
Cryo vials
Easy GripTM tissue culture dish (60 mm) BD FalconTM
75 mm filter unit Nalge Nunc International
Glass pasteur pipettes (150 mm, 230 mm) Brand GmbH & Co. KG
4-well LabTek R© chambers No. 1.0 Nalge Nunc International
8-well LabTek R© chambers No. 1.0 Nalge Nunc International
NALGENE R© Cryo 1 ◦C freezing container Nalge Nunc International
35-mm MatTek petri dishes No. 1.5 MatTek Corporation
NUAIRETM Cellgard class II biological safety
cabinet
Integra Biosciences
T75 tissue culture flask BD FalconTM
Tissue culture plate (12 well) BD FalconTM
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Vacusafe comfort Integra Biosciences
Vi-CellTM XR cell viability analyzer Beckman Coulter, Inc.
General Material and Equipment
Eppendorf safe lock tubes (0.5 ml, 1.5 ml,
2.0 ml)
Eppendorf
Falcon tubes (15 ml, 50 ml) BD FalconTM
Heatable magnetic stirrer “IKAMAG R©
RCT”
IKA R© Labortechnik
Heating block “QBD4” Grant Instruments
Nanodrop R© ND-1000 spectrophotometer Peqlab Biotechnologie GmbH
Parafilm R© Pechiney Plastic Packaging
PFE powder-free latex exam gloves (M) Kimberly-Clark
Pipetboy acu Integra Biosciences
Safegrip R© nitril gloves (M) Su¨d-Laborbedarf GmbH
Sarstedt serological pipettes (5 ml, 10 ml,
25 ml)
Sarstedt Aktiengesellschaft & Co.
Scale “Precisa 62 A” Precisa Instruments AG
Scale “Precisa 620 C” Precisa Instruments AG
Scale “type 1574” Sartorius AG
Surgical disposable scalpel (No. 11, No.
21)
Braun Melsungen AG
Thermomixer comfort Eppendorf
“Vortex Genie 1” touch mixer Scientific Industries
2.1.10 Microscopes
“Axiovert 200 M” inverse fluorescence micro-
scope
Carl Zeiss MicroImaging GmbH
“CellR” Olympus
Compact lifetime and FCS upgrade kit for LSMs PicoQuant GmbH
“LSM510” Confocal laser scanning system Carl Zeiss MicroImaging GmbH
“E-665 LVPZ” controller/amplifier Physik Instrumente GmbH & Co.
KG
Fiber coupling unit PicoQuant GmbH
“FluoView FV1000” confocal laser scanning bi-
ological microscope
Olympus
“IU-LH75XEAPO” 75 W xenon APO lamp Olympus
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“IX 81” inverse microscope Olympus
“IX2-UCB” controlling unit Olympus
LIFA fluorescent lifetime signal generator Lambert Instruments
LI2CAM MD modulated intensified camera Lambert Instruments
“PR-IX2” motorised stage Olympus
“PZ 116E” computer interface and command in-
terpreter submodule for PZT controller
Physik Instrumente GmbH & Co.
KG
Scan Stage Olympus
“Sepia II” computer controlled multi-channel pi-
cosecond pulsed laser diode
PicoQuant GmbH
“U-HSTR2” hand switch Olympus
UPLSAPO 40x/0.9 NA Olympus
UPLSAPO 60xW/1.2 NA Olympus
“U-RFL-T” Olympus
2.1.11 Software
Adobe Illustrator Adobe Systems Inc.
BibDesk 1.5.3 http://bibdesk.sourceforge.net
FeliX32 PTI R© - Photon Technology International
FV10-ASW Fluoview Software Olympus
ImageJ 1.42 http://rsbweb.nih.gov/ij/index.html
LIFA software Lambert Instruments
Microsoft Excel 2003 Microsoft Corporation
MikTex 2.8 http://miktex.org/
MacPyMOL http://www.pymol.org/
SymPhoTime v5.12 PicoQuant GmbH
TeX Live 2009 http://www.uoregon.edu/ koch/texshop/
Vector NTI 10 InvitrogenTM Life Technologies
39
Material and Methods
2.2 Methods
2.2.1 Cloning
2.2.1.1 Bacterial Cultures
E. coli cells were grown in solution (LB + appropriate antibiotic) at 37 ◦C and 225 rpm
if not stated otherwise. Cultures of 4 ml LB medium were inoculated with a single clone
(colony) grown on agar plates. After 6-10 h, the pre-culture was used to inoculate the
desired volume of main culture.
2.2.1.2 Transformation of Chemically Competent E. coli
Transformation is defined as the non-viral introduction of foreign DNA in competent
bacterial cells and is used to amplify recombinant DNA. Chemical transformation of
bacteria usually has a transformation efficiency of 1 x 106-1 x 108 colonies/µg DNA.
50 µl chemically competent E. coli XL 10 Gold were incubated with 1.75 µl 2.25 mM
DTT and 0.1 µl plasmid DNA, or 2.5 -7.5 µl ligation mix, respectively, for 20-30 min on
ice. The transformation mix was heat shocked for 60 sec at 42 ◦C and placed back on
ice for 2 min. 250 µl of SOC medium were added and bacteria were allowed to recover
for 45-60 min at 37 ◦C, 225 rpm. 100 µl cell suspension were plated on LB agar plates
containing the required antibiotics and placed at 37 ◦C overnight or at RT over the
weekend, respectively.
2.2.1.3 Transformation of Electro-Competent E. coli
Electroporation is considered to be the gold standard for transformation of competent
bacteria as transformation efficiencies of up to 1 x 1010 colonies/µg DNA can be achieved.
Usually chemically competent cells were used for amplification of recombinant DNA.
Especially complicated or difficult cloning experiments were instead performed using
electro-competent XL10 Gold.
For electroporation 50 µl electro-competent E. coli XL 10 Gold were mixed with 50
µl ice-cold 10 % glycerol and 5.0 µl recombinant DNA on ice. The transformation mix
was transferred to a sterile, pre-cooled electroporation cuvette and exposed to an electric
field (1.3 V, 25 µF, 800 Ω) in the electroporation chamber. Time constants shown by
the device were always between 4 and 6 ms. Cells were transferred to a 15 ml Falcon
tube containing 950 µl SOC medium. Bacteria were allowed to recover for 45-60 min at
37 ◦C, 225 rpm. 100 µl of cell suspension were plated on LB agar plates containing the
required antibiotics and placed at 37 ◦C overnight.
2.2.1.4 Plasmid Preparation Using QIAprep R© Spin Miniprep Kit
The QIAprep R© Spin Miniprep Kit provides a fast (less than 30 min) and simple small-
scale plasmid preparation method for routine molecular biology applications. It is de-
signed for the purification of up to 20 µg high-copy plasmid DNA in sequencing quality.
The procedure is based on alkaline lysis of bacterial cells and the subsequent absorption
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of the plasmid DNA onto a patented silica membrane in the presence of high salt con-
centrations. Plasmid DNA can then be eluted from the membrane with a low-salt buffer
or ddH2O.
Plasmid DNA was prepared according to the QIAprep R© Miniprep Handbook. Bacte-
rial cultures were grown overnight in 4 ml LB medium supplemented with the appropriate
antibiotics at 37 ◦C, 225 rpm. Cell suspensions were transferred to 2 ml Eppendorf tubes
and sequentially centrifuged for 3 min at 6,800 x g, RT. Plasmid DNA was eluted by
adding 30 µl ddH2O to the centre of the spin column and subsequent centrifugation for
1 min at 16,100 x g, RT.
2.2.1.5 Endotoxin-Free Plasmid DNA Preparation Using NucleoBond R© Xtra Maxi
EF Kit
For transfection of mammalian cells (see 2.2.4.3), endotoxin-free plasmid DNA was pre-
pared on a large scale.
The outer sheet of the outer membrane that encloses the inner membrane and cell wall
of Gram-negative bacteria consists of amphiphilic lipopolysaccharides, also called endo-
toxins. Bacterial cells release endotoxins in small amounts during cell growth and large
amounts upon cell death and lysis. In mammalian cell culture, endotoxins can seriously
affect transfection rates and cell viability. Due to their amphiphilic nature and negative
charge, endotoxins can be co-purified with many common plasmid purification systems.
The NucleoBond R© Xtra Maxi EF Kit provides a fast and highly efficient method for
the preparation of endotoxin-free plasmid DNA. It is designed for purification of up to
1000 µg high-copy plasmid DNA.
Endotoxin-free plasmid DNA was prepared according to the NucleoBond R© Xtra Maxi
EF Kit user manual. 300 ml bacterial cultures were inoculated with 4 ml pre-culture in
LB medium supplemented with the appropriate antibiotics and grown overnight at 37
◦C, 225 rpm. Cells were harvested by centrifugation at 4500 x g, 4 ◦C for 20 min.
Endotoxin-free plasmid DNA was eluted from NucleoBond R© finalizers twice with the
same 500 µl buffer TE-EF. To increase yield the finalizer was washed once more with
250 µl buffer TE-EF and the eluate added to the previous one.
2.2.1.6 Agarose Gel Electrophoresis of dsDNA
Agarose gel electrophoresis is used to separate nucleic acid fragments by their size. Poly-
merised agarose in gels forms pores with sizes depending on the agarose concentration.
Due to their negative charge, nucleic acids migrate in electric fields to the anode and
the smaller the fragment, the faster it migrates.
DNA molecules were electrophoretically separated on agarose gels prepared with 1x
TAE buffer supplemented with 2 µl ethidium bromide (EtBr)/50 ml gel. EtBr can be
used to visualise dsDNA in agarose gels because it intercalates into double stranded
DNA molecules and emits orange light of λ = 590 nm when excited with UV light at
λ = 312 nm. 1x TAE buffer was used as running buffer. Electrophoresis took place at
a constant voltage of 120 V for about 20 min. Samples were prepared by mixing DNA
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with the appropriate amount of loading buffer and ddH2O to a final volume as small as
possible. For size estimation of dsDNA fragments, a DNA-marker with different bands
of known sizes was added in one lane of the gel. The concentration of the agarose gel
was chosen according to the size of the DNA molecules in question:
Agarose concentration in % (w/v) Size of dsDNA molecules
2.5 < 100 bp
2.0 0.1 - 1.0 kb
1.8 0.2 - 2.0 kb
1.5 0.3 - 3.0 kb
1.2 0.5 - 5.0 kb
1.0 0.5 - 7.0 kb
0.8 0.8 - 12.0 kb
0.5 1.0 - 30.0 kb
2.2.1.7 Isolation of DNA from Agarose Gels Using QIAquick R© Gel Extraction Kit
The QIAquick R©Gel Extraction Kit is a simple and fast method to purify DNA fragments
in a range of 70 bp to 10 kb from agarose gels. The procedure is based on DNA binding
to a silica membrane in the presence of high salt concentrations, while contaminants are
washed through the column. DNA fragments to be isolated were excised from the agarose
gel, transferred to a 2 ml Eppendorf tube and purified according to the manufacturer’s
manual.
2.2.1.8 Purification of DNA Using QIAquick R© PCR Purification Kit
The QIAquick R© PCR Purification Kit is designed for the fast purification of DNA
fragments in a range of 100 bp to 10 kb from PCR or enzymatic reactions. Similar
to the QIAquick R© Gel Extraction Kit, the purification of PCR products is based on
DNA binding to a silica membrane in the presence of high salt concentrations, while
contaminants are washed through the column, and was performed according to the
manufacturer’s manual.
2.2.1.9 Restriction Digest
Restriction endonucleases type II bind to specific DNA sequences called “restriction
sites”. They catalyse the hydrolysis of 3’→5’-phosphodiesterbonds in each DNA-strand
and thereby the formation of a double strand break. Restriction digests were used for
the control of cloning experiments as well as to linearise vector DNA and to create DNA
fragments with sticky ends for ligation.
To completely digest y µg of dsDNA in 1 h at a certain restriction site, the DNA was
mixed with 1/10 of an enzyme-specific 10x reaction buffer, 1/10 10x BSA if necessary
and excess restriction enzyme and the reaction replenished with ddH2O to a final volume
of x µl (which was kept as small as possible). Reactions were incubated at least 1 h at
37 ◦C to achieve complete digestion.
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2.2.1.10 Dephosphorylation of 5’-Phosphorylated DNA Fragments
To prevent self-ligation of vector DNA during the ligation of two DNA fragments, the
5’-phosphorylated ends of the digested vector DNA were dephosphorylated with alkaline
phosphatase (shrimp alkaline phosphatase, CIP). The DNA fragment was mixed with
1/10 of the 10x NEB reaction buffer 3, 0.5 U CIP/µg DNA and the reaction mix was
replenished with ddH2O to a final volume of x µl. Reactions were incubated at least 1
h at 37 ◦C to achieve complete digestion and the DNA subsequently purified using the
QIAquick R© PCR Purification Kit.
2.2.1.11 Ligation of dsDNA Fragments
In DNA ligation, DNA ligase catalyses the formation of a 3’→5’-phosphodiester bond
between the free 3’-hydroxyl- and the 5’-phosphate group of linear DNA fragments while
consuming ATP. Usually 100 ng vector DNA were ligated with a three-fold molar excess
of insert DNA ends. The required amount of insert was calculated according to the
following formula:
Amount insert [in ng] =
amount vector [in ng] x insert size [in bp]
vector size [in bp]
The appropriate amounts of vector and insert DNA were supplemented with 10 µl 2x
Quick Ligation Reaction Buffer and 1 U Quick T4 DNA Ligase and replenished with
ddH2O to a final volume of 20 µl. The reaction was incubated at RT for 5-15 min and
then transformed into competent E. coli XL 10 Gold.
2.2.1.12 TOPO R©-Blunt Cloning
Zero Blunt R© TOPO R© PCR cloning is a highly efficient, fast, one-step cloning procedure
for the insertion of blunt-end PCR products into a cloning vector. The pCR R©-Blunt II-
TOPO R© cloning vector is a linearised plasmid vector with the Vaccinia virus DNA
topoisomerase I covalently bound to the 3’-end of each DNA strand. Topoisomerase I
binds to specific sites in dsDNA and cleaves its phosphodiester backbone while conserving
the energy by formation of a covalent bond between the 3’-phosphate of the cleaved
strand and a tyrosyl residue of topoisomerase I. As this reaction is reversible, the stored
energy of the phosphodiester backbone cleavage can be used to form a new covalent
bond between the 5’-hydroxyl of a blunt-end PCR product and the 3’-phosphate of the
vector DNA, thereby releasing the enzyme. The Zero Blunt R© TOPO R© PCR cloning kit
was used as a cloning vector system to save and store PCR products and to provide an
efficient dsDNA basis for subcloning of defined DNA fragments.
For Zero Blunt R© TOPO R© PCR cloning, 4 µl blunt-end PCR product were mixed with
1µl of the included salt solution and 1 µl pCR R©-Blunt II-TOPO R© cloning vector, gently
mixed, incubated 5-15 min, RT, and then placed on ice. Finally, 2 µl of the TOPO R©
cloning reaction were transformed into chemically competent E. coli One Shot R© TOP10.
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2.2.2 Polymerase Chain Reaction (PCR)
2.2.2.1 Amplification of dsDNA Fragments by PCR
The polymerase chain reaction (PCR) can be used to amplify specific DNA sequences
exponentially and is based on repeated cycles of enzymatic, in-vitro DNA synthesis of the
target sequence. Two oligonucleotide primers direct the specific amplification of target
DNA sequences by DNA polymerase. The primers flank the DNA sequence of interest and
can hybridise to their complementary sequence on opposite DNA single strands. Double
stranded DNA molecules are separated into single strands by heat denaturation, enabling
hybridisation of the primers to the single stranded DNA molecules at temperatures of
45-60 ◦C. Excess primer concentrations in the reaction ensure that formation of primer-
template complexes is in favour of renaturation of DNA single strands. Heat-stable DNA
polymerases elongate primers at an intermediary temperature as an exact copy of the
original template and enabling repeated cycling of PCR without the need to add more
enzyme. Since this process takes place at both DNA single strands, one cycle doubles
the target DNA sequence. Cycle repetition leads to the exponential amplification of the
target sequence as every dsDNA molecule synthesised in a previous cycle can serve as a
template in the following cycles (Saiki et al., 1988; Mu¨lhardt, 2003).
Platinum R© Pfx DNA polymerase was used for standard PCR. Pfx polymerase is a
recombinant DNA polymerase isolated from Thermococcus sp. and provides high fidelity
(approx. one mistake every 106 bases) because of its proofreading activity (3’→5’ exo-
nuclease activity). PCR was performed in 50 µl reaction volumes. The desired amount
of template DNA was mixed with 5.0 µl 10x reaction buffer, 1.5 µl of a 2 mM dNTP
mix, 1.0 µl 50 mM MgSO4, 1.5 µl of 10 mM forward primer, 1.5 µl of 10 mM reverse
primer and 2.5 U Platinum R© Pfx DNA polymerase and replenished with ddH2O to the
final volume.
Platinum R© Pfx DNA polymerase is provided in inactive form, due to specific binding
of the Platinum R© antibody. Polymerase activity is restored by an initial denaturation
step at 94 ◦C for 2 min, leading to an “automatic hot start” that increases specificity,
sensitivity and yield of the PCR reaction. PCR consisted of 30-32 PCR amplification
cycles, formed by denaturation at 94 ◦C for 30 sec, primer annealing at the appropriate
annealing temperature for 30 sec and elongation at 68 ◦C for 1 min per kb. The last
PCR cycle was followed by an additional 5 min at 68 ◦C for elongation of unfinished
PCR fragments before the reaction was cooled to 8 ◦C. PCR products were analysed by
agarose gel electrophoresis.
For problematic and/or GC-rich templates, PCRx Enhancer Solution was added to
the reaction as recommended by the manufacturer’s manual.
2.2.2.2 In-Vitro Site-Directed Mutagenesis
In-vitro site-directed mutagenesis is used to introduce point mutations and/or exchange,
delete or insert single or a limited number of amino acids in protein sequences of interest.
The procedure uses plasmid DNA and a set of two synthetic, complementary oligonuc-
leotide primers encoding for the region to be mutated including the desired mutation.
44
Material and Methods
The oligonucleotide primers bind to their complementary sequences on opposite strands
of the vector and are amplified by PCR which generates a mutated plasmid contai-
ning staggered single strand breaks. Following PCR, parental vector DNA is digested
by type II endonuclease DpnI (target sequence: 5’-Gm6ATC-3’), specific for methylated
and hemimethylated DNA. DNA isolated from most E. coli strains is dam-methylated
and therefore susceptible for DpnI digestion. Digested mutated PCR products are trans-
formed into competent E. coli. Bacteria repair the single strand breaks, producing a
functional, mutated plasmid. Mutants can be generated with efficiencies greater than 80
%.
One set of mutagenic oligonucleotide primers contained the desired mutation and
annealed to the same sequence but on opposite strands of the template DNA. The
desired mutation was approximately in the middle of the primer with 15-25 nucleotides
of correct sequence on both sides. Primers always ended with one or more C- or G-bases.
For mutagenesis 125 ng of each primer were used. To convert nanograms to picomoles,
the following formula was used:
X pmol of oligo = (ng primer x 1000)/(330 x number of oligo bases)
For mutagenesis PCR either Platinum R© Pfx DNA polymerase of PfuUltra High-
Fidelity DNA polymerase were used as suggested by the respective manufacturer. Mu-
tation PCR was performed in 50 µl reaction volumes. 50 ng plasmid DNA was mixed
with 5.0 µl of the respective 10x reaction buffer, 2.0 µl of a 2 mM dNTP mix, 1.0 µl 50
mM MgSO4 (only for Platinum R© Pfx DNA polymerase), the appropriate amounts of
primer and 2.5 U DNA polymerase and replenished with ddH2O to the final volume.
PCR reactions were started by initial denaturation of template DNA and activation of
DNA polymerase as recommended by the manufacturer, followed by 25-32 PCR ampli-
fication cycles of denaturation at the enzyme’s specific denaturation temperature for 30
sec, primer annealing at 55 ◦C for 30 sec and elongation at the appropriate temperature
for 1 min per kb. Final elongation for 7 min was followed by cooling to 8 ◦C.
PCR products were digested with 1.0 µl DpnI (10 U/µl) for 60 to 120 min at 37 ◦C
and 2.5 µl of digested PCR product were transformed into chemically competent E. coli
as described in 2.2.1.2. If possible, the mutated DNA sequence of the gene of interest was
subcloned into the same position of the parental vector to eliminate potential mutations
introduced by PCR.
2.2.2.3 Directed Mutagenesis of dsDNA by PCR
PCR can also be used to introduce, delete, exchange or insert larger numbers of amino
acids into a protein sequence of interest, a technique, here referred to as directed mu-
tagenesis of dsDNA by PCR. The method is based on amplification of plasmid DNA
by PCR using a set of two synthetic mutagenic oligonucleotide primers encoding for
amino acids to be inserted or exchanged. The 3’-end of each primer encodes for 15-25
nucleotides of opposite strands of the original gene directly adjacent to the desired muta-
tion. Their 5’-end harbours one of two halves of the mutation to be introduced. Primers
should always end with one or more C- or G-bases. The oligonucleotide primers bind
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to their complementary sequences on opposite strands of the vector and vector DNA is
then amplified by PCR. A linear, blunt end DNA molecule is generated encoding for
the entire plasmid with the mutations on its 3’- and 5’-ends, each encoding for a part of
the polypeptide to be introduced. The length of the introduced polypeptide stretch is
limited by the length of oligonucleotide primers that can be synthesised. For deletion of
any number of amino acids the respective nucleotide sequence can be excluded from the
amplified plasmid regions. After generation of linear, mutated, blunt-end plasmid DNA
encoding for the mutant protein of interest, parental DNA is digested by DpnI. Blunt
ends are then ligated and transformed into competent E. coli.
For mutagenesis PCR, either Platinum R© Pfx DNA polymerase of Pfu polymerase were
used as recommended by the respective manufacturer. Mutation PCR was performed in
conditions as described in 2.2.2.2.
PCR products were digested with 1 µl DpnI (10 U/µl) for 60 to 120 min at 37 ◦C and
purified using the QIAquick R© PCR Purification Kit. 100 ng of the digested and purified
PCR product were then ligated as described in 2.2.1.11 and transformed into competent
E. coli XL 10 Gold. If possible, the mutated DNA sequence of the gene of interest was
subcloned in the same position of the parental vector to eliminate mutations introduced
by PCR.
2.2.2.4 Two-Step Fusion PCR
Two step fusion PCR was used to create mutant DNA molecules that were too long to
be synthesised synthetically on oligonucleotide primers. First, the two fragments to be
linked were amplified separately. Here, primers for the 3’-end of the N-terminal part of
the final protein were designed such that sequences at the 3’-end of the primer had a
sequence overlapping with the 5’-end of the primer starting the C-terminal part of the
final protein. Both PCR products from the first amplification step were then fused in
a second standard PCR by amplification of both fragments in the same reaction using
the 5’- and 3’- end primers for the N- and C-terminal parts of the final fusion protein,
respectively. The overlapping sequence in both DNA fragments allows the annealing
of the two separate fragments. Using the flanking primer set from the first PCR step,
DNA polymerases can synthesise the gap from the 5’- end primer of leading and lagging
strand to the annealed second DNA fragment, thereby amplifying the whole construct.
For the second PCR, fragments encoding N- and C-terminal parts of the final protein
were adjusted to equimolar concentrations. Fused DNA constructs were cloned into the
pCR R©-Blunt II-TOPO R© vector and their identity confirmed by sequencing.
2.2.2.5 DNA Sequencing
Sequencing of dsDNA was performed according to the dideoxy chain terminating method
(Sanger et al., 1992). The used variant utilises fluorescently labelled 2’,3’-dideoxy-nuc-
leotides (ddNTPs) in addition to 2’-deoxynucleotides (dNTPs), that cannot be used to
form new phosphodiester-bonds due to the missing 3’-OH group and therefore lead to the
termination of the synthesised DNA strand after insertion of a ddNTP. The fluorescent
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ddNTP indicating the last incorporated nucleotide can then be detected by capillary
gel electrophoresis. Capillary gel electrophoresis was done by the Zentrale Einrichtung
Biotechnologie at the Max-Planck-Institute for Molecular Physiology, Dortmund.
Sequencing PCRs were performed using the BigDye R© Terminator v3.1 Cycle Sequen-
cing Kit. 150-300 ng plasmid DNA, 4.0 µl ready reaction premix, 2.0 µl BigDye R© se-
quencing buffer and 2.0 µl primer (20 pmol/µl) were replenished with ddH2O to a final
volume of 20 µl. After initial denaturation at 96 ◦C for 1 min, PCR cycles consisted of
denaturation at 96 ◦C for 10 sec, 5 sec annealing at 50 ◦C and elongation at 60 ◦C for 4
min. Cycle number was 25 and finished PCR reactions were cooled to 4◦C until further
treatment.
Excess ddNTPs were removed from finished sequencing reactions with the DyeEx R©
2.0 Spin kit according to the manufacturer’s manual and transferred to new 0.5 ml
Eppendorf tubes. Purified reactions were dried in a vacuum centrifuge and then sent for
capillary gel electrophoresis.
2.2.3 Protein Analytics
2.2.3.1 Expression and Purification of Fluorescently Tagged MAPKs
The fluorescently tagged mammalian MAPK ERK2 and ERK2 mutants were expressed
in E. coli and subsequently purified for in-vitro studies.
The expression plasmid encoding fluorescently tagged ERK2 or ERK2 mutants were
transformed into RosettaTM2(DE3) SinglesTM competent E. coli as recommended by the
manufacturer and plated on LB agar plates supplemented with 100 µg/ml Ampicillin
(LB/Amp). Pre-cultures of 15 ml LB/Amp medium were inoculated with a single colony
and incubated overnight at 37 ◦C, 225 rpm. Main cultures were set up by diluting the
pre-culture 1:50 in LB/Amp to yield 500 ml of culture and then incubated for 2 - 4
h at 37 ◦C, 225 rpm until the OD reached 0.5 - 0.6. Protein expression was induced
by addition of IPTG to a final concentration of 0.5 mM IPTG and cells were grown
overnight at 15 ◦C, 225 rpm before being harvested by centrifugation at 4,500 x g for 20
min, 4 ◦C. Samples were snap-frozen in liquid nitrogen and stored at -20 ◦C.
2 ml of Ni-NTA His•Bind R© resin were equilibrated with 5 ml ERK2 wash buffer by
incubation in a 50 ml Falcon tube at RT for 5 min, gentle centrifugation and removal
of the supernatant. Bacterial pellets were resuspended in 7.5 ml lysis buffer, sonicated
(3x 30 sec, 40 % power) and cell suspensions were centrifuged for 20 min at 4,500 x
g, 4 ◦C. Supernatants were filtered through an empty Econo-Pac R© 10 DG disposable
chromatography column into the 50 ml Falcon tube containing the equilibrated Ni-NTA
His•Bind R© resin. Protein solutions were incubated with the Ni-NTA His•Bind R© resin
for 1 h at 4 ◦C on a rotational shaker and then loaded on an Econo-Pac R© 10 DG
disposable chromatography column. Columns were allowed to empty by gravity flow
and washed three times with one column volume ERK2 wash buffer. The protein was
then eluted from the resin by repeated addition of one gel volume ERK2 elution buffer.
Flow-through of wash and elution steps was collected in 1 ml fractions.
Eluted fractions containing fluorescently tagged ERK2 as observed by eye were pooled
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and applied to an Amicon Ultra-15 centrifugal filter unit with a nominal molecular weight
limit of 30 kDa. 2 to 5 ml ERK2 storage buffer were added and solutions centrifuged
for 10 to 20 min until they were concentrated to a volume of approximately 500 µl.
Storage buffer addition and centrifugation were repeated three times and purified protein
transferred to a new 1.5 ml Eppendorf tube. Protein concentrations in the solution were
estimated by the micro BCA assay method as described in 2.2.3.7, samples aliquoted in
100 µl fractions, snap-frozen in liquid nitrogen and stored at -80 ◦C.
2.2.3.2 In-Vitro Phosphorylation of Purified MAPKs
Purified ERK2 proteins were autophosphorylated or phosphorylated in-vitro by incuba-
tion with commercially available active MEK1 for further use in substrate phosphoryla-
tion experiments and in-vitro ES-imaging experiments.
In-vitro phosphorylation was performed in a modified version of a protocol published
by (Shapiro et al., 1998). Briefly, reactions contained 25 mM HEPES (pH 7.4), 10 mM
MgCl2, 1 mM DTT, 1 mM ATP, 0.1 µg active MEK1 if necessary and 1 µg purified
ERK2 in a final volume of 50 µl and were incubated for 1 h at 30 ◦C. Samples were
placed on ice until further use.
2.2.3.3 In-Vitro Phosphorylation of ERK2 Substrate Peptide
In-vitro phosphorylation of ERK2 substrate peptide was performed in a modified version
of a protocol published by (Shapiro et al., 1998) as described in 2.2.3.2. ERK2 substrate
peptide was added to a final concentration 50 µM. Samples were incubated for 1 h at 30
◦C and then placed on ice until further use.
2.2.3.4 In-Vitro ES-Interaction Spectroscopy
In-vitro ES-interaction spectroscopy was performed in reaction conditions as described in
2.2.3.2. ES-interactions were determined in time-based experiments with fixed excitation
(λ = 516 nm) and emission wavelength (λ = 529 nm). Emission intensity was measured
as a function of time. 50 µl of the ERK2 phosphorylation reaction were transferred
into a fluorescent cuvette and placed into the sample chamber of the PTI fluorescent
spectrometer. Spectroscopic measurements were taken for a few minutes to record a
baseline. Data acquisition was paused and fluorescently labeled ERK2 substrate peptide
was added in different concentrations as indicated. Data acquisition was continued as
quickly as possible. Data were exported in text format and imported to Excel for further
analysis.
Normalised fluorescence donor emission values were corrected for the intensity
decrease generated by the dilution effect arising from substrate addition. The average
difference in normalised fluorescence donor emission values of negative controls before
and after substrate addition was determined. The obtained value was added to fluore-
scence values after substrate addition in all samples.
48
Material and Methods
Alternatively, ES-interaction spectroscopy was performed as emission scan experi-
ments with a fixed excitation wavelength of (λ = 480 nm) while the emission spectrum
was measured from λ = 485 nm to λ = 700 nm. The emission intensity was measured
as a function of excitation wavelength. 50 µl of ERK2 phosphorylation reaction were
mixed with increasing substrate concentrations, transferred into a fluorescent cuvette
and spectroscopic measurements were taken with the PTI fluorescent spectrometer. Data
were exported in text format and imported to Excel for further analysis.
Recorded emission spectra were normalised according to the following formula: nFi =
(λiFi)/
∑
(λiFi), with nFi as the normalised fluorescence intensity at each wavelength,
λi as the wavelength measured and Fi as the fluorescence intensity at each wavelength.
2.2.3.5 In-Vitro Fluorescent Lifetime Spectroscopy
In-vitro fluorescent lifetime spectroscopy was performed in reaction conditions as de-
scribed in 2.2.3.2 using a commercial frequency-domain fluorescent lifetime microscope
(Lambert Instruments/Olympus). Reference measurements of Alexa488 and sample
recordings were basically performed as suggested by the manufacturer’s manual using
a 40x water objective. mCitrine was excited with a 493 nm LED. Emission intensity
was measured as a function of time. 50 µl of phosphorylated ERK2 (see 2.2.3.2) were
placed in an 8-well LabTek chamber and the LabTek chamber mounted onto the sam-
ple holder of the Olympus IX 81 inverse microscope. The focus was adjusted to regions
with maximum light intensity of the solution. Measurements were taken every 30 sec.
Fluorescently labeled peptides were added in the indicated concentrations directly after
a baseline recording.
2.2.3.6 Preparation of Whole Cell Lysates
Whole cell lysates for protein analysis in western blots were prepared from mammalian
cells cultivated in 60-mm Easy GripTM tissue culture dishes. Cells were washed once
with ice-cold PBS and harvested immediately after the addition of ice-cold 1x cell lysis
buffer (1 ml 10x Cell Lysis Buffer, 1 tablet Complete Mini EDTA-free protease inhibitor
and 100 µl phosphatase inhibitor cocktail 1 and 2). Lysates were transferred to 1.5 ml
Eppendorf tubes, incubated for 3 min on ice and snap-frozen in liquid nitrogen. Samples
were thawed on ice and centrifuged for 5 min at 16,100 x g, 4 ◦C to remove cell debris.
The supernatant was transferred to new 1.5 ml Eppendorf tubes and stored at -20 ◦C.
Cells and cell lysates were kept on ice during all steps of the procedure starting from
washing with PBS to avoid degradation of proteins.
2.2.3.7 Estimation of Protein Concentrations Using the Micro BCA Assay
For determination of protein concentrations in cell extracts the BCA protein assay was
used. The BCA assay is compatible with many detergents that may be present in buffers
used. The assay is based on reduction of Cu2+-ions by proteins in an alkaline environment
forming Cu+, which can then form a purple-coloured complex with bicinchonic acid
(BCA) with an absorbance maximum at λ = 562 nm.
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The assay was performed in 96-well plates what allows analysis of multiple protein
samples and requires only small sample volumes. The micro BCA working reagent was
prepared by mixing 25 parts reagent A with 24 parts reagent B and one part reagent C to
yield a volume that is a product of 150 µl. Protein standards were prepared by diluting
a BSA standard in the appropriate sample buffer to concentrations from 0.5 to 10 µg/µl.
5 µl of each protein standard were added to separate wells of a 96-well plate using the
appropriate sample buffer as blank. Unknown protein samples were diluted to have an
approximate concentration 0.5 to 10 µg/µl. All samples were set up as triplicates. Wells
were complemented with 150 µl micro BCA working reagent and samples incubated for
2 h at 37 ◦C. 96-well plates were cooled to RT and absorbance was measured at λ =
562 nm. Obtained absorbance values were plotted against protein concentrations of each
standard. Protein concentrations of the unknown samples were determined by comparing
their absorbance values at λ = 562 nm against the standard curve.
2.2.3.8 Denaturing Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Denaturing SDS-PAGE is used to separate proteins according to their size in a discontin-
uous polyacrylamide gel. SDS is an anionic detergent that binds to proteins in amounts
proportional to their size (approx. one molecule SDS per two amino acid residues) and
breaks physiological protein folding. Therefore proteins bound to SDS display a similar
charge/size ratio. Due to this negative charge the denatured proteins migrate to the
positive pole when subjected to an electric field. When this electric field applied to a
discontinuous polyacrylamide gel, smaller polypeptide chains migrate faster depending
on the pore size formed by polymerised acrylamide.
The acrylamide concentration of the separating gel was adjusted to the molecular
weight of the protein of interest to be either 10 or 12 % (v/v), respectively. Separating
gels were poured into 1.0 mm western blot cassettes according to the following recipe
(volumes produced one gel):
10 % Gel 12 % Gel
Acrylamide 2.08 ml 2.50 ml
Separating Gel Buffer 2.35 ml 2.35 ml
10 % SDS (w/v) 62.5 µl 62.5 µl
50 % Sucrose (w/v) 1.0 ml 1.0 ml
ddH2O 0.6 ml 176 µl
TEMED 5 µl 5 µl
10 % APS (w/v) 150 µl 150 µl
Immediately after pouring, separating gels were overlaid with 1 ml ddH2O and the
acrylamide allowed to polymerise for 15 to 45 min. Stacking gels were poured on top of
the separating gels, consisting of 0.835 ml acrylamide, 2.1 ml stacking gel buffer, 62.5
µl 10 % SDS, 2.82 ml ddH2O, 6.25 µl TEMED and 0.5 ml 10 % APS. 10-well combs
were inserted into the stacking gel directly after pouring to allow the formation of sample
pockets. Gels could be stored overnight at 4 ◦C when wrapped in paper towels humidified
with ddH2O and protected from drying by a plastic bag.
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Whole cell lysates were centrifuged for 1 min at 16,100 x g, 4 ◦C to remove cell
debris and other aggregates. Samples were prepared by mixing the appropriate amount
of whole cell lysate with 5 µl 5x SDS sample buffer and ddH2O to a final volume of 25
µl. Samples were incubated for 5 min at 95 ◦C to denature proteins by heat and enable
their reduction by 2-mercapto-ethanol and the association with SDS. Samples were then
incubated for 2 min on ice, centrifuged briefly to remove condensed water from the lid
and placed back on ice until further use.
For electrophoresis, gels were inserted into XCell SureLockTM Mini-Cell gel cham-
bers, gel chambers assembled and filled with 1x SDS running buffer according to the
manufacturer’s manual. Sample pockets were washed with running buffer and loaded
with the prepared samples. For size determination of separated proteins, 10 µl Precision
Plus ProteinTM Standard containing different bands of known molecular weight were
loaded in one well. Electrophoresis was performed with constant voltage of 80 V until
the samples reached the separating gel and 150 V for approximately 90 min.
2.2.3.9 Western Blotting
In western blotting (immuno-blotting) proteins separated during discontinuous, denatu-
ring SDS-PAGE are electrophoretically transferred to a positively charged nitrocellulose
membrane to enable immunological detection by antibody binding.
After electrophoresis blots were assembled in XCell IITM blot modules according to
the manufacturer’s manual and placed in XCell SureLockTM Mini-Cell gel chambers.
Blot module were filled with 1x transfer buffer and gel chambers with approximately
600 ml ddH2O. Proteins were blotted on nitrocellulose membrane (90 x 70 mm) for 60
min at a constant voltage of 30 V.
Before immunological detection of proteins membranes were transferred from blotting
modules to Li-Cor R© incubation boxes for western blotting and the remaining binding
sites of the membrane blocked with Odyssey infrared imaging system blocking buffer
(Li-Cor R© Biosciences) for either 1 h, RT, or overnight at 4 ◦C. Membranes were then
incubated with primary antibodies raised in different species, diluted in 5 ml Odyssey
infrared imaging system blocking buffer according to the manufacturer’s recommenda-
tions for either 1 h, RT, or overnight at 4 ◦C. Blots were washed three times, 5 min each
with a 1:1 mixture of 1x TBST and blocking buffer for near infra-red fluorescent western
blotting (Rockland Inc.) and incubated with secondary antibodies of different colours,
diluted 1:15,000 (green labeled secondary antibodies) or 1:7,500 (red labeled secondary
antibodies) in 5 ml Odyssey infrared imaging system blocking buffer for 1 h, RT. Li-Cor R©
incubation boxes protected the fluorescent secondary antibodies from light. Finally, blots
were washed three times, 5 min each with a 1:1 mixture of 1x TBST and blocking buffer
for near infrared fluorescent western blotting. Antigen-antibody complexes were detected
with the Odyssey Imaging System.
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2.2.3.10 In-Vivo-Labeling of Proteins Inside Living Cells with Biarsenical
Fluorophores
Cells plated in 4-well LabTek R© chambers and expressing tetracysteine-tagged proteins
were incubated for 45 - 60 min with µM ReAsH in 250 µl OptiMEM. ReAsH concen-
tration was chosen to be in the middle of the range recommended by the manufacturer.
Cells were washed twice with 250 µM BAL buffer in OptiMEM for 15 min each before
further treatment.
Alternatively, cells in 250 µl starvation medium were incubated with the desired con-
centration of ReAsH pre-diluted in 250 µl starvation medium and proceeded to imaging
without washing.
2.2.4 Mammalian Cell Culture
Cos7, HeLa and MDA cells were maintained in Dulbecco’s Modified Eagle’s Medium
(DMEM) supplemented with 10 % fetal bovine serum (FBS) and 1 % glutamine. MCF-7
cells were grown in DMEM supplemented with 10 % FBS, 1 % glutamine and 0.01 mg
Insulin/ml. All cells were grown at 37 ◦C in a 90 % humidified incubator with 5 % CO2.
Medium was changed every two days to maintain appropriate growth conditions. Cells
were starved in DMEM/0.5 % FCS/1 % glutamine.
2.2.4.1 Subculture of Mammalian Cells
When exponentially growing cells become confluent, i.e. they reach a density when all
available substrate of the culture dish or flask is occupied, their growth is usually in-
hibited by contact inhibition (change of cell growth from log-phase to a plateau phase).
Therefore cultured cells need to be split before they reach confluency.
80-90 % confluent cells were washed once with PBS and trypsinised for approximately
5 min at 37 ◦C. Detached cells were washed off the surface with 10 ml growth medium
to inactivate trypsin and gently pipetted up and down 10-20 times to disperse cells to
a single cell suspension. For maintenance of cell lines, cells were split in ratios of 1:8 to
1:15 into new cell culture flasks depending on the needs of the experiment. Alternatively,
cell number per ml cell suspension was determined using the Vi-CellTM XR cell viability
analyzer and the desired number of cells was seeded into cell culture dishes for further
experiments.
2.2.4.2 Cryo-Conservation and Long-Term Storage of Cell Lines
Cryo-conservation is the long time storage of cells, cell lines or whole tissues to sub-
zero temperatures below -80 ◦C. For maximal viability of stored material after cryo-
preservation the use of cryo-preservatives such as DMSO or glycerin is inevitable as
intracellular ice crystal formation and regional formation of high-concentration solutes
could greatly reduce cell viability.
Sub-confluent cells from a T75 tissue culture flask were split as described above,
counted and diluted to a concentration of 1 x 106 to 1.5 x 106 cells/ml in cryo-medium
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(70 % normal growth medium, 20 % FBS, 10 % DMSO). Cells were then aliquoted
into cryo-vials and transferred to a room temperature NALGENE R© Cryo 1 ◦C freezing
container. This container is filled with room temperature isopropanol and allows for a
controlled freezing rate of 1 ◦C per minute to avoid damage of cells by the freezing pro-
cess. The freezing container was placed into an -80 ◦C freezer overnight and individual
vials were then transferred to a liquid nitrogen tank for long-term storage.
Cell thawing was done as quick as possible to avoid toxic effects of the cryo-preservative
and thereby loss of cell viability. Cells were transferred from the liquid nitrogen tank to a
37 ◦C water bath and the cell suspension quickly diluted in 10 ml growth medium. Cells
were pelleted by centrifugation at 200 x g for 5 min, resuspended in 10-12 ml growth
medium and seeded into a new T75 flask.
2.2.4.3 Transfection with DNA
Transfection is defined as the artificial introduction of genetic material or nucleic acids
into higher eukaryotic cells by non-viral means. There are numerous methods, protocols
and variants as well as transfection reagents to transfect cells, ranging from classical
calciumphosphate co-precipitation to electroporation. In this study, all cells were trans-
fected with endotoxin-free plasmid DNA via lipofection, the introduction of DNA into
higher eukaryotic cells by fusion of DNA loaded lipidic micells with their plasma mem-
brane. The transfection reagent used was Fugene R© 6, a multi-component reagent that
forms complexes with DNA and displays high transfection efficiency in many different
cell types, virtually no cytotoxicity and can be used with or without serum present in
the medium.
Cells were either plated in 60-mm Easy GripTM tissue culture dishes, 35-mm MatTek
petri dishes or 4-well LabTek R© chambers as specified. They usually were transfected di-
rectly after passaging while plating them into the vessel chosen for a specific experiment.
Fugene R© 6 reagent-DNA ratios of 3:1 have been used in all experiments.
For transfection of cells in 35-mm MatTek dishes, 3.0 µl Fugene R© 6 reagent were
diluted in 100 µl serum-free DMEM and incubated for 5 min, RT. 1.0 µg plasmid DNA
was added, the solution mixed and incubated for 15-30 min, RT. During incubation 2 x
105 cells per dish were plated in 2 ml full growth medium (1 x 105 cells/ml). 100 µl of
Fugene R© 6 reagent-DNA complex were added to the cells drop-wise and culture vessels
swirled to ensure distribution over the entire surface. Cells were incubated at 37 ◦C in a
90 % humidified incubator with 5 % CO2 until further treatment. For transfection of cell
culture vessels other than 35-mm MatTek dishes, amounts of Fugene R© 6 reagent, DNA
and DMEM were adjusted accordingly (e.g. doubled for 60-mm tissue culture dishes or
divided by four for 4-well LabTek R© chambers).
2.2.5 Microscopy
2.2.5.1 Laser Scanning Confocal Microscopy (LSCM)
Confocal images of live cells were obtained with an Olympus FluoView FV1000 confocal
laser scanning biological microscope. Hoechst 33342 was excited with the 405 nm line
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Figure 2.1: Instrumental alignment for LSCM. Lasers (vertical coloured lines) and AOTF
adjustments (coloured, transparent rectangles) used for laser scanning confocal microscopy.
For demonstration purposes, excitation and emission spectra of Hoechst 33528, mCitrine and
mCherry are displayed as well (courtesy of Dr. Hernan E. Grecco).
and EGFP and mCitrine with the 488 nm line of an multiline Argon laser. mCherry
and ReAsH were excited with the 561 nm line of a DPSS laser. Excitation light for all
dyes was focused into the sample by a 40x/0.9 NA air objective or a 60x/1.2 NA water
objective using a DM405/488/561/633 dichroic mirror. Fluorescence was recorded by the
microscope’s acousto-optic tunable filter (AOTF) and SIM scanner. Hoechst fluorescence
was detected by collecting photons with a wavelength of 415-478 nm, directed to the
scanner by a SDM490 emission beam splitter. Photons with wavelength of 498-551 nm
were recorded to detect EGFP and mCitrine, while mCherry and ReAsH fluorescence
were detected by collecting photons with a wavelength of 590-690 nm. EGFP/mCitrine
and mCherry/ReAsH channels were separated by a SDM560 emission beam splitter (Fig.
2.1). Live cell imaging was performed in a temperature-controlled incubation chamber
in conditions appropriate for normal cell growth.
2.2.5.2 Ratiometric FRET Imaging
Ratiometric FRET imaging was performed using a Zeiss LSM510 confocal laser scanning
microscope. Images were collected with the multi-track option in the image acquisition
software. Images required for ratiometric FRET analysis were recorded in the same
track, while mCherry and Hoechst 33342 fluorescence were recorded on single track each
to avoid bleedtrough of the Hoechst dye into the red channel. Excitation light for all dyes
was focused into the sample by an Apochromat 40x/1.2 NA water objective using an HFT
405/488/561 dichroic beam splitter. The emission light passed an adjustable pinhole. To
allow the maximal number of photons to be collected from the sample, the pinhole
was opened completely. Donor (mCitrine) fluorescence and donor excitation/acceptor
emission images were excited by a 488 nm argon laser. A NFT 565 dichroic beam splitter
separated the emitted light into two different detection channels where BP 505-550 and
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Figure 2.2: Instrumental alignment for ratiometric FRET imaging. Lasers (vertical
coloured lines) and filter adjustments (coloured, transparent rectangles) used for ratiometric
FRET imaging. For demonstration purposes, excitation and emission spectra of Hoechst 33528,
mCitrine (donor) and mCherry (acceptor) are displayed as well (courtesy of Dr. Hernan E.
Grecco).
LP 575 emission filters were used for spectral selection. Laser power of the Argon laser
was set to 50 % to minimise photobleaching and phototoxicity. Hoechst 33342 was excited
by the 405 nm diode laser and its emission recorded using a NFT 490 dichroic beam
splitter and LP 420 or BP 420-480 emission filter, while mCherry was excited with
a 561 nm diode laser and emission detected using a NFT 515 dichroic beam splitter
and LP 575 emission filter. Laser lines and filter adjustments are outlined in Fig. 2.2.
Transmission for all lasers was set to 1 %. Fluorescence was detected by avalanche
photodiodes (APDs). Excitation light was focused into the sample by an Apochromat
40x/1.2 NA water objective. Live cell imaging was performed in a temperature-controlled
incubation chamber in conditions appropriate for normal cell growth.
2.2.5.3 Fluorescence Lifetime Imaging Microscopy (FLIM)
The FLIM microscope used in this study is a commercial setup composed of a Olympus
FluoView FV1000 laser scanning confocal microscope and PicoQuant’s compact FLIM
and FCS upgrade kit for laser scanning microscopes as an external extension. The in-
strumental setup is schematically outlined in Fig. 2.3. The pulsed lasers are coupled the
FluoView FV1000 via the existing UV and IR ports while the continuous wave lasers for
simple image acquisition enter the microscope independently. Pulsed lasers are controlled
by a driver that also sends its synchronisation signal for excitation pulses to the data
acquisition unit (PicoHarp 300). The laser scanner of the microscope is controlled via
Olympus software but the Olympus LSM controller also connects to the PicoHarp 300
unit to provide information about the scanning process. Emission light can be directed to
one or a combination of two single photon avalanche diodes (SPAD) as detectors which
then transmit their signal to the PicoHarp 300 data acquisition unit.
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Figure 2.3: General layout of the instrumental time-domain FLIM setup. The instru-
mental setup for time-domain FLIM consists of an Olympus FluoView FV1000 laser scanning
confocal microscope equipped with PicoQuant’s compact FLIM and FCS upgrade kit for LSCMs
as an external extension (adapted from http://www.picoquant.com/technotes/technote lsm up-
grade kit.pdf).
Figure 2.4: Instrumental alignment for FLIM. Laser (vertical coloured line) and filter
(coloured, transparent rectangle) used for FLIM. For demonstration purposes, excitation and
emission spectra of mCitrine (donor) and mCherry (acceptor) are displayed as well (courtesy of
Dr. Hernan E. Grecco).
FLIM images were obtained using 40x/0.9 NA air objectives or 60x/1.2 NA water
objectives (Olympus). mCitrine was excited every 25 ns with the 470 nm line of a pulsed
diode laser and the excitation light directed into the sample by DM405/470 dichroic
mirror. mCitrine fluorescence was detected by an APD using a 525/50 bandpass filter
(Fig. 2.4). Pulsed lasers and APDs were controlled with the Sepia II software (PicoQuant
GmbH). Image integration interval was approximately 30 sec (with an average total
photon count of 1.0 x 106 to 3.0 x 106 per image). Confocal images to demonstrate the
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presence of donor and acceptor fluorophores were recorded as described in 2.2.5.1. Live
cell imaging was performed in a temperature-controlled incubation chamber in conditions
appropriate for normal cell growth.
2.2.5.4 Image Manipulation and Analysis
Confocal images were converted to 32-bit images and background corrected using
ImageJ. If required, brightness and contrast of images were adjusted to improve the
signal-to-noise ratio.
Ratiometric FRET images were analysed with and quantified using ImageJ. Image
stacks were converted to 32-bit images and each image in individual stacks was
background corrected individually. Relative FRET efficiencies were calculated as the
ratio of donor fluorescence (ID) and donor excitation/acceptor emission intensity (IA)
for each pixel (ID/IA). ID/IA images have been defined as FRET ratio images and were
produced by dividing donor (mCitrine) images by donor excitation/acceptor emission
images. Results were masked and used to quantify the change in FRET ratio and
displayed as pseudocolour images.
FLIM data were analysed using PicoQuant’s SymPhoTime v5.12 software. Donor in-
tensity images were recalculated from the original TTTR files stored by the software
during image acquisition. Images were interactively masked by selecting pixels of similar
intensities to create an ROI and to exclude background intensities from the analysis. TC-
SPC histograms were recalculated for every ROI. Time-domain fluorescent lifetime data
are best analysed by fitting fluorescence decay models to the decay curves (Fig. 1.17).
Tail-fit analysis was performed on the TCPSC decay curves to alleviate the influence of
the instrument response function (Lakowicz, 2006). When it was reasonable to assume
that the decay follows a single-exponential decay model (i.e. for donor only images), a
mono-exponential decay model according to equation 1.8 was employed. In case, more
than one lifetime was to be expected in the sample (when acceptor fluorophores were
present in the sample), a bi-exponential fluorescence decay model was fitted according
to equation 2.1 (Lakowicz, 2006):
I(t) = A1 exp(−t/τ1) +A2 exp(−t/τ2) +B (2.1)
with B as background, the pre-exponential factors A1 and A2 as amplitudes, and τ1
and τ2 as the fluorescent lifetimes. The fitted regions of the curves were kept as wide
as possible excluding the onset of the decay curve but including a part representing
background counts. Lifetime images were calculated by the software on a pixel-by-pixel
basis. Lifetime data were presented as pseudo-coloured lifetime maps. Colours for lifetime
representation were adjusted manually in the software.
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Aim of the Thesis
As discussed in Chapter 1, the dynamic properties of biological systems are a result
of the underlying dynamic interactions of their individual components. Thus, a
complete understanding of signal transduction systems requires information about the
spatio-temporal dynamics of the involved protein-protein interactions (Miyawaki, 2003;
Schultz, 2007; Verveer and Bastiaens, 2008; Grecco and Verveer, 2011).
Traditional, biochemical methods to analyse signalling activities such as affinity
chromatography, co-immunoprecipitation, yeast two-hybrid screens, immunoblots, and
mass spectrometry are restricted to population averages and therefore provide very
little or no spatio-temporal information. Immunofluorescence offers only poor temporal
information about protein activities due to the fixation process. Only dynamic, live
cell imaging approaches using fluorescent biosensors offer sufficient spatio-temporal
resolution to probe enzyme or specifically MAPK activity (Wouters et al., 2001;
Miyawaki, 2003; Yasuda, 2006; Schultz, 2007; Grecco and Verveer, 2011).
Previously published FRET-based biosensors for ERK1/2 activity suffer from
several serious disadvantages, including the indirect detection of ERK2 activity
via substrate modification (Green and Alberola-Ila, 2005; Sato et al., 2007; Harvey
et al., 2008a) or conformational change (Fujioka et al., 2006), a low dynamic range and
insufficient spatial resolution (Fujioka et al., 2006; Sato et al., 2007; Harvey et al., 2008a).
Therefore the aim of the present thesis was to develop a new FRET-based, fluorescent
biosensor that would directly report ERK2 activity with high spatio-temporal resolution
and a large dynamic range.
The ERK2 biosensor would preferably be able to resolve previously inaccessible
features of MAPK signalling such as spatial gradients and travelling waves of phospho-
proteins (Kholodenko, 2006) or the signalling endosome hypothesis (Howe and Mobley,
2004; Kholodenko, 2006) and offer the possibility to obtain quantitative data that
could be integrated into computational models of MAPK signalling. Other potential
applications are the analysis of compartmental and differential MAPK signalling upon
growth factor stimulation and the investigation of feedback loops in the MAPK module
(Santos et al., 2007; Nakakuki et al., 2010).
Three different strategies were employed to achieve this goal:
In one approach a tetracysteine (4C) motif was introduced into fluorescently labeled
ERK2. Specific labeling of the 4C motif with biarsenical fluorophores would allow to
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measure FRET between the fluorescent (donor) protein and the biarsenical acceptor.
The activation-induced conformational change of ERK2 would then change the FRET
signal.
The most direct approach to measure kinase activity would be the direct observation
of transient ES interactions (Yudushkin et al., 2007) as the modification of a substrate
by its kinase requires their physical interaction. Thus, it should be possible to detect ES
complexes by measuring FRET/FLIM between donor-tagged ERK2 and an acceptor-
labeled substrate peptide. However, FLIM approaches require high fractions of donor
molecules undergoing FRET (i.e. high fractions of ERK2 in complex with its substrate)
and KM-values of known ERK2 substrates are usually in a range of 100 µM to 1 mM.
It is thus difficult to get sufficient substrate concentrations inside living cells.
In an attempt to increase local substrate concentrations, the substrate peptide was
fused to ERK2 via a flexible peptide linker. The chimeric sensor proteins was sandwiched
by fluorescent proteins that could function as a FRET pair and thereby formed an
intramolecular FRET-based biosensor for ERK2 activity. The advantage of the sensor
would lie in its ability to report ERK2 activity directly, while being relatively inert to
influences from endogenous proteins. It could potentially be used for FLIM as well as
technically less challenging, intensity-based FRET methods.
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3.1 A Simple Assay to Assess ERK2 Activation
It is well-known, that - despite having cytosolic substrates - the main pool of phosphory-
lated MAPKs translocates quickly (in less than ten minutes) to the nucleus after growth
factor stimulation (Chen et al., 1992; Gonzalez et al., 1993; Lenormand et al., 1993;
Volmat et al., 2001; Ando et al., 2004; Burack and Shaw, 2005; Costa et al., 2006; Fu-
jioka et al., 2006; Cohen-Saidon et al., 2009; Shankaran et al., 2009). This phenomenon
can be used to monitor activation of the Raf/MEK/ERK network upon growth factor
stimulation by observing the translocation of fluorescently tagged ERK2.
3.1.1 Cloning of Fluorescently Tagged ERK2 Proteins
For cloning of a fluorescently tagged ERK2, the rat ERK2 coding sequence (CDS)
(NCBI accession number: NM 053842) was amplified from pET-ERK2 by standard PCR
as described in 2.2.2.1 and cloned into pEGFP-C1 via BspE I and SalI. mCitrine-ERK2
was constructed by replacing EGFP in EGFP-ERK2 with mCitrine using AgeI and
BspE I. ERK2-mCitrine was created by subcloning the ERK2 sequence into mCitrine-N1
using XhoI and BamH I. The stop codon was removed and a Kozak sequence introduced
by site-directed mutagenesis as described in 2.2.2.2 in a single PCR reaction. MEK1
was subcloned into pcDNA3.1(+) from EYFP-MEK1 using HindIII and BamH I. The
identity of all constructs was confirmed by sequencing (data not shown). In EGFP-
ERK2 and all resulting constructs Ala2 of ERK2 was missing.
To determine if the fluorescent protein tag still allowed phosphorylation of the
ERK2 fusion proteins, mCitrine-ERK2 and ERK2-mCitrine were co-expressed with
MEK1 in HeLa cells. Cells were starved overnight and stimulated with 100 ng/ml EGF
for 5 min. ERK2 phosphorylation in stimulated versus non-stimulated cells was ana-
lysed in whole cell lysates (see 2.2.3.6) by western blots as described in 2.2.3.8 and 2.2.3.9.
Both mCitrine-ERK2 or ERK2-mCitrine phosphorylation was markedly increased
when isolated from EGF-stimulated HeLa cells in a fashion similar to endogenous ERK2
(Fig. 3.1). This result shows that activation of N- or C-terminally tagged ERK2 is not
impaired by the FP. It may be noteworthy, that phosphorylation of ERK1/2 is already
apparent in imunoblots for total ERK by the band shift in stimulated samples (Fig. 3.1).
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Figure 3.1: Fluorescently labeled ERK2 can be phosphorylated in-vivo. Western blot
showing the phosphorylation of fluorescently labeled ERK2. HeLa cells were co-transfected with
MEK1 and mCitrine-ERK2 or MEK1 and ERK2-mCitrine, starved overnight and stimulated
with 100 ng/ml EGF for 5 min. Whole cell extracts were subjected to SDS-PAGE and western
blotting.
3.1.2 ERK2 Translocation As a Read-Out of Its Activation
ERK2 translocation was observed in various cell types co-transfected with EGFP-ERK2
and MEK1-mCherry (kind gift of Dr. Piet Lommerse, MPI-Dortmund/Germany).
Co-transfection of MEK1 is necessary to prevent nuclear ERK2 accumulation (Fukuda
et al., 1997; Rubinfeld et al., 1999; Adachi et al., 2000; Burack and Shaw, 2005). Cells
were starved overnight and imaged every 60 sec for approx. 60 min using either an
Olympus FluoView 1000 or Zeiss LSM510 confocal microscope. Cells were stimulated
with 100 ng/ml EGF a few minutes after the start of an image sequence.
Upon stimulation with EGF, ERK2-EGFP translocated to the nucleus in various cell
types. ERK2 translocation started on average approx. 3 min after EGF addition with a
sudden rise of nuclear ERK2 levels, a peak after 8.1 ± 1.8 min and a slow exit from the
nucleus, while displaying high cell to cell variability (Fig. 3.2). To measure cell to cell
variability of peak timing, the coefficient of variation (CV), defined as the ratio between
standard deviation and the mean (CV = SD/mean) (Cohen-Saidon et al., 2009), was
calculated to be 22 %. Average nuclear ERK2 levels did not return to basal levels during
the time of observation, again with great cell to cell variability (CV of lowest nuclear
fluorescence value after the peak = 23 %). While in some cells indeed nuclear fluorescence
returned to basal levels, in others it slowly started increasing after an initial decline phase
of nuclear fluorescence (Fig. 3.2). The time point of lowest fluorescence after the peak
was 23.6 ± 9.3 min with a CV of 40 %.
Nuclear EGFP-ERK2 levels after EGF stimulation follow a defined fold-change (here:
1.94 ± 0.59) defined as ratio of nuclear fluorescence at maximal EGF stimulation and
initial nuclear fluorescence again with high cell to cell variability (CV = 25 %). The
relationship between intial and maximal nuclear ERK2 levels is approximately propor-
tional in each cell (R2 = 0.94), meaning that cells with higher initial nuclear ERK2
levels also show a larger absolute increase (Fig. 3.2 insert). As shown by (Cohen-Saidon
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Figure 3.2: EGFP-ERK2 accumulates in the nucleus upon EGF stimulation. A) Rep-
resentative pseudocolour image sequence of MCF7 cells expressing EGFP-ERK2 (upper panel)
and mCherry-MEK1 (middle panel) as well as merged images of both (lower panel) showing the
translocation of EGFP-ERK2 to the nucleus. Cells were starved overnight and stimulated with
100 ng/ml EGF. Scale bar = 20 µm. B) Graphs representing nuclear fluorescence. For each
cell, the ratio of nuclear EGFP fluorescence and whole cell mCherry fluorescence was normalised
to nuclear fluorescence before EGF addition to allow better cell to cell comparability. Coloured
lines denote average nuclear fluorescence of EGFP-ERK2 in individual cells, the black line de-
notes average nuclear fluorescence of EGFP-ERK2 in all measured cells with S.E.M. (n=34). The
insert shows the correlation of nuclear fluorescence at maximal EGF stimulation with nuclear
fluorescence at t=0. Each circle represents a value from one individual cell. Black line represents
the best linear fit (R2 = 0.94).
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et al., 2009), this behaviour can be called a “fold-change response” where the amount of
ERK2 translocating to the nucleus is a constant fraction of the initial levels. However,
here the ERK2 returns to a nuclear level higher than the original basal level as demon-
strated by the ratio of the final and initial fluorescence level of 1.23 ± 0.29 (mean ± S.D.).
Translocation of ERK2 to the nucleus was used to assess and control successful growth
factor stimulation of cells throughout this study.
3.2 An Intramolecular ReAsH-Based FRET-Biosensor for
ERK2 Activation
A genetically encoded ERK2 biosensor, based on the conformational change of ERK2
upon its activation has been developed before (Fujioka et al., 2006). Here, the N- and C-
terminus of ERK2 were fused to cyan and yellow fluorescent protein (CFP and YFP) as
a FRET pair, translating the phosphorylation-induced, conformational change of ERK2
and concurrently the positional change of the N- and C-terminus relative to each other
into a change of FRET efficiency. However, the dynamic range of the sensor is rather
small (Fujioka et al., 2006). In an attempt to extend that approach to obtain a sensor
construct with a higher dynamic range, mCitrine-tagged ERK2 was tagged with an
acceptor fluorophore in regions of ERK2 that change conformation upon phosphorylation
of the kinase. Unfortunately, the introduction of a large (27 kDa), second fluorescent
protein (FP) may disrupt the protein’s functionality (McLean et al., 2001; Vilardaga
et al., 2003; Andresen et al., 2004). Thus, short tetracysteine (4C) tags were introduced
into ERK2 at the desired positions, that could be labeled with biarsenical dyes.
3.2.1 Development of an Intramolecular ReAsH-based FRET Biosensor
for ERK2 Activation
By superimposing crystal structures of phosphorylated and unphosphorylated ERK2
(Zhang et al., 1994; Canagarajah et al., 1997), four regions of conformational sensitive
regions of ERK2 were identified that would also be accessible for labeling by a
chemical fluorophore (Fig. 3.3B). Especially - but not exclusively - the ERK2 activation
loop undergoes a dramatic conformational change upon phosphorylation (Fig. 3.3B)
(Canagarajah et al., 1997). Thus, amino acids of the activation loop (Val171 to Phe181,
excluding Thr183, Tyr185 and adjacent amino acids) and amino acids 9-14, 30-35 and
327-336 of rat ERK2 were chosen for replacement with either the minimal or optimised
version (Martin et al., 2005) of the 4C motif (Fig. 3.3B and C and Fig. S.1.1) in
mCitrine-tagged ERK2. In additon, the N- or C-terminus of ERK2 were tagged with
the 4C motif in ERK2-mCitrine or mCitrine-ERK2, respectively. The conformational
change induced by phosphorylation of ERK2 would lead to a change of distance and/or
orientation of mCitrine to ReAsH bound to the 4C motif (Fig. 3.3A and B). Since
mCitrine and ReAsH form a good FRET pair, the conformational change could be
detected by the resulting change in FRET signal (Fig. 3.3A).
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Figure 3.3: Principle and design of the ReAsH-based FRET sensor for ERK2. A)
Principle of the ReAsH-based FRET sensor for ERK2. Phosphorylation of ERK2 induces a
conformational change of the kinase which is translated into a change in FRET efficiency between
donor and acceptor fluorophore. FRET can be measured ratiometrically or by FLIM. ReAsH is
represented by the red hexagon. B) Crystal structures of phosphorylated (green and red) and
unphosphorylated (blue and yellow) ERK2 were superimposed. Domains in ERK2 that change
conformation upon phosphorylation are in yellow, amino acids that were replaced by the 4C motif
are highlighted in red in ppERK2, phosphorylatable Thr183 and Tyr185 are marked in purple. C)
Schematic representation of the ERK2 biosensor constructs cloned. All constructs were derived
from rat ERK2 fused to mCitrine on the N- or C-terminus, respectively. The tetracysteine motif
(red) replaced original amino acids. Amino acid sequences of wt and recombinant ERK2 proteins
are detailed in Fig. S.1.1.
The 4C motif was introduced at the indicated positions (Fig. 3.3B and C) by directed
mutagenesis of either ERK2-mCitrine or mCitrine-ERK2, respectively, as described
in 2.2.2.3 to create nineteen different sensor constructs as listed in Table S.1.1. The
identity of all constructs was confirmed by sequencing (data not shown).
To determine, whether the introduced 4C motif would hamper phosphorylation of
mutant ERK2 proteins in the activation loop, sensor constructs were co-expressed
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individually with MEK1 in HeLa cells. Cells were starved for 4-6 h and stimulated
with 100 ng/ml EGF for 5 min. Sensor protein phosphorylation in stimulated versus
non-stimulated cells was analysed in whole cell lysates by SDS-PAGE and western
blotting.
Figure 3.4: Tetracysteine motif containing ERK2 mutants can be phosphorylated in-
vivo. Western blot showing the phosphorylation of 4C motif containing ERK2 mutants derived
from mCitrine-ERK2 (A) or ERK2-mCitrine (B). HeLa cells were co-transfected with MEK1
and one of 19 ERK2 biosensor construct, starved overnight and stimulated with 100 ng/ml EGF
for 5 min. Whole cell extracts were subjected to SDS-PAGE and western blotting. endog. ERK2
= endogenous ERK2
Every 4C motif containing ERK2 biosensor construct tested was strongly phosphory-
lated upon EGF stimulation, following closely phosphorylation of endogenuos or fluo-
rescently labeled ERK2 (Fig. 3.4). This demonstrates that the presence of the 4C motif,
especially in the activation loop, does not influence phosphorylation of the mutant ERK2
proteins. Interestingly, the phosphorylation of sensor constructs cannot be observed by
a band shift with total ERK antibodies, in contrast to endogenous ERK1/2 (Fig. 3.4).
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Figure 3.5: FRET between mCitrine and ReAsH in ERK2. A) Representative image
sequence showing the occurence of FRET between mCitrine and ReAsH upon binding of ReAsH
to the 4C motif. HeLa cells co-expressed MEK1 and mCitrine-ERK2-4C(171-176). Cells were
starved for 4-6 h and incubated with 5.0 µM ReAsH. FLIM images were recorded at various
time points after ReAsH addition. Confocal images of mCitrine (upper row) and ReAsH (middle
row) as well as pseudocolour fluorescent donor lifetime maps (bottom row) are shown. Scale bar
= 20 µm. B) ReAsH labeling kinetics. HeLa cells transiently transfected with MEK1 and either
mCitrine-ERK2 or mCitrine-ERK2-4C(171-176) were incubated with 5.0 µM ReAsH. Fluorescent
donor lifetimes were determined at various time points after ReAsH addition.
3.2.2 Labeling Tetracysteine-Tagged ERK2 with Biarsenical Fluorophores
To test whether it was in principle possible to specifically label 4C-tagged proteins
with biarsenical fluorophores in the present experimental system, one arbitrarily chosen
ReAsH-ERK2 sensor constructs (mCitrine-ERK2-4C(171-176)) was co-transfected with
MEK1/pcDNA3.1(+) into HeLa cells and cells incubated with 5.0 µM ReAsH as
described in 2.2.3.10. FRET between mCitrine and ReAsH was detected by measuring
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mCitrine fluorescent lifetime using FLIM as described in 2.2.5.3 at various time points
after ReAsH addition in the presence or absence of EGF. Background labeling of non-
tagged proteins by ReAsH was assessed by measuring donor lifetime of mCitrine-ERK2
expressed in HeLa cells. Data were analysed and displayed according to 2.2.5.4.
ReAsH labeling kinetics of mCitrine-ERK2-4C(171-176) in the presence or absence of
EGF were virtually identical (Fig. 3.5B). Addition of ReAsH to the cell culture medium
resulted in a decrease of mCitrine lifetime of 0.41 ± 0.09 ns in the presence and 0.42 ±
0.03 ns in the absence of EGF (Fig. 3.5B), displaying the occurence of FRET between
mCitrine and ReAsH. Instead, donor lifetime of mCitrine-ERK2 decreased only for
0.14 ± 0.02 ns after ReAsH addition. Labeling kinetics of mCitrine-ERK2-4C(171-176)
by ReAsH could be described by a sigmoidal function. However, the time scale for
full labeling until no further decrease in fluorescent lifetime could be observed was 40
- 50 min (Fig. 3.5B). Taken together, these data demonstrate that it was possible to
specifically label recombinant proteins containing the 4C motif with ReAsH.
Figure 3.6: Background labeling by ReAsH can be significantly reduced by using
the optimised version of the 4C motif. Representative confocal images comparing the
background labeling of cells expressing mCitrine-ERK2 fusion proteins tagged with either the
optimised (Martin et al., 2005) or minimal version of the 4C motif (CCPGCC). HeLa cells were
co-transfected with MEK1 and the desired sensor construct as indicated, starved overnight and
labeled with 5.0 µM ReAsH as described in 2.2.3.10. 4C motif sequence in the first two rows
(mCitrine-ERK2-4C and ERK2-4C(327-336)-mCitrine) was FLNCCPGCCMEP. mCitrine (top),
ReAsH (middle) and false colour merge images (bottom) are shown. Scale bar = 25 µm.
It may be interesting to note, that while unspecific background staining by ReAsH
was always observed, it could be markedly decreased by using the optimised version
(Martin et al., 2005) of the tetracysteine motif (Fig. 3.6). Background reduction,
however, required washout of ReAsH by the washing buffer British anti-Lewisite (BAL).
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Similarly high background intensity was observed with both versions of the 4C motif 60
min after incubation with ReAsH but before washout with BAL (Fig. 3.6).
3.2.3 Screening of Tetracysteine-Tagged ERK2 Biosensor Constructs
Using Fluorescence Lifetime Imaging Microscopy
FLIM was used to identify a functional sensor construct with a high dynamic range.
Each sensor construct was co-expressed with MEK1 in HeLa cells. Cells were starved
overnight and sensor constructs labeled with 5.0 µM ReAsH as described in 2.2.3.10.
Cells were stimulated with 100 ng/ml EGF and the fluorescent lifetime of donor
molecules determined by FLIM before and 5, 10 and 20 min after stimulation as
described in 2.2.5.3 and 2.2.5.4.
Out of the nineteen ERK2 sensor constructs, only mCitrine-ERK2-4C(174-179)
showed a significant change in lifetime of 0.03 ± 0.01 ns after EGF stimulation (Fig.
3.7). In addition, none of the constructs showed a lifetime change resembling known
ERK2 activation profiles. For most constructs, lifetime changes observed (usually less
than 30 ps) were in a similar range as those for mCitrine-tagged ERK2 and/or - even
more profoundly - lifetimes did not change consistently in only one direction (shown
exemplarily for mCitrine-ERK2-4C(9-14) in Fig. 3.8, see also Table S.1.2-S.1.21).
In addition to mCitrine-ERK2-4C(174-179), only ERK2-4C(175-180)-mCitrine and
ERK2-4C(327-336)-mCitrine displayed a consistent change in lifetime (Tables S.1.10,
S.1.12 and S.1.18).
While most of the nineteen ReAsH-ERK2 biosensor constructs failed to report
ERK2 activity, mCitrine-ERK2-4C(174-179), ERK2-4C(175-180)-mCitrine and ERK2-
4C(327-336)-mCitrine were tested in more detail to assess their potential. Since the
observed fluorescent donor lifetime changes after labeling with ReAsH but prior to EGF
stimulation were in many cases surprisingly small (Fig. 3.7), stimulation of the chosen
sensor constructs with 100 ng/ml EGF was performed in the presence of 5.0 µM ReAsH
without wash-out of ReAsH by BAL.
All three constructs showed markedly decreased mCitrine fluorescent lifetimes 60
min after incubation with ReAsH (Fig. 3.9). However, none showed a significant donor
lifetime change upon EGF stimulation. Donor lifetimes for mCitrine-ERK2-4C(174-179)
decreased as opposed to the increase seen in the first screen (compare Tables S.1.22 and
S.1.18). ERK2-4C(327-336)-mCitrine displayed no consistent donor lifetime change (Ta-
ble S.1.24). Thus, labeling efficiency of sensor constructs by ReAsH could be improved by
omitting wash-out of ReAsH, but these tests did not reveal a functional sensor construct.
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Figure 3.7: Screening of ReAsH-based FRET biosensors. Average fluorescent donor
lifetimes of ReAsH-based ERK2 biosensor constructs based on ERK2-mCitrine A) or mCitrine-
ERK2 (B). HeLa cells expressing MEK1 and one of nineteen sensor constructs were starved
for 4-6 h, labeled with 5.0 µM ReAsH and stimulated with 100 ng/ml EGF. Fluorescent donor
lifetimes were determined before and 5 min, 10 min and 20 min after stimulation.
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Figure 3.8: Fluorescent donor lifetimes do not change consistently in only one direc-
tion. Graphs showing representative single cell measurements of one of nineteen ReAsH-based
ERK2 biosensors. HeLa cells expressing MEK1 and mCitrine-ERK2-4C(9-14) were starved for
4-6 h, labeled with 5.0 µM ReAsH and stimulated with 100 ng/ml EGF. Fluorescent donor
lifetimes were determined before and 5 min, 10 min and 20 min after stimulation.
Figure 3.9: Test of ReAsH-based FRET biosensors without ReAsH wash-out. Av-
erage fluorescent donor lifetimes of mCitrine-ERK2-4C(174-179), ERK2-4C(175-180)-mCitrine
and ERK2-4C(327-336)-mCitrine. HeLa cells expressing MEK1 and one of the above mentioned
sensor constructs were starved for 4-6 h, incubated with 5.0 µM ReAsH for 60 min and stimu-
lated with 100 ng/ml EGF. Fluorescent donor lifetimes were determined before and 5 min, 10
min and 20 min after stimulation.
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In summary, even though it was possible to establish in-vivo labeling of proteins by
biarsenical fluorophores, no construct could be identified as a functional fluorescent
biosensor for ERK2 activity.
3.3 Visualising ERK2 Activity by Imaging Transient
Enzyme-Substrate Interactions
Enzymatic modification of a substrate requires its binding to the active site of the
enzyme forming a transient ES complex. Visualising ES interactions in living cells
is the most direct approach to assess spatio-temporal enzyme activity and has been
successfully employed to dissect spatial PTP1B regulation (Yudushkin et al., 2007).
Imaging of transient ERK2-substrate interactions would follow a similar principle as
visualisation of PTP1B-substrate complexes: the occurence and loss of FRET upon
binding and release of an acceptor-labeled substrate peptide to donor-tagged ERK2 is
recorded in spatio-temporal manner (Fig. 3.10).
Figure 3.10: Principle of imaging ERK2-substrate interactions with FRET. The
acceptor-labeled substrate peptide (blue) cannot bind to inactive, donor-tagged ERK2. Acti-
vation of the kinase induces binding of the substrate peptide to ERK2’s active site and FRET,
monitored by FLIM and/or emission intensity changes. After catalysis, the phosphorylated pep-
tide dissociates from the kinase, resulting in a loss of FRET (modified from Yudushkin et al.,
2007).
mCitrine-ERK2 was used as donor in all attempts to establish ES complex visuali-
sation (see Section 3.1.1). The substrate peptide corresponded to amino acids 379-403
of the human transcription factor Elk1. Elk1 is a known substrate of ERK2 including
the consensus MAPK phosphorylation site (P-X-S/T-P) (Gille et al., 1995; Yang et al.,
1998b,a) and contains a DEF-domain (F-X-F-P) (Jacobs et al., 1999; Fantz et al., 2001).
The DEF-domain binds only to phosphorylated ERK2 as its binding pocket close to the
active site of ERK2 is masked by ERK2’s activation loop when in the inactive, unphos-
phorylated conformation (Lee et al., 2004; Yoon and Seger, 2006). Substrate binding
affinity to ERK2 was thus supposed to increase with incorporation of the DEF domain
into the substrate peptide sequence.
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3.3.1 Detection of ERK2 Enzyme-Substrate Interactions In-Vitro
In order to test whether formation of ES-complexes could be visualised, in-vitro ex-
periments with purified components were performed as a proof of principle.
In all in-vitro experiments a shorter, synthetic version of the substrate peptide,
corresponding to amino acids 382 to 403 of hElk1 was used. The peptide was a kind gift
of Prof. Dr. Christian Becker (Dept. of Physical Biochemistry, Max-Planck-Institute
of Molecular Physiology, Dortmund, Germany) and was synthesised and labeled with
lissamine-rhodamine B by Sascha Gentz.
Monitoring ES-complexes in-vitro required purified, fluorescently labeled, active as
well as inactive ERK2. An elegant protocol for the purification of active ERK2 is based
on the co-expression of constitutively active MEK1 in E.coli (Khokhlatchev et al., 1997).
This, however, depends on the availability of bacterial expression vectors encoding
mutant MEK1. For reasons of simplicity, mCitrine-ERK2 wt and constitutively active
as well as kinase dead mutants of ERK2, mCitrine-ERK2 L73P/S151D (Emrick et al.,
2001) and mCitrine-ERK2 K52R (Robbins et al., 1993), were expressed individually in
E. coli and purified in non-phosphorylated form. mCitrine-labeled mutants of ERK2
were created by site-directed mutagenesis as described in 2.2.2.2 using MAPK1 K52R
for and rev or MAPK1 L73P for and rev and MAPK1 S151D for and rev, respectively.
mCitrine-ERK2 wt and its mutants were subcloned into the bacterial expression vector
pProEx HTB using NcoI and SalI. The identity of all constructs was confirmed by
sequencing (data not shown). Purified ERK2 proteins were then activated in-vitro by
commercially available active MEK1.
3.3.1.1 In-Vitro Phosphorylation of Purified ERK2 and Its Substrate
First, it was tested, whether purified, inactive, fluorescently tagged ERK2 proteins
could be activated in-vitro by commercially available MEK1. In-vitro phosphoryla-
tion was performed as described in 2.2.3.2 and results subjected to SDS-PAGE and
immunoblotting as described in 2.2.3.8 and 2.2.3.9. Purified His-ERK2 wt (kind gift
by Piet Lommerse, Dept. of Systemic Cell Biology, Max-Planck-Institute of Molecular
Physiology, Dortmund, Germany) was used as an internal control.
All ERK2 proteins and mutants showed a marked increase in phosphorylation levels
upon incubation with active MEK1 (Fig. 3.11A). As expected, no phosphorylation of
His-ERK2 wt, mCitrine-ERK2 wt and mCitrine-ERK2 K52R could be detected when
active MEK1 was omitted from the reaction. In contrast, mCitrine-ERK2 L73P/S151D
was already substantially phosphorylated before addition of MEK1, due to the increased
autophosphorylation activity (Emrick et al., 2001), but incubation with active MAPKK
could still increase phosphorylation of ERK2 L73P/S151D (Fig. 3.11A).
Next, it was asked, whether purified ERK2 phosphorylated in-vitro was still active
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Figure 3.11: Purified ERK2 can phosphorylate a synthetic substrate peptide after
activation by MEK1 in-vitro. A) Western blot analysis of purified ERK2 proteins after in-
cubation with active MEK1. B) Western blot analysis of the synthetic ERK2 substrate after
incubation with in-vitro phosphorylated ERK2 and active MEK1. The lissamine rhodamine B
signal was used as loading control. 12 % SDS gel; ERK2 KD = kinase dead ERK2 (ERK2 K52R);
ERK2 CA = constitutively active ERK2 (ERK2 L73P/S115D); Liss.-Rho. = lissamine-rhodamine
B.
and could in turn phosphorylate the synthetic, fluorescently labeled ERK2 substrate
peptide. In-vitro phosphorylation of ERK2 and the substrate was performed as des-
cribed in 2.2.3.3 and results subjected to SDS-PAGE and immunoblotting.
ERK2 proteins and mutants could be phosphorylated in-vitro by active MEK1
(Fig. 3.11B). Curiously, there was only a faint band detectable for autophosphorylated
mCitrine-ERK2 L73P/S151D. No phosphorylation of His-ERK2 wt, mCitrine-ERK2 wt
and mCitrine-ERK2 K52R could be detected when active MEK1 was omitted from the
reaction. More importantly, phosphorylated substrate peptide could be detected only in
samples containing activated ERK2 (Fig. 3.11), demonstrating that at least a fraction
of ERK2 was active after purification and could indeed modify its substrate in-vitro. As
expected, no detectable phosphorylated substrate peptide could be observed in samples
containing mCitrine-K52R, due to a lack of catalytic activity. Phosphorylated substrate
peptide was also not observed in mCitrine-ERK2 L73P/S151D samples lacking MEK1,
as expected from the low phosphorylation level.
These data show, that purified and in-vitro phosphorylated ERK2 is still active and
able to phosphorylate a fluorescently labeled, synthetic substrate peptide in-vitro. Thus,
detection of transient ES-complexes is theoretically possible.
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3.3.1.2 In-Vitro ERK2 ES-Interaction Fluorescence Spectroscopy
FRET leads to a decrease in donor and an increase in acceptor intensity. It should
therefore be possible to observe binding and consumption of the substrate peptide
to ERK2 by measuring donor emission intensity at a fixed wavelength as a function
of time. Formation of transient ES-complexes would be detected as a sudden drop
in donor emission intensity upon substrate addition, displaying occurence of FRET.
Donor intensity would then more or less slowly recover to initial values as the substrate
peptide is modified and released from the kinase.
In-vitro ERK2 ES-interaction spectroscopy was performed as described in 2.2.3.4
using the constitutively active mutant in time-based experiments with fixed excitation
(λ = 516 nm) and emission wavelength (λ = 529 nm). Substrate concentrations
employed, ranged from 2.0 µM to 20.0 µM. The substrate peptide was serially diluted to
allow the addition of the same volume to all samples. In negative controls, one volume
of substrate dilution buffer was used.
Figure 3.12: Substrate addition leads to a stable decrease in donor emission intensity
in in-vitro ERK2 ES-interaction spectroscopy. A) Donor emission intensity was measured
as a function of time at fixed excitation wavelength. Blue line represents normalised average fluo-
rescence of mCitrine-ERK2 L73P/S151D corrected for the dilution effect of adding one volume
substrate buffer with S.E.M. (n=3). Yellow to dark red lines represent the fluorescence signal
of mCitrine-ERK2 L73P/S151D for increasing substrate concentrations (2.0 µM with S.E.M.,
n=6) and corrected for the dilution effect of adding one volume substrate buffer. B) Correlation
of the fluorescence signal after substrate addition with the substrate concentration. Each circle
represents fluorescence values at t = 1 sec after substrate addition from A). Black line represents
the best linear fit (R2 = 0.86).
Dilution corrected donor emission intensity values decreased upon LRh-hElk1(382-
403) addition (Fig. 3.12A) in an approximately linear fashion (Fig. 3.12B), arguing
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for the concentration-dependent occurence of FRET. However, no recovery of the
donor emission intensity could be observed in any sample, indicating unspecific FRET
independent of ERK2 activation state.
Figure 3.13: FRET can be observed between the reporter substrate peptide and
mCitrine-ERK2 K52R independent of its activation state. A) Incubation of purified
mCitrine-ERK2 K52R with LRh-hElk1(382-403) in the presence of ATP before and after in-
cubation with active MEK1 resulted in FRET, observed as quenching of mCitrine fluorescence
and increased emission of LRh upon excitation at 470 nm. FRET was independent of ERK2’s
phosphorylation state. B) Dependence of the FRET efficiency on the concentration of substrate
peptide for phosphorylated and unphosphorylated mCitrine-ERK2 K52R. C) Correlation of nor-
malised fluorescence intensity values at the donor emission maximum with substrate concen-
tration. Blue circles represent fluorescence peak values of non-phosphorylated ERK2 K52R at
increasing substrate concentrations from B); red circles represent fluorescence peak values of
phosphorylated ERK2 K52R at increasing substrate concentrations from B). Blue and red lines
represent the best linear fit for the respective data set (R2K52R = 0.85; R
2
ppK52R = 0.84).
Emission scan experiments allow simultaneous detection of donor emission decrease
and sensitised acceptor emission increase characterising FRET. But the FRET signal
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may be missed due to high specific activity of the purified kinase rapidly consuming the
substrate. In case of ES-imaging with PTP1B, the problem was circumvented by using
a “substrate trapping” mutant of PTP1B (Yudushkin et al., 2007). Unfortunately, at
least to current knowledge, there are no such mutants for ERK2 described. However,
mutation of lysine 52 to arginine (ERK2 K52R) renders the kinase catalytically in-
active (Robbins et al., 1993) while still enabling phosphorylation of the activation
loop. Since this mutant could enable substrate binding upon activation without its
modification, it was suspected that ERK2 K52R might function as a “substrate
trapping” mutant for ERK2. Thus, mCitrine-ERK2 K52R was employed in emission
scan experiments in an attempt to stabilise transient ES intermediates and facilitate
FRET detection.
Emission scan in-vitro ES-interaction spectroscopy was performed as described
in 2.2.3.4. Substrate concentrations employed, ranged from 0.5 µM to 2.0 µM. The
substrate peptide was serially diluted to allow addition of the same volume to all
samples. In negative controls, one volume of substrate dilution buffer was used.
Incubation of purified mCitrine-ERK2 K52R with LRh-hElk1(382-403) resulted in
FRET, observed by the approximately linear, concentration-dependent quenching of the
donor (mCitrine) emission and the concurrent acceptor (lissamine) intensity increase
(Fig. 3.13). However, these apparent FRET signals were largely independent of the
phosphorylation state of mCitrine-ERK2 K52R (Fig. 3.13A and B), indicating that ob-
served FRET was mainly due to unspecific interactions of substrate peptide and ERK2.
Interestingly, quenching of donor fluorescence as well as acceptor emission increase after
LRh-hElk1(382-403) addition were slightly stronger for phospho-mCitrine-ERK2 K52R
(Fig. 3.13A and C) while the emission spectra and intensity of phosphorylated and
non-phosphorylated mCitrine-ERK2 K52R in the absence of substrate peptide were
identical. Although this effect was not very prominent, it was consistent throughout
most substrate concentrations (Fig. 3.13C) and might therefore argue for the presence
of small amounts of ES-intermediates.
In an attempt to further clarify the result obtained from emission scan experiments,
purified mCitrine-ERK2 wt was activated in-vitro and subjected to in-vitro fluorescent
lifetime spectroscopy as described in 2.2.3.5. Lissamine-rhodamine B-labeled hElk1(382-
403) was serially diluted to allow addition of the same volume to all samples. As a
further negative control, a lissamine-rhodamine B-labeled synthetic substrate peptide
with the amino acid sequence DADEYL has been used (Yudushkin et al., 2007).
LRh-DADEYL was a kind gift of Dr. Carsten Schultz, Gene Expression Unit, EMBL
Heidelberg/Germany and synthesised by Andrea Giordano.
Addition of LRh-labeled hElk1(382-403) to purified mCitrine-ERK2 wt led to an im-
mediate and stable drop in fluorescent donor lifetime irrespective of the phosphorylation
state of ERK2 (Fig. 3.14A and C) indicating the occurence of unspecific FRET between
labeled substrate peptides and ERK2. This lifetime drop, however, was again more pro-
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Figure 3.14: FRET occurs between mCitrine-ERK2 wt and LRh-labeled substrate
peptides. A) Addition of LRh-hElk1(382-403) to purified mCitrine-ERK2 led to a stable de-
crease of donor fluorescent lifetime. Graphs (shown with S.E.M.) represent donor fluorescent
lifetimes of unphosphorylated mCitrine-ERK2 wt (light to dark blue lines) and phosphory-
lated mCitrine-ERK2 wt (yellow to dark red lines) before and after the addition of increasing
concentrations of ERK2 substrate peptide. Occurence of FRET was independent of ERK2’s
phosphorylation state but more pronounced for ppERK2. nERK2 + 5 µM=2; nERK2 + 50 µM=2;
nppERK2 + 50 µM=8. B) Addition of LRh-DADEYL to purified mCitrine-ERK2 resulted in a sta-
ble decrease of donor fluorescent lifetime. Graphs (shown with S.E.M.) represent donor fluorescent
lifetimes of unphosphorylated mCitrine-ERK2 wt (light grey to black lines) before and after the
addition of increasing concentrations of LRh-DADEYL. Graphs representing mCitrine lifetime
for ppERK2 after the addition of LRh-DADEYL (green), and ERK2 (blue, n=2) and ppERK2
(red, n=8) after the additon of LRh-hElk1(382-403) are shown for comparison. C) Correla-
tion of the fluorescent donor lifetime at t = 30 sec with substrate concentration. Grey and red
lines represent the best exponentiell fit for the respective data set(R2ERK2 + DADEYL = 0.99;
R2ppERK2 + hElk1(382-403) = 0.99). There were not enough data points to reliably fit data points
for ERK2 + hElk1(382-403).
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nounced in samples containing phosphorylated ERK2 (Fig. 3.14A and C). Although this
additional drop argues for the formation of small amounts of ES-complexes, no recovery
of donor lifetime neither to initial lifetime values nor to lifetime values representing com-
plexes of substrate peptide and inactive ERK2 could be detected (Fig. 3.14A), which
would have argued more conclusively for the formation of ES-intermediates.
Interestingly, when the LRh-DADEYL peptide was added to unphoshphorylated
ERK2, again a concentration dependent decrease in mCitrine lifetime was observed,
pointing to lissamine-rhodamine B as the cause of the unspecific FRET signals (Fig.
3.14B). It should be noted, however, that mCitrine lifetimes for both unphosphorylated
and phosphorylated ERK2 were progressively lower after addition of LRh-hElk1(382-
403) than after the addition of LRh-DADEYL, with an even stronger lifetime decrease
for ppERK2 than for ERK2 (Fig. 3.14B).
In conclusion, the in-vitro experiments indicate that it might indeed be possible to de-
tect ES-intermediates of ERK2 and a substrate peptide in-vitro, although the occurence
of unspecific FRET signals between purified mCitrine-ERK2 and LRh-labeled peptides,
probably mediated by the fluorescent dye lissamine-rhodamine B itself, prevents a clear
proof.
3.3.2 In-Vivo Fluorescence Lifetime Imaging Microscopy of ERK2
ES-Interactions
Since the in-vitro experiments pointed to a possible use of the approach to detect ES
interactions in-vitro, in-vivo experiments were carried out to visualise ERK2 activity in
living cells.
To avoid highly manipulative techniques to introduce synthetic peptides into living
cells, hElk1(379-403) was fused to the C-terminus of mCherry by amplifying the
mCherry sequence from mCherry-C1 using ERK2 substrate for and rev (2.2.2.1)
and subsequent cloning of the PCR product into AgeI and XhoI restriction sites of
mCherry-C1. The genetically encoded, fluorescently labeled substrate peptide could
thus be easily transfected into cells and expressed together with donor-labeled ERK2.
The short substrate peptide would be protected from degradation by the attached FP.
mCherry-hElk1(379-403) was co-transfected with MEK1/pcDNA3.1(+) and mCitrine-
ERK2 wt into MDA cells. For negative controls, MDA cells were co-transfected with
mCherry-C1, MEK1/pcDNA3.1(+) and mCitrine-ERK2 wt. Cells were starved over-
night, stimulated with 100 ng/ml EGF and the fluorescent lifetime of donor molecules
determined by FLIM before and at various time points after stimulation as described in
2.2.5.3 and 2.2.5.4.
Pseudocolour lifetime maps of donor lifetimes did not display any colour change
upon EGF stimulation in MDA cells expressing MEK1, mCitrine-ERK2 wt and either
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Figure 3.15: No significant formation of ES-complexes between ERK2 and
hElk1(379-403) could be detected by FLIM. A) FLIM of live cells showing no visible donor
fluorescent lifetime change after EGF stimulation. Representative image sequences of MDA cells
co-expressing MEK1, mCitrine-ERK2 wt and either mCherry-C1 (upper panel) or mCherry-
hElk1(379-403) (lower panel). Donor intensity images and pseudocolour lifetime maps with ave-
rage lifetime of the whole cell are shown as indicated. Scale bar = 20 µm; τ = fluorescent lifetime.
B) Graphs showing the average donor fluorescent lifetime of cells expressing mCherry-C1 (blue)
or mCherry-hElk1(379-403) (red) with S.E.M.
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mCherry-C1 or mCherry-hElk1(379-403) that would represent a change in fluorescent
lifetime of mCitrine (Fig. 3.15A). Similarly, no significant donor lifetime change could
be detected after averaging several measured cells (Fig. 3.15B). Specifically, the lifetime
change observed was 20 ± 20 ps on average at 5 min EGF stimulation with a maximal
change of 100 ps, 5 min after stimulation, in an individual cell (see Table S.2.1 and Table
S.2.2). The shape of the curves for cells expressing mCherry or mCherry-hElk1(379-403)
was nearly indistinguishable (Fig. 3.15B).
In conclusion, it has not been possible to visualise transient ES complexes of ERK2
and a genetically encoded, fluorescently tagged substrate peptide.
3.4 Development of an Intramolecular FRET-Based
Biosensor for ERK2 Activity Employing Transient
Enzyme-Substrate Interactions
An alternative approach to increase substrate concentrations in the immediate environ-
ment of ERK2 is to directly link the kinase to its substrate peptide. A flexible peptide
linker would allow reversible formation of transient ES complexes. The approach requires
a recombinant protein consisting of ERK2, the peptide linker and an ERK2 substrate
peptide sequence sandwiched by a FRET pair of FPs, producing a genetically encoded,
intramolecular FRET sensor. Similar to intermolecular ES-imaging, upon activation of
ERK2, kinase and substrate peptide form a transient ES-complex before the phospho-
rylated substrate peptide dissociates from the active site (Fig. 3.16A). Since the sensor
is specifically designed as an intramolecular FRET sensor, FRET between donor and
acceptor fluorophores could be detected by FLIM and ratiometric FRET imaging.
3.4.1 Cloning of Intramolecular FRET-based Fluorescent Biosensor
Constructs for Detection of ERK2 Activity
Four different sensor constructs were designed, named ERK Activity Sensor 1 to 4
(EAS1-4), each containing ERK2, a flexible peptide linker based on the amino acid
sequence L(GGGGS)xAAA and amino acids 375-404 from human Elk1, flanked by
mCitrine as donor on the N-terminus and mCherry as acceptor on the C-terminus.
Constructs differed in the position of the substrate peptide in respect to the enzyme
and the length of the peptide linker as shown in Fig. 3.16B.
The main parts of the ERK2 Activity Sensor constructs were cloned by a two-step
fusion PCR as described in 2.2.2.4. Briefly, in a first PCR step N- and C-terminal parts
of the sensor constructs (hElk1(375-404) and ERK2 for EAS1 and EAS2 or ERK2
and hElk1(375-404) for EAS3 and EAS4, respectively) were created separately with a
BspE I site at the 5’- and the linker sequence at the 3’-end of the N-terminal part and
the same linker sequence at the 5’- and a HindIII site at the 3’-end of the C-terminal
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Figure 3.16: Principle and design of the intramolecular ERK2 Activity Sensor Con-
structs. A) Principle of the intramolecular FRET sensor. Formation of an enzyme-substrate
intermediate to phosphorylate the substrate peptide (blue, phosphorylation is indicated by the
orange dot) after activation of ERK2 (grey) changes the FRET signal obtained from two fluo-
rescent proteins on the N- and C-terminus of the sensor molecule. FRET can be measured
ratiometric or by FLIM (modified from Yudushkin et al., 2007). B) Design of the intramolecular
FRET sensor. Schematic representation of the four different constructs. Each construct consisted
of mCitrine on the N- and mCherry on the C-terminus as donor and acceptor fluorophore, rat
ERK2 CDS, a flexible peptide linker and amino acids 375-404 of hElk1. The constructs differed
in the substrate peptide position in respect to ERK2 and peptide linker length. Short peptide
linker sequence was L(GGGGS)2AAA, long peptide linker sequence L(GGGGS)3AAA.
part. In a second PCR step both PCR products were fused using 5’- and 3’- forward
and reverse primers from the first step. mCherry CDS was amplified from mCherry-C1
by PCR as described in 2.2.2.1 using mCherry (HindIII) for and mCherry (BamH I)
rev to introduce the respective restriction sites. Final sensor constructs were cloned by
insertion of the main parts of each sensor construct and mCherry between the BspE I
and BamH I sites of mCitrine-C1. The identity of all constructs was confirmed by
sequencing (data not shown).
3.4.2 FLIM Screening of ERK2 Activity Sensor Constructs
To identify a functional sensor construct, displaying the highest dynamic range,
the sensor constructs were screened using FLIM. MEK1 and one of the four sensor
constructs were co-expressed in HeLa cells. Cells were starved overnight, stimulated
with 100 ng/ml EGF and the fluorescent donor lifetime was determined by FLIM before
and 5, 10 and 20 min after stimulation as described in 2.2.5.3 and 2.2.5.4.
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Figure 3.17: ERK Activity Sensor 4 (EAS4) exhibits the highest dynamic range
of all four sensor constructs. A) FLIM of live cells expressing one of four different ERK2
activity sensor constructs showing a visible donor fluorescent lifetime change after stimulation
with 100 ng/ml EGF only for EAS4. Donor intensity images (top) and pseudocolour lifetime
maps (bottom) with average lifetime of the whole image for each sensor construct are shown
as indicated. Scale bar = 20 µm; τ = fluorescent lifetime. B) Graphs showing the average
donor fluorescent lifetime change after EGF stimulation for each sensor construct with S.E.M.
as indicated. Only lifetime changes for EAS3 and EAS4 were significant (α = 0.01)
All four sensor constructs displayed a change in fluorescent donor lifetime 5 - 10 min
after stimulation with EGF returning more or less to the pre-stimulation value after
20 min (Fig. 3.17). However, this change was statistically significant only for EAS3
and EAS4 (pEAS1 = 0.50, pEAS2 = 0.50, pEAS3 = 0.38 x 10
−8, pEAS4 = 0.12 x 10−9;
α = 0.01, one-tailed t-test). EAS4 was the sensor construct with the highest dynamic
range of 70 ± 10 ps on average and 140 ps observed in individual cells (Fig. 3.17 and
Table S.3.4). Surprisingly, the direction of observed lifetime change was not consistent
among the four different constructs as expected from their design principle. In agreement
with the principle of ES-imaging, EAS1 and EAS2 exhibited a decrease in lifetime after
stimulation of cells with EGF, indicating an increase in FRET upon binding of the
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substrate peptide to activated ERK2 (Fig. 3.16B and Fig. 3.17). In contrast, EAS3 and
EAS4 displayed an increase in donor lifetime after EGF stimulation rather than the
expected decrease, indicating for a loss of FRET upon sensor activation and substrate
peptide binding to ERK2’s active site (Fig. 3.17). The fact that the observed lifetime
change was more or less reversible in all constructs indicates that the underlying ES-
interactions mediating the change in FRET efficiency indeed reflect the activation state
of ERK2.
3.4.3 Specificity of the ERK2 “ES-Imaging” Intramolecular FRET Sensor
Construct 4
Two investigate the specificity of the observed lifetime change of the EAS4 construct
to EGF stimulation three different control constructs were cloned (Fig. 3.18A). EAS4
K52R harbours the lysine 52 to arginine mutation of ERK2 rendering the kinase
catalytically inactive. In EAS4 TAYA amino acids Thr183 and Tyr185 of the ERK2
sequence were mutated to alanine to prevent phosphorylation and thus activation of
ERK2. In EAS4 ElkMut, amino acids corresponding to positions 383-404 of hElk1 were
scrambled and reconstructed into a peptide sequence that was build from the same
amino acids but lacking any structural similarity to the original hElk1 peptide se-
quence including the consensus phosphorylation sites and the DEF domain (Fig. 3.18A).
EAS4 K52R, EAS4 TAYA and EAS4 ElkMut were generated by in-vitro site-directed
mutagenesis using MAPK1 K52R for and rev, MAPK1 TAYA for and rev, or MutElk1
for and rev, respectively. The identity of all constructs was confirmed by sequencing
(data not shown).
Phosphorylation of EAS4 mutants in their cellular environment upon EGF stimulation
was analysed by co-expressing each mutant with MEK1 in HeLa cells and comparing
phosphorylation of ERK2 and hElk1(375-404) in the mutant chimeric proteins to the
wt construct after EGF stimulation in western blots.
Endogenous ERK2 phosphorylation increased substantially upon stimulation with 100
ng/ml EGF in all samples. Accordingly, phosphorylation of ERK2 in EAS4 wt, EAS4
K52R and EAS4 ElkMut was also substantially elevated after EGF treatment (Fig.
3.18B). However, no phosphorylation of EAS4 TAYA, lacking the amino acid residues
important for ERK2 activation, could be detected (Fig. 3.18B).
In addition, substantially more phospho-Elk1, indicating phosphorylation of the
substrate peptide, could be detected after EGF stimulation in EAS4 wt, while the
phospho-Elk1 antibody did not recognise the scrambled substrate peptide in EAS4
ElkMut. Unexpectedly, a minor increase in substrate peptide phosphorylation was
observed for EAS4 K52R and EAS4 TAYA(Fig. 3.18B).
Next, specificity of the lifetime change of EAS4 wt to ERK2 activation was analysed
by measuring donor fluorescent lifetimes of each EAS4 mutant before and 5, 10 and 20
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Figure 3.18: Wild-type ERK2 Activity Sensor 4 and its mutants. A) Schematic re-
presentation of wild-type EAS4 and its mutants. Primary sequence of the substrate peptide
of EAS4 wt is shown with the minimal consensus phosphorylation sites (highlighted in green)
and the DEF-domain (underlined). Mutated amino acid residues in EAS4 K52R and EAS4
TAYA are indicated by red lines. Primary sequence of the substrate peptide in EAS4 ElkMut
(indicated in blue) is made from the same amino acids found in hElk1(375-404) but scrambled
and reconstructed into a new sequence lacking any structure that can be recognised by ERK2. B)
EAS4 mutants are being phosphorylated according to their mutation. Western blot analysis of
whole cell lysates from cells expressing one of four EAS4 mutants in either starved or stimulated
(7 min, 100 ng/ml EGF) conditions. 50 µg of protein were loaded on a 10 % polyacrylamide gel.
Endogenous MAPK expression and phosphorylation was used as an internal control.
min after stimulation with 100 ng/ml EGF using FLIM.
EAS4 wt displayed a significant change in average donor lifetime of 60 ± 10 ps or 140
ps in indivual cells as described above (pwt = 0.36 x 10
−10, α = 0.01, one-tailed t-test)
as well as translocation of the sensor protein to the nucleus shortly after stimulation
(Fig. 3.19 and Table S.4.1). Similarly, EAS4 K52R also showed translocation of the
sensor construct to the nucleus. The observed average lifetime change 5 - 10 min after
EGF stimulation was statistically significant (pK52R = 0.18 x 10
−8, α = 0.01, one-tailed
t-test) but with only 30 ± 10 ps on average smaller than for the wt construct (Fig.
3.19 and Table S.4.2). In sharp contrast to the wildtype construct, the lifetime change
observed with EAS4 K52R was more or less stable for times longer than 20 min after
EGF stimulation.
As expected, the non-phosphorylatable mutant of EAS4, EAS4 TAYA, did not translo-
cate to the nucleus at any time point after EGF stimulation as ERK2 requires phospho-
rylation of Thr183 and Tyr185 in the activation loop for translocation. Accordingly,
EAS4 TAYA did not show any change in lifetime after EGF stimulation as binding of
the substrate peptide to the active site of ERK2 requires phosphorylation (Fig. 3.19 and
Table S.4.3).
Since the ERK2 sequence in EAS4 ElkMut was not affected, the construct translo-
cated to the nucleus in a fashion similar to the wt construct. But due to the inability
of ERK2 to recognise the mutated substrate peptide, no lifetime change was detected
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Figure 3.19: ERK Activity Sensor 4 specifically reports ERK2 activity. A)FLIM of
live cells expressing one of four different EAS4 mutants showing a visible donor fluorescent
lifetime change after stimulation with 100 ng/ml EGF only for EAS4 wt. Representative image
sequences of cells co-expressing MEK1 and one EAS4 mutant. Fluorescent intensity images (top)
and pseudocolour lifetime maps (bottom) for each EAS4 mutant are shown as indicated. Scale
bar = 20 µm; τ = fluorescent lifetime. B) Graphs showing the average donor fluorescent lifetime
change after EGF stimulation for each sensor construct with S.E.M. as indicated. Only lifetime
changes for EAS4 wt and EAS4 K52R were significant (α = 0.05).
after EGF stimulation (Fig. 3.19 and Table S.4.4).
These results show, that EAS4 wt specifically reports ERK2 activity in a time-de-
pendent manner.
3.4.4 Ratiometric FRET Imaging of ERK2 Activity Sensor 4
EAS4 was designed as an intramolecular FRET sensor. Thus, FRET between donor
and acceptor fluorophore could be detected by ratiometric FRET imaging, offering sig-
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nificantly improved spatial and temporal resolution, greatly simplifying data acquisition
and analysis and increasing the signal-to-noise ratio (Yasuda, 2006). Ratiometric FRET
imaging was implemented on a confocal microscope, because the low light sensitivity of
cameras installed on accessible widefield fluorescent microscopes required long exposure
times, thereby compromising the photostability of the fluorophores (data not shown)
To allow the maximally possible number of photons to be collected from the sample,
the pinhole was opened completely, virtually transforming the confocal into a widefield
microscope.
Figure 3.20: ERK2 activation precedes ERK2 translocation. Ratiometric FRET imaging
can be used to analyse ERK2 activity in living cells with high spatio-temporal resolution. A)
Representative image sequence of HeLa cells co-expressing MEK1 and EAS4 wt and stimulated
with 100 ng/ml EGF. Fluorescent intensity (top) and pseudocolour FRET ratio images (bottom)
are shown. Scale bar = 20 µm. B) Representative graphs of two cells (blue and red) depicting
nuclear fluorescence (dashed lines) as a measure of ERK2 translocation and average FRET ratio
per cell (continuous lines). C) Graphs depicting average whole cell FRET ratio of HeLa cells
expressing EAS4 wt (red) or EAS4 TAYA (blue) after stimulation with 100 ng/ml EGF at t =
0 min. Graphs are shown with S.E.M.
To test EAS4 in ratiometric FRET imaging, EAS4 wt was co-expressed with MEK1
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in HeLa cells. Cells were starved overnight and nuclei stained with Hoechst 33342 to
simplify quantification. Ratiometric FRET imaging was performed as described in
2.2.5.2. Images were taken every 60 sec and cells stimulated with 100 ng/ml EGF after
3-5 min. Data were analysed as described in 2.2.5.4. FRET ratios were quantified as
FRET ratios per whole individual cell.
Improved temporal resolution is demonstrated by the ability to follow translocation
of EAS4 wt to the nucleus of HeLa cells after EGF stimulation (Fig. 3.20A) in a fashion
similar to fluorescently labeled ERK2 (see Section 3.1.2). Whole cell FRET ratios of
individual cells displayed a sudden rise 1 - 5 min after EGF addition reflecting a rapid
and strong activation of the sensor construct. FRET ratios peaked between 5 - 15 min
after EGF addition before slowly decreasing to approximately one third of the peak
value (Fig. 3.20B). Maximal FRET ratio change observed in individual cells was 18
%. This change in FRET ratio could also be observed in pseudocolour FRET ratio
images by a shift of blue to green colours at corresponding time points (Fig. 3.20A). The
change in FRET ratio of the sensor generally resembles the characteristic translocation of
phosphorylated ERK2 to the nucleus (see Fig. 3.2). The observed time profile for FRET
ratios of EAS4 also demonstrates the reversibility of the underlying ES-interactions.
More importantly, improved temporal resolution revealed that activation of EAS4 wt
actually precedes ERK2 translocation (Fig. 3.20B).
In addition, FRET ratios of EAS4 TAYA did not rise significantly above pre-stimu-
lation values for more than 40 min after EGF treatment (Fig. 3.20C).
Ratiometric FRET imaging was used for further analysis of ERK2 activation due to
its superior temporal resolution and simplicity.
3.5 Resolving Spatio-Temporal Regulation of the
MAPK-Module in MCF-7 (Epithelial Breast Cancer
Derived) Cells
MCF-7 is a transformed mammary epithelial cell line derived from human breast
epithelial adenocarcinoma (Brooks et al., 1973; Soule et al., 1973). In MCF-7 cells, EGF
induces transient ERK1/2 activation encoding a proliferative signal, while heregulin
(HRG) generates sustained ERK1/2 activation resulting in cell differentiation (Thot-
tassery et al., 2004; Nagashima et al., 2007). To test the potential of EAS4 in resolving
spatio-temporal ERK2 activity in breast cancer cells, EAS4 was used to analyse MAPK
activation in response to EGF and HRG in MCF-7 cells.
EAS4 was co-expressed with MEK1 in MCF-7 cells. Cells were starved overnight
and stimulated with 100 ng/ml EGF or 100 ng/ml HRG. Whole cell lysates were
prepared, and phosphorylation of endogenous ERK1/2 and ectopically expressed EAS4
was analysed by quantitative western blotting.
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Previously described transient and sustained activation (i.e. phosphorylation) in
response to treatment with 100 ng/ml EGF or HRG (Fig. 3.21) was observed for
endogenous ERK1/2. Overexpressed EAS4 wt showed similar phosphorylation patterns
after stimulation with EGF or HRG (Fig. 3.21).
Figure 3.21: Transient vs. sustained ERK2 activity in MCF-7 cells upon stimulation
with EGF vs. HRG. A) Western blot of ERK1/2 and EAS4 phosphorylation in response
to EGF and HRG treatment in MCF-7 cells. Cells co-transfected with MEK1 and EAS4 wt
were starved overnight and stimulated with either 100 ng/ml EGF or HRG. Whole cell lysates
were prepared and subjected to SDS-PAGE and western blotting. B) Quantitative western blot
data showing activity, i.e. phosphorylation state, of ERK1/2 (ppERK1/2) and EAS4 (ppEAS4)
in response to EGF and HRG stimulation of MCF-7 cells as shown in A). Phospho-protein
(ppERK1/2 and ppEAS4) was normalised to total protein (ERK1/2 or EAS4, respectively). For
direct comparison, pre-stimulation values of EGF and HRG stimulation were normalised to 1.
Data are averages from two independent experiments and shown with S.E.M.
Ratiometric FRET imaging was performed on MCF-7 cells co-expressing EAS4 and
MEK1 as described in 2.2.5.2. Cells were starved overnight and stimulated with 100
ng/ml EGF or 100 ng/ml HRG. Nuclei were stained with Hoechst 33342 to simplify
quantification. Images were taken every 60 sec and cells stimulated after an initial
baseline recording of 3-5 min. Data were analysed as described in 2.2.5.4.
FRET ratios of EAS4 revealed the transient ERK2 response after EGF treatment,
known from the literature, in both the cytosol and nucleus (Fig. 3.22B and C). Sur-
prisingly, however, HRG-induced sustained ERK2 activity was predominantly cytosolic
(Fig. 3.22C), while HRG-induced nuclear ERK2 activity was found to be transient (Fig.
3.22B).
These results show that EAS4 can indeed be used to resolve biologically meaningful
characteristics of ERK2 activation that were previously unknown.
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Figure 3.22: HRG-induced sustained ERK2 activity in MCF-7 cells is predominantly
cytosolic. A) Ratiometric FRET imaging showing transient vs. sustained ERK2 activation upon
stimulation with EGF or HRG. Representative image sequences of MCF-7 cells co-expressing
MEK1 and EAS4 wt. Cells were starved overnight and stimulated with 100 ng/ml EGF or
HRG. Fluorescent intensity (top) and pseudocolour FRET ratio images (bottom) for each growth
factor are shown as indicated. Scale bar = 20 µm. B) and C) Average FRET ratio data showing
that sustained ERK2 activity upon HRG stimulation is cytosolic. Graphs representing average
normalised FRET ratios in the nucleus (B) or cytosol (C) of MCF-7 cells stimulated with EGF
(blue) or HRG (red) are shown with S.E.M.
If sustained ERK2 signalling in response to HRG in MCF-7 cells is dependent on
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continuous activation of ERK2, inhibition of upstream activators of ERK1/2 should
abrogate the ERK signalling as well as the FRET signal obtained by EAS4. To test
this hypothesis, MEK inhibitor U0126 was added to HRG-stimulated cells.
MCF-7 cells were co-transfected with EAS4 wt and MEK1, starved overnight and
stimulated with 100 ng/ml HRG. 20 min after growth factor stimulation 100 µM U0126
were added. Cells were then subjected to ratiometric FRET imaging or whole cell
lysates were prepared for western blotting.
Addition of U0126 to HRG-stimulated cells led to a reduction of the endogenuos
ppERK1/2 below detection limits (Fig. 3.23A) in western blots. Also phosphorylation
of EAS4 was markedly decreased after U0126 addition, although not as completely (Fig.
3.23A).
Figure 3.23: HRG-induced sustained ERK2 activation is dependent on continuous
MEK1 signalling. A) Western blot of ESA4 and endogenuos ERK1/2 phosphorylation showing
that addition of U0126 20 min after HRG stimulation leads to a loss of ERK activity. MCF-7 cells
co-expressing MEK1 and EAS4 were starved overnight and stimulated with 100 ng/ml HRG. 100
µM U0126 were added 20 min after HRG stimulation. B) FRET ratios of MCF-7 cells expressing
MEK1 and EAS4 showing decreasing ERK2 activity after U0126 treatment of HRG-stimulated
cells. Graphs show average whole cell FRET ratio in cells stimulated with HRG (red) and cells
where U0126 was added 20 min after stimulation (blue) with S.E.M.
In agreement with this, FRET ratios of EAS4 slowly decreased after U0126 addition
over a time course of 20 min to approximately 25 % of the pre-stimulation value (Fig.
3.23B). These results indicate that continuous signalling via MEK1 is required for the
HRG-induced sustained ERK2 reponse.
In PC12 cells, EGF-induced transient ERK1/2 activity can be converted into a
sustained ERK1/2 response by introducing a PKC-mediated feedback loop in the
MAPK module via PMA stimulation (Santos et al., 2007). To test whether it might be
possible to induce a similar feedback loop in MCF-7 cells and to investigate its effect
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on spatio-temporal ERK signalling, MCF-7 cells were stimulated with EGF, EGF and
PMA, or PMA alone. ERK2 activation was analysed by quantitative western blotting
and ratiometric FRET imaging.
MCF-7 cells were starved overnight and stimulated with 100 ng/ml EGF, 100 ng/ml
EGF and 100 nM PMA, or 100 nM PMA alone. Whole cell lysates were prepared for
quantitative western blotting. Because they were derived from the same extract of
untreated cells, pre-stimulation values of cells treated with EGF, EGF + PMA, or PMA
alone were normalised to 1. In accordance with that, values for EGF treated cells from
different gels were averaged as they have also been derived from the same cell extracts.
Alternatively, cells co-expressing EAS4 wt and MEK1 were subjected to ratiometric
FRET imaging.
Stimulation of MCF-7 cells with EGF and PMA resulted in sustained ERK1/2 phos-
phorylation as shown by quantitative western blotting (Fig. 3.24A and B). Stimulation
with EGF or PMA alone, led to transient or sustained, but markedly lower ERK1/2
phosphorylation, respectively (Fig. 3.24A and B).
Likewise, using EAS4, sustained cytosolic ERK2 activity was detected in MCF-7 cells
stimulated with EGF and PMA (Fig. 3.24D). Stimulation with PMA alone also resulted
in sustained cytosolic ERK2 activity, but the amplitude of the signal was lower than in
the cytosol of cells stimulated with EGF and PMA. In contrast, cytosolic ERK2 activity
in cells stimulated with EGF and nuclear ERK2 activity in all cells was transient (Fig.
3.24C and D). These data hint at the existence of PKC-mediated feedback loops in
the MAPK module that may be responsible for sustained ERK activation in MCF-7 cells.
These data do not only show the usefulness of EAS4 for the investigation of ERK
signalling in living cells but also demonstrate its potential in uncovering previously
inaccessible spatio-temporal signalling caracteristics of ERK.
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Figure 3.24: Co-activation of PKC can convert EGF-induced transient ERK2 sig-
nalling in a sustained ERK2 response in MCF-7 cells. A) Western blot of ERK1/2 in
MCF-7 cells in response to treatment with EGF, EGF + PMA, or PMA alone. Cells were starved
overnight and stimulated with 100 ng/ml EGF, 100 ng/ml EGF and 100 nM PMA, or 100 nM
PMA alone. Whole cell lysates were prepared and subjected to SDS-PAGE and western blot-
ting. B) Quantitative western blot data showing activity, i.e. phosphorylation state, of ERK1/2
(ppERK1/2) as shown in A). Phospho-ERK1/2 was normalised to total ERK1/2. For direct
comparison, pre-stimulation values of EGF, EGF + PMA, or PMA stimulation were normalised
to 1. Values for EGF treatment are the average of both gels shown in A) as they have been
derived from the same cell extracts. C) and D) Average FRET ratio data showing that EGF-
induced transient ERK2 activity can be converted into a sustained cytosolic ERK2 response by
co-stimulation with PMA. Graphs representing average normalised FRET ratios in the nucleus
(C) or cytosol (D) of MCF-7 cells stimulated with EGF (blue), EGF + PMA (red), or PMA
alone (green) are shown with S.E.M. A part of the EGF + PMA curve is missing because no
reliable signal could be obtained from a few of the measured cells.
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4 Discussion
4.1 An Intramolecular ReAsH-Based FRET-Biosensor for
ERK2 Activation
Large sized tags like GFP (27 kDa) can disrupt the functionality of fluorescently labeled
proteins(McLean et al., 2001; Lisenbee et al., 2003; Vilardaga et al., 2003; Andresen et al.,
2004) and can be avoided by labeling with smaller, chemical fluorophores (Andresen
et al., 2004; Hoffmann et al., 2005; Nakanishi et al., 2006; Roberti et al., 2007). Usually,
this requires in-vitro modification of the purified protein of interest and subsequent re-
introduction of the labeled protein into the biological system in question. This process
is complicated and time consuming.
By specific, in-vivo labeling of recombinant proteins tagged with a short tetracysteine
(4C) motif by biarsenical fluorescent dyes, namely fluorescein arsenical hairpin binder
(FlAsH) and resofurin arsenical hairpin binder (ReAsH) (Fig. 4.1A), the size addition
can be kept to less than 2 kDa (Griffin et al., 1998). FlAsH and ReAsH are able to
bind to four cysteine residues in a hairpin structure (Griffin et al., 1998; Martin et al.,
2007; Madani et al., 2009). In principle, this 4C motif can be as short as six amino
acids (CCPGCC), although an optimised version of the 4C motif contains 12 amino
acids (FLNCCPGCCMEP) (Martin et al., 2005). As FlAsH-EDT2 and ReAsH-EDT2
are cell-permeable, the dye can simply be added to the medium for intracellular protein
labeling and will then diffuse across the cell membrane. Only when bound to the 4C
motif, the virtually non-fluorescent dyes become brightly fluorescent (Fig. 4.1B) (Griffin
et al., 1998). To allow visualisation of specifically labeled proteins, excess, non-bound
dye can be washed out with small dithiols like 2,5-dimercaptopropanol (British anti-
Lewisite, BAL) or 1,2-ethandithiol (EDT), which have higher affinities for biarsenical
dyes than cellular thiols (Griffin et al., 1998).
FlAsH- and ReAsH-labeling of 4C-tagged proteins has been used in a variety of
organisms from bacteria to mammalian cells (Andresen et al., 2004; Hwang et al., 2009;
Copeland et al., 2010) and approaches to image - among others - gap junction protein
trafficking (Gaietta et al., 2002), yeast microtubule association (Andresen et al., 2004),
amyloid formation in neurons (Roberti et al., 2007; Taguchi et al., 2009; Gaspersic
et al., 2010), virus production and trafficking (Rudner et al., 2005; Turville et al.,
2008) and flagellar dynamics in E.coli (Copeland et al., 2010). Additonally, biarsenical
dye-based FRET approaches have been extensively used to study G protein-coupled
receptor activation in living cells (Hoffmann et al., 2005; Nakanishi et al., 2006; Nikolaev
et al., 2006; Maier-Peuschel et al., 2010). However, no FRET-based approach to assess
kinase activity using biarsenical fluorophores has been found in the literature until today.
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Figure 4.1: Structure and principle of biarsenical fluorophores. A) Chemical structure
of FlAsH-EDT2 and ReAsH-EDT2 ligands (adapted from Gaietta et al., 2002). B) Binding
of nonfluorescent biarsenical dyes to a recombinantly expressed 4C motif results in a highly
fluorescent complex (adapted from www.invitrogen.com/site/us/en/home/Products-and-Ser-
vices/Applications/Cell-and-Tissue-Analysis/Cellular-Imaging/High-Content-Screening/FlAsH-
and-ReAsH.html).
In an attempt to identify regions in ERK2 that change conformation upon activa-
tion of the kinase and are accessible for labeling by an external chemical fluorophore,
crystal structures of phosphorylated and unphosphorylated ERK2 (Zhang et al., 1994;
Canagarajah et al., 1997) were superimposed. Four suitable regions were identified (Fig.
3.3B and Canagarajah et al., 1997). Of those regions, especially the activation loop of
ERK2 undergoes a dramatic conformational change upon phosphorylation of the kinase
(Canagarajah et al., 1997). The original amino acid sequence of ERK2 in the identified
regions were chosen for replacement with either the minimal or optimised 4C motif (Fig.
3.3B and C and Fig. S.1.1) similar to the approach of Nakanishi et al., 2006. In addi-
tion, the N- or C-terminus of ERK2 were tagged with the 4C motif in ERK2-mCitrine
or mCitrine-ERK2, respectively. A FRET pair of FPs were fused to ERK2 at the N-
and C-terminus to form a functional, intramolecular, conformational FRET-sensor for
ERK2 (Sato et al., 2007). Therefore, labeling of mCitrine-tagged ERK2 with ReAsH at
the N- or C-terminus was supposed to build a functional sensor construct, theoretically
offering an increased dynamic range due to a possible smaller distance between the two
fluorophores.
The conformational change of ERK2 induced by its phosphorylation would concur-
rently lead to a change of distance and/or orientation of mCitrine to ReAsH, bound
to the 4C motif (Fig. 3.3A and B). Since mCitrine and ReAsH form a good FRET
pair, the conformational change could be detected by the resulting change in FRET
signal (Fig. 3.3A). FRET could theoretically be measured ratiometrically or by FLIM.
It should be kept in mind that although the sensor design and principle is based on
intramolecular FRET, labeling efficiency by ReAsH may not reach 100 %. Correct
ratiometric FRET analysis, however, relies on equimolar stoichiometries of donor and
acceptor fluorophores (Miyawaki, 2003; Yasuda, 2006). Indeed, although the fluorescent
lifetime decay of mCitrine is reported to be mono-exponential (Walther et al., 2011)
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and fitted well to a single exponential when expressed as an ERK2 fusion protein alone
(data not shown), fluorescent lifetime decays in the presence of ReAsH could never be
described by a mono-exponential decay model (data not shown), indicating labeling
efficiencies of less than 100 %. Therefore, FLIM or other FRET approaches appropriate
for intermolecular FRET should be used to determine FRET.
Specific binding of ReAsH to the 4C motif introduced into fluorescently labeled ERK2
could be shown by a marked decrease in fluorescent donor (mCitrine) lifetime (Fig. 3.5B),
due to the occurence of FRET between mCitrine and the biarsenical dye. Addition of
ReAsH to the medium of cells that did not express 4C motif-tagged proteins led to a
markedly smaller decrease in mCitrine lifetime. It is interesting to note that the observed
changes in lifetime as a measure of the FRET efficiency were highly dependent on the
positions of the donor fluorophore and the 4C motif (Fig. 3.9). For example, positions
of the 4C-motif in mCitrine-ERK2-4C(174-179) and ERK2-4C(175-180)-mCitrine differ
only in one amino acid, but still they display remarkably different fluorescent donor
lifetimes after 60 min of incubation with ReAsH. This exemplifies the importance of the
donor fluorophore position for FRET in general.
Kinetics of binding of ReAsH to the 4C motif could be described by a sigmoidal func-
tion, in contrast to previous reports (compare Fig. 3.5B and Griffin et al., 1998; Hoffmann
et al., 2005). There is no good explanation for that discrepancy as those data were also
measured in living mammalian cells. Slow diffusion of the DMSO-dissolved ReAsH can-
not be considered as the cause, because ReAsH was pre-diluted in 250 µl medium before
being added to cells covered by 250 µl medium. However, the time scale for full labeling
until no further decrease in fluorescent lifetime could be observed was similar to pre-
viously published results (compare Fig. 3.5B and Griffin et al., 1998; Hoffmann et al.,
2005).
Taken together, these data demonstrate that it is possible to specifically label
recombinant proteins containing the 4C motif with ReAsH in agreement with previously
published data. It may be interesting to note that unspecific background staining by
ReAsH was always present, but could be markedly decreased by using the optimised
version (Martin et al., 2005) of the tetracysteine motif (Fig. 3.6). Background reduction,
however, required washout of ReAsH by BAL. Similarly high background intensity was
observed with both versions of the 4C motif 60 min after incubation with ReAsH but
before washout with BAL (Fig. 3.6). Since ReAsH (acceptor) background fluorescence
may influence results of intensity-based fluorescent imaging techniques, the use of
biarsenical dyes for protein labeling can only be recommended for fluorescence lifetime
approaches or in-vitro studies with purified proteins (researchers should make sure there
are no other cysteine residues that could bind to the biarsenical dyes).
Interestingly, the ReAsH-ERK2 biosensor construct used for the labeling experiments
accumulated slowly in the nucleus of HeLa cells over the time course of ReAsH incubation
(Fig. 3.5A). Two scenarios are conceivable: The conformational state of the activation
loop in ERK2 represents a dynamic equilibrium. In phosphorylated ERK2, the activa-
tion loop primarily adopts the active, “open” conformation, while in non-phosphorylated
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ERK2, the equilibrium is shifted to the “closed”, inactive conformation. Biarsenical dyes
may preferably label the 4C motif in the activation loop when in the “open” conforma-
tion. Binding of ReAsH to the 4C motif in the small fraction of non-phosphorylated
ERK2 with the activation loop in the “open” conformation may then “lock” the activa-
tion loop in the active conformation, mimicking full activation of ERK2 and subsequent
translocation. In addition, basal levels of active ERK2 exists even in resting cells (Ando
et al., 2004; Fujioka et al., 2006; Santos et al., 2007 and Fig. 3.24). ReAsH labeling of
basally active ERK2 would also add to the pool of ReAsH bound ERK, slowly accu-
mulating in the nucleus. As a consequence, ReAsH labeling kinetics of active 4C-ERK2
(e.g. in the presence of EGF) should be faster than those of inactive ERK2 and could
already be used as a sensor of active ERK2 by itself. Alternatively, sensor construct
translocation could be an artifact of the imaging process, e.g. ERK2 activation via a
light-induced stress response.
However, the first scenario is rather unlikely because of a number of reasons:
First and most importantly, labeling kinetics of the tested ReAsH-ERK2 biosensor
construct in the presence or absence of EGF were virtually identical (Fig. 3.5B).
Second, slow nuclear accumulation of other chimeric proteins containing ERK2 in
starving cells has also been observed after imaging for more than 20-30 min or high
laser powers (Fig. S.5.1). Third, ERK2 activity as measured by a newly developed
FRET-based biosensor for ERK2 (see Sections 3.4 and 4.3) slowly increases in starving
cells when imaged for more than 20-30 min, coinciding with slow nuclear accumulation
(Fig. S.5.1). Fourth, membrane translocation of fluorescently labeled RafRBD as
a measure of Ras activation (Rocks et al., 2005) can be observed without growth
factor stimulation at late time points during imaging (Dr. Ali Kinkhabwala, personal
communication). Taken together, these results strongly hint at a light-induced artifact
for the cause of the observed slow nuclear accumulation of ReAsH-ERK2 biosensor
constructs. Indeed, light-induced ERK1/2 activation as well as both the light-induced
production of reactive oxygen species (ROS) and activation of ERK1/2 by ROS are
known in the literature (Chen et al., 1995; Obrietan et al., 1998; Rittie´ and Fisher, 2002).
Cloned ReAsH-ERK2 sensors were screened for a functional sensor construct by
FLIM. From the nineteen constructs, only one showed a significant change in lifetime
after EGF stimulation (Fig. 3.7). With no construct, lifetime changes resembling known
ERK2 activation profiles could be observed. For most constructs, lifetime changes were
in a similar range as those observed for donor only samples and/or did not change
consistently in only one direction. Three constructs were tested further in an experiment
omitting the washing step with BAL. FLIM measures only the donor fluorescent
lifetime while acceptor fluorescence is not detected, allowing the presence of saturating
amounts of acceptor or acceptor-labeled molecules (Bastiaens and Pepperkok, 2000).
Thus, removal of ReAsH from the medium is in principle not required. Omitting the
washing step with BAL led to significantly lower fluorescent lifetimes of mCitrine in the
ReAsH-ERK2 sensor constructs (Fig. 3.9). On the other hand, unspecific FRET signals
as measured by a decrease in fluorescent lifetime also increased due to background
labeling in cells without 4C motif-tagged cells (Fig. 3.5). Also, without ReAsH washout
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no labeling difference between the minimal and optimised 4C motif could be detected
anymore (Fig. 3.6).
As a result, it has not been possible to identify a functional sensor construct. Poten-
tially, the attempted design simply does not yield a functional ERK2 sensor. Confor-
mational changes in the aa 9-14 and aa 30-35 regions have been estimated to be in the
range of less than 1 nm and might therefore be too small to result in a significant change
in FRET efficiency, as protein conformational changes optimal for FRET are in a range
of 4-7 nm (Li et al., 2006). On the other hand, changes in FRET efficiencies are thought
to result most often from reorientation of the fluorophore rather than distance changes
(Giepmans et al., 2006). Thus, it is possible that a conformational change that could
change the FRET efficiency is counteracted by a concurrent opposite change in dipole
orientation.
Structural studies of phosphorylated ERK2 show that amino acids between Asp173
and His176 are important for the coordination of the phosphorylated activation loop
to the so-called L16 lip essential for ERK2 activation (Canagarajah et al., 1997). In all
mutant ERK2 proteins containing the 4C motif in the activation loop, at least one of
these amino acids is replaced by amino acids of the 4C motif. It is thus very likely that
these mutant ERK2 proteins simply cannot undergo the normal conformational change
induced by phosphorylation.
Although, C- or N-terminal fusions of mCitrine-tagged ERK2 with the 4C motif, did
not yield a functional ERK2 sensor, ERK2 sandwiched by a FRET-pair of FPs did
(Fujioka et al., 2006). This, in contrast, might be an indication that other reasons play
a role for the inability to identify at least those ReAsH-ERK2 sensor constructs as a
functional sensor.
In summary, it was possible to establish in-vivo labeling of tetracysteine-tagged pro-
teins with biarsenical fluorophores. Important points to consider, when planning to use
biarsenical fluorophores are: a) use of the optimised 4C motif provides reduced back-
ground labeling after the washout of the biarsenical fluorophores. b) ReAsH is known to
be less photo-stable than FlAsH, therefore, FlAsH is the biarsenical dye recommended
for labeling 4C motifs, if possible, in the given experimental setup (TC-FlAsHTM TC-
ReAsHTM II In-Cell Tetracysteine Tag Detection Kit manual, InvitrogenTM). c) ReAsH
can induce transient morphological changes (TC-FlAsH TC-ReAsH II In-Cell Tetracys-
teine Tag Detection Kit manual, Invitrogen), possibly due to generation of ROS when
ReAsH is exposed to light (Adams et al., 2002). d) Relatively long incubation times
(more than 60 min) for full labeling may be required. It may be reasonable to label cells
before starvation, if starvation is required for the planned experiment.
However, the technique could not be successfully employed to create a ReAsH-based,
intramolecular FRET biosensor for ERK2 activity. The sensor design followed principles
previously used to create biosensors for GPCR activity (Nakanishi et al., 2006) or con-
formational ERK2 FRET-sensors (Fujioka et al., 2006) and would have been the first
kinase sensor based on biarsenical dyes.
Nevertheless, the presented data do not rule out the possibility that a conformational
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ERK2 sensor based on labeling with biarsenical fluorophores can function in principle.
Introduction of the 4C motif as an additonal loop between adjacent amino acids in
the activation loop rather than replacing a number of amino acids might conserve
the activation loop properties required for normal protein function. Relatively slow
image acquisition times of the time-domain FLIM microscope may compromise the
dynamic range of the approach as discussed in detail in Section 4.2.2. Faster FLIM
equipment (Yasuda, 2006; Harvey et al., 2008b) or a fast intensity-based FRET
method circumventing the problem of ReAsH background labeling might help to detect
significant fluorescent donor lifetime changes. Improvements may also result from the
use of mTFP as a donor fluorophore for FLIM (Padilla-Parra et al., 2009; Walther
et al., 2011) and FlAsH with its higher photostability and lack of potential to induce
morphological changes.
4.2 Visualising Spatio-Temporal ERK2 Activity by Imaging
Transient Enzyme-Substrate Interactions
Traditional, biochemical methods to analyse MAPK signaling using immunoblots and
radioactive labeling are restricted to population averages and therefore provide very little
or no spatio-temporal information. Immunofluorescence also only provides poor temporal
information about protein activities, due to the fixation process. According to present
knowledge, only dynamic, live-cell imaging approaches using fluorescent biosensors are
able to resolve protein activity in spatio-temporal manner (Miyawaki, 2003; Yasuda,
2006; Schultz, 2007).
An approach to detect and potentially even measure enzyme activity directly with
high spatio-temporal resolution is the visualisation of transient enzyme-substrate (ES)
complexes. As shown in Fig. 3.10, the binding of a substrate peptide to the active site
of the enzyme required for modification and thus the formation of the ES complexes
can be detected by measuring FRET/FLIM between a donor-tagged enzyme and an
acceptor-labeled substrate peptide (Yudushkin et al., 2007). Exclusive specificity is
achieved by attaching the donor fluorophore specifically to the enzyme of interest
(Schultz, 2007). Fluorescent lifetimes can be converted into fractions of unbound and
bound enzyme populations, with the latter representing the amount of ES complex, by
global analysis (Verveer et al., 2000; Lakowicz, 2006; Yudushkin et al., 2007; Schultz,
2007; Grecco et al., 2009). High amounts of ES complexes denote low enzyme activity
and vice versa (Schultz, 2007). This technique can potentially provide information about
binding affinities and kinetics of protein interactions as well as enzymatic activities
both in-vitro and in-vivo (Yudushkin et al., 2007; Gru¨nberg and Serrano, 2010) and has
been successfully employed to reveal spatio-temporal regulation of PTP1B upon growth
factor stimulation (Yudushkin et al., 2007).
In an attempt to visualise MAPK activity by imaging transient ES intermediates
of ERK2 and a short substrate peptide, both in-vitro and in-vivo experiments were
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performed (see Section 3.3).
4.2.1 In-Vitro Detection of Transient ERK2 Enzyme-Substrate Interactions
In the proof-of-principle in-vitro experiments, bacterially expressed and purified wt and
mutant mCitrine-ERK2 proteins and a lissamine-rhodamine B-labeled, synthetic ERK2
substrate peptide representing amino acids 382-403 of the human transcription factor
Elk1 were employed. Elk1 is a known substrate of ERK2 including the consensus MAPK
phosphorylation site (P-X-S/T-P) (Gille et al., 1995; Yang et al., 1998b,a) and contains
a DEF-domain (F-X-F-P) (Jacobs et al., 1999; Fantz et al., 2001). The DEF-domain
binds only to phosphorylated ERK2 as it cannot access its binding pocket when the
unphosphorylated activation loop of ERK2 is in the inactive conformation (Lee et al.,
2004; Yoon and Seger, 2006).
Elegant protocols for the purification of active ERK2 have been described in the lit-
erature. One is based on the co-expression of constitutively active MEK1 in E. coli
(Khokhlatchev et al., 1997). This, however, depends on the availability of bacterial ex-
pression vectors encoding for constitutively active MEK1. Also, one has to express and
purify ERK2 proteins without the presence of mutant MEK1 for control experiments,
significantly exentending the number of samples with all the associated disadvantages.
Other protocols uses immunoprecipitation of HA-tagged ERK2 proteins from resting
and growth factor-stimulated mammalian cells (Brunet et al., 1994). While immuno-
precipitation is a highly laborious technique by itself, again ERK2 and ppERK2 have
to be purified from different samples and in addition for full activation of ERK2, also
the time point of purifcation is crucial, causing even more potential errors. For rea-
sons of simplicity, mCitrine-ERK2 wt and mutants were expressed in E. coli, purified in
non-phosphorylated form and phosphorylated in-vitro by commercially available MEK1.
MEK1 requires ERK1/2 to adopt their native conformation to become phosphorylated
(Seger et al., 1992) and to exert its activity, a protein has to be correctly folded. Bac-
terially expressed and purified ERK2 proteins acquired their native conformation and
were active after purification, as demonstrated by their ability to become well phospho-
rylated by MEK1 and to phosphorylate the synthetic substrate peptide in-vitro (Fig.
3.11). Although a high degree of specific activity of purified ERK2 is crucial for the
implementation of in-vitro observations of ES complexes, because a change in FRET
efficiency might be obscured by measuring a majority of non-interacting enzyme, a de-
tailed kinase activity assay was not performed. This may explain, why phospho-Elk1
staining was not very prominent (Fig. 3.11B) as it cannot be excluded that purified
ERK2 only exhibits low specific activity. However, all phospho-Elk1 antibodies used in
this study recognised Ser383 of hElk1 rather than Ser389, which was used as the major
phospho-acceptor site of the ERK2 substrate here. Thus, although the ERK2 substrate
did include Ser383, it is likely, that the phosphorylated ERK2 substrate peptide epitope
simply was no optimal recognition.
Using purified and in-vitro phosphorylated mCitrine-ERK2, a concentration-depen-
dent occurence of FRET could be observed consistently, irrespective of the phospho-
101
Discussion
rylation state of ERK2 by timebased experiments with fixed excitation and emission
wavelength, fluorescent emission scan experiments and in-vitro fluorescent lifetime spec-
troscopy (see Section 3.3.1). The occurence of unspecific FRET was further confirmed
by using a lissamine-rhodamine B-labeled substrate peptide (LRh-DADEYL) that could
not be phosphorylated by ERK2 (Yudushkin et al., 2007) (Fig. 3.14). This strongly
indicates that the fluorescent dye LRh mediates the binding of substrate peptides to
mCitrine-ERK2. Indeed, rhodamine dyes are known to be highly lipophilic and tend to
associate to intracellular membranes (Dittrich et al., 2001). It thus seems very likely,
that rhodamine dyes may also associate with hydrophobic protein surfaces, especially in
aqueous solutions, further explaining the observed results.
It should be noted, though, that binding of LRh-hElk1(382-403) to ppERK2 usually
led to a higher FRET efficiency in fluorescent emission scan and in-vitro fluorescent
lifetime spectroscopy experiments (Fig. 3.13 and Fig. 3.14). In addition, fluorescent
donor lifetime values for ERK2 and LRh-hElk1(382-403), ERK2 and LRh-DADEYL,
and ppERK2 and LRh-DADEYL exhibited more or less the same value during the
course of the experiment (Fig. 3.14). While this difference on one hand does argue
for an activity-dependent occurence of FRET on top of unspecific, LRh-mediated
substrate binding to ERK2, the time course of LRh-hElk1(382-403) binding to ppERK2
complicates the matter. If LRh-hElk1(382-403) binding to ppERK2 was activity
dependent, a recovery of donor fluorescent lifetime to at least fluorescent lifetime values
of unphoshporylated ERK bound to LRh-hElk1(382-403) should have been observed,
which was not the case. Instead, donor fluorescent lifetime remained more or less stable
after substrate addition for the time of the experiment (Fig. 3.14).
In summary, the in-vitro experiments maintain the possibility that direct detection
of ERK2 interactions with a substrate peptide using FRET is possible, although the
formation and consumption of ERK2 ES intermediates could not be conclusively de-
tected in-vitro. However, establishing the technique would require a careful and detailed
analysis of the specific activity of purified ERK2 proteins and well designed, detailed
in-vitro experiments in combination with the exchange of the chemical fluorophore on
the synthetic substrate peptides.
4.2.2 In-Vivo Visualisation of Spatio-Temporal ERK2 Activity by Imaging
Transient Enzyme-Substrate Interactions
As the in-vitro experiments did not definitely exclude the potential detection of ERK2
ES complexes and thereby the visualisation of ERK2 activity, it was attempted to estab-
lish the approach in-vivo (see Section 3.3.2). To avoid highly manipulative techniques
like microinjection or protein transfection methods to introduce the synthetic substrate
peptides into living cells, hElk1(379-403) was fused to the C-terminus of a fluorescent
protein that could serve as an acceptor fluorophore for mCitrine. The genetically
encoded, fluorescently labeled substrate peptide could thus be easily expressed together
with donor-labeled ERK2 in the experimental system. In addition, the short substrate
peptide would be protected from degradation by the attached FP (Wharton and
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Hipkiss, 1984; Corish and Tyler-Smith, 1999).
It has not been possible to detect a significant fluorescent donor lifetime change upon
stimulation of MDA (Fig. 3.15) or COS-7 (data not shown) cells with 100 ng/ml EGF.
The lifetime change observed was 20 ± 20 ps on average at 5 min EGF stimulation
with a maximal change of 100 ps 5 min after stimulation in an individual cell (see Table
S.2.2). The shape of the curves for cells expressing mCherry or mCherry-hElk1(379-403)
was nearly indistinguishable. Also, no spatial aspects of ERK2 signaling could be
revealed. This, however, cannot necessarily be interpreted as a failure of the approach
in general. Several scenarios are conceivable:
First, it is possible that the observed small change in donor lifetime represents true
formation of ERK2 ES complexes and therefore activation of ERK2 but the relatively
low number of measured cells does not allow to determine a significant result. A low
number of ERK2 molecules activated upon growth factor stimulation or a low FRET
efficiency even when substrate is bound to ERK2 (e.g. because of a too large Fo¨rster
radius or unfavorable orientation of donor and acceptor fluorophore) could be an
explanation. Measuring a large number of cells (as many as possible) may allow more
meaningful statement, but this would be very laborious and time consuming without
a guarantee of success. Also, careful quantitative western blot analysis in combination
with calibration of the number of ERK1/2 molecules used could determine the fraction
of active ERK2. However, this possibility is rather unlikely, as fluorescent lifetimes for
5 min EGF stimulation (which should be maximal activation of ERK2 and therefore
should show maximum FRET efficiency) did not consistently decrease in cells expressing
the ERK2 substrate (see Table S.2.2).
Second, formation of ERK2 ES complexes is detected with the low dynamic range
observed in Fig. 3.15 due to the inherent fundamental principles of time-domain FLIM
and the setup of the used FLIM microscope. Time-domain FLIM using TCSPC is an
inherently relatively slow technique because it requires large numbers of photons to be
collected for an exact estimation of fluorescent decay kinetics (Gratton et al., 2003; Peter
and Ameer-Beg, 2004; Thaler et al., 2005; Lakowicz, 2006; Pelet et al., 2006; Yasuda,
2006). To complicate the matter even further, ERK2 activation is a rather rapid process
(Ando et al., 2004; Burack and Shaw, 2005; Costa et al., 2006; Fujioka et al., 2006),
at least compared to the relatively long integration times for image acquisition. As a
consequence, the dynamic range of the method as well as spatial resolution may be
compromised due to an averaging effect. This effect would be based on merging different
fluorescent lifetimes occurring in each pixel during image acquisition, due to formation
of ES intermediates, into a single value (see Fig. 4.2). Different lifetimes could arise from
the short-lived formation of ES complexes that would persist for only a fraction of the
image acquisition period, or from the “migration” of active ERK2 proteins through a
pixel. This single value then represents the average lifetime value per integration time
per pixel, which is naturally in between maximum values. This explains the low signal-
to-noise ratio in the fluorescent lifetime maps (Fig. 3.15A), as image acquisition times
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were reduced to maximal 30 sec as a trade-off between spatial resolution and the signal-
to-noise ratio. Technical advances in form of faster imaging equipment could aid in this
issue. Image acquisition with the available frequency-domain FLIM instrument (Squire
et al., 2000), however, was only marginally faster than with the time-domain FLIM
microscope (data not shown).
Figure 4.2: In ES-imaging the fraction of (donor-labeled) enzyme bound to
(acceptor-labeled) substrate should be high. Schematic representation of the influence
of enzyme saturation on the measured lifetime and dynamic range of an ES-imaging assay. A)
The average fluorescent lifetime in a region of interest is equal to the qhenched lifetime of the
donor when the enzyme is saturated with substrate. In the special case of τDA = constant, τAve =
τDA. B) The average fluorescent lifetime in a region of interest is a mixture of quenched and un-
quenched lifetimes when the enzyme is not saturated with substrate. τAve = average fluorescent
lifetime in the region of interest; τDA = fluorescent lifetime of donor in complex with acceptor
(quenched lifetime); τD = fluorescent lifetime of non-bound donor (donor lifetime); n = number
of donor molecules.
Third, the substrate concentration in living cells is not sufficiently high to take ad-
vantage of the full, theoretically possible dynamic range of the ES complex visualisa-
tion/imaging approach. For any FRET assay, the fraction of donor molecules undergoing
FRET (i.e. the fraction mCitrine-ERK2 in complex with its fluorescently labeled sub-
strate peptide) should be as high as possible, preferably 100 %, as illustrated in Fig.
4.2. It should be kept in mind that a high fraction of donor molecules undergoing FRET
and a high FRET efficiency are two separate things. The former is simply the amount
of donor in sufficient proximity to the acceptor for FRET to occur. In contrast, the
FRET efficiency characterises the fraction of energy transfer per donor excitation event
and is dependent on the distance between donor and acceptor, the spectral overlap bet-
ween donor emission and acceptor excitation spectrum and the relative orientation of
donor emission and acceptor excitation dipoles (Lakowicz, 2006). For FLIM, the FRET
efficiency should not be 100 %, because if all energy is transferred to the acceptor, no
photons could be emitted from the donor fluorophore preventing the determination of
its fluorescent lifetime.
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If ERK2 is saturated with substrate peptide, i.e. the fraction of donor molecules under-
going FRET is 1, the average fluorescent lifetime (τAve) of the region of interest (e.g.
the whole image, a cell or pixel) can be calculated according to the equation in Fig.
4.2A, or in a more simplified version, τAve is equal to the quenched lifetime (fluorescent
lifetime of the donor in complex with the acceptor, τDA). In this case, the difference
between donor fluorescent lifetimes for inactive (no substrate bound and therefore no
FRET) and active ERK2 is maximal and thus the dynamic range of the assay as well.
In contrast, if only a fraction of ERK2 molecules would be in complex with substrate
peptide (Fig. 4.2B), the sample would contain a mixture of quenched and unquenched
lifetimes. Average fluorescent lifetime of the region of interest would then be calculated
according to the equation in Fig. 4.2B and would adopt a value in between maximal (no
FRET) and minimal lifetime.
Thus, substrate concentrations sufficiently high to saturate ERK2 are crucial for the vi-
sualisation of ES complexes. According to Michealis-Menten kinetics, saturated enzymes
operate at their maximum reaction velocity (Vmax). Since it is difficult to determine the
substrate concentration of Vmax ([S](Vmax)), the Michaelis constant KM can be used to at
least get an idea about the order of magnitudes in substrate concentrations that would
have to be used. The KM-value is defined as the substrate concentration at which the
reaction velocity is Vmax/2 (Nelson and Cox, 2004) and is sometimes (inappropriately)
used to characterise the affinity of an enzyme to its substrate. Michealis-Menten kinetics
implicate that [S](Vmax) is considerably higher than KM (Fig. 4.3.
Figure 4.3: Saturating substrate concentrations for an enzyme can be estimated
from its KM-value. Saturated enzymes operate at their maximum reaction velocity (Vmax).
According to Michealis-Menten kinetics [S](Vmax) may have to be orders of magnitudes higher
than KM, defined as Vmax/2.
However, KM-values of ERK2 for short peptides reported in the literature are usually
in the range of 0.1 - 1 mM (Table 4.1). KM-values for Elk1 were determined either
using a 121 aa petide (Jacobs et al., 1999; Fantz et al., 2001; Matsuura et al., 2005) or
a synthetic peptide based on hElk1(387-399) with two additional Arg residues at the
N-terminus (Jacobs et al., 1999; Fantz et al., 2001). Both peptides include the consensus
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phosphorylation site of the substrate peptide used in this study and resulted inKM-values
from 0.8 - 1.8 µM or 51 - 130 µM, respectively (Table 4.1). It is therefore reasonable to
assume, that the KM-value of ERK2 for hElk1(379-403) is situated in a similar range,
although the exact KM-values for hElk1(379-403) or mCherry-hElk1(379-403) have not
been determined experimentally.
Table 4.1: KM-values of ERK2 for different proteins or peptides.
Protein/Peptide KM (in µM) Reference
Aop(480-732) 0.7 ± 0.3 (Jacobs et al., 1999)
DAPK - Serum 35.8 (Chen et al., 2005)
DAPK + Serum 17.4 (Chen et al., 2005)
EGFR(661-668) 470 ± 90 (Jacobs et al., 1999)
Elk1(307-428) 1.5 ± 0.5 (Jacobs et al., 1999)
0.8 ± 0.3 (Fantz et al., 2001)
1.8 ± 0.3 (Matsuura et al., 2005)
Elk1(387-399) 130 ± 30 (Jacobs et al., 1999)
51 ± 6 (Fantz et al., 2001)
ERK1(182-199) > 5000 (Gonzalez et al., 1991)
Ets1 5.1 ± 1.2 (Seidel and Graves, 2002)
Ets1(1-138) 19 (Waas and Dalby, 2001)
6.8 ± 1.8 (Seidel and Graves, 2002)
Ets1(1-52) 190 ± 35 (Seidel and Graves, 2002)
Ets2(1-172) 2.8 ± 0.4 (Seidel and Graves, 2002)
Jun(230-255) 520 ± 30 (Gonzalez et al., 1991)
KSR1(281-479) 3.4 ± 0.9 (Jacobs et al., 1999)
1.2 ± 0.1 (Fantz et al., 2001)
LIFR(856-1097) 3.9 ± 1.7 (Schiemann et al., 1995)
LIN(281-441) 0.8 ± 0.5 (Jacobs et al., 1999)
MBP 5.1 ± 1.0 (Matsuura et al., 2005)
MBP(89-107) 280 ± 20 (Gonzalez et al., 1991)
Myc(51-66) 640 ± 50 (Gonzalez et al., 1991)
Raf1 0.1 (Lee et al., 1992)
Smad3 11.8 ± 2.3 (Matsuura et al., 2005)
As a general rule inferred from Table 4.1, the shorter a substrate peptide for ERK2, the
higher are obtained KM-values. This can be easily understood for certain circumstances
(two step reactions with the rate constant for substrate formation from the ES complex
(k2) as the rate limting step) when KM indeed represents a measure of the affinity of the
enzyme to its substrate (Nelson and Cox, 2004). Here, the affinity of the enzyme for its
substrate decreases (and thus the KM-value increases) with truncation of the substrate
protein as it looses domains and/or structures important for the interaction with the
enzyme.
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In principle, this may explain the high KM-values obtained for short substrate pep-
tides, e.g. taken from EGFR, ERK1, Ets1, Jun, MBP or Myc (Table 4.1). Strikingly, the
KM-values especially for Elk1(387-399) are considerably lower than those for comparably
short peptides (Table 4.1), most probably due to the DEF-domain of Elk1 (Jacobs et al.,
1999; Fantz et al., 2001) which is lacking in EGFR, ERK1, Ets1, Jun, MBP and Myc.
Still, with an assumed KM-value of 10 - 100 µM and the notion that [S](Vmax) has
to be considerably, probably orders of magnitudes, higher than KM, sufficiently high
substrate concentrations for the visualisation of ES complexes would probably have to
be in a range of at least 10 - 100 mM. Further adding to the problem is the sequestration
of substrate peptide by endogenous (unlabeled) ERK1/2 and potentially other proteins
able to bind hElk1(379-403) which require even higher substrate concentrations to
compensate the sequestration effect (Blu¨thgen et al., 2006). It is impossible to achieve
mM-expression levels of plasmid encoded proteins in mammalian cells. While protein
transfection methods and microinjection may perform better, they are still not able to
provide sufficiently high substrate concentrations in living cells that would allow the
visualisation of transient ERK2 ES interactions.
KM-values for longer peptides of Elk1 are in the range of 1 µM (Jacobs et al.,
1999; Fantz et al., 2001; Matsuura et al., 2005) and thus KM-values for the whole
protein might be even lower. The detection of FRET between donor-labeled ERK2 and
acceptor-labeled, overexpressed Elk1 with FLIM might be more likely. Additionally,
while Elk1 is primarily a nuclear protein (Janknecht et al., 1994; Pingoud et al., 1994), it
can also be found in the cytoplasm of cells (Sgambato et al., 1998; Salinas et al., 2004).
Therefore, probing spatio-temporal ERK2-Elk1 interactions in living cells would be a
variant of the visualisation of transient ERK2 ES-interactions with acceptor-labeled
Elk1 as the substrate for ERK. However, it was not possible to show the interaction of
mCherry-Elk1 and mCitrine-ERK2 with FRET (data not shown), unlike MEK1-ERK2
interactions (Burack and Shaw, 2005). In addition to reasons discussed for the substrate
peptide-based ES-imaging approach (such as too low substrate = Elk1 concentrations
inside cells), the distance between the donor and acceptor fluorophores simply might
have been too far. It might be interesting to see whether intermolecular FRET can
be observed between donor-labeled ERK2 and two acceptor-labeled, high affinity
substrate proteins of ERK2, one with a cytosolic and the other with a primarily
nuclear localisation. Since a potential lifetime change of the donor fluorophore would
be sufficient to probe ERK2 activity, substrate proteins could be labeled with the same
acceptor molecule. Alternatively, three-chromophore FRET (Galperin et al., 2004)
could be applied.
In summary, it has not been possible to visualise transient ERK2 ES interactions
in-vivo, most likely because low binding affinities of the used substrate peptide to ERK2
and insufficient substrate concentrations prevented the detection of FRET between
donor-labeled ERK2 and acceptor-labeled substrate.
Many protein kinases display low affinities to peptide substrates and higher affinities
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are only provided by additional docking or binding domains (Adams, 2001). This is
an essential requirement, given the number of existing bona fide phosphorylation sites
in the background of up to 106 potentially phosphorylatable residues (Ubersax and
Ferrell, 2007), further demonstrated by the fact that highly specific protein kinases (e.g.
MEK1) can display low KM-values (Ferrell, 1996). However, it greatly complicates the
visualisation of transient kinase-substrate interactions.
Recently, short, modular substrate peptides for ERK were designed using docking
peptides that increase binding affinities 200-fold (Fernandes et al., 2007). It may be
worth testing these peptides for their potential in visualising ERK2 ES-interactions.
Fluorescence cross correlation spectroscopy may help to circumvent the issue of low
binding affinities of substrate peptides to ERK2 as it does not rely on averaging different
fluorescent lifetimes displaying different activity states of the kinase but is rather able
to detect ES complexes and kinase-substrate interactions on a single molecule level
(Kettling et al., 1998; Haustein and Schwille, 2003).
Alternative approaches are conceivable to evade the problem that detection of enzyme-
substrate intermediates using FRET is prohibited by low binding affinities of substrate
peptides to their kinase. For example, in case of a kinase with a specific subcellular
localisation, e.g. the plasma membrane, substrate peptides could be enriched in that
particular intracellular compartment, e.g. by tethering it to the plasma membrane, so
that its local concentration on the plasma membrane is elevated and the pool of enzyme
molecules can be more readily saturated. This approach, however, is not available for
ERK2 as it is (in the inactive state) primarily a cytosolic protein. One could also try
to increase local substrate concentrations by linking the substrate peptide to a matrix
(Zhang et al., 2002; Niethammer et al., 2007), e.g. silicon beads, for in-vitro experiments
(Grecco et al., 2010) or microinjection into living cells.
4.3 An Intramolecular FRET-Based Biosensor for ERK2
Activity Employing Transient Enzyme-Substrate
Interactions
As another promising alternative to increase substrate concentrations in the immediate
environment of ERK2, it was suggested to directly link the substrate peptide to ERK2
via a flexible peptide linker. The peptide linker would allow the reversible binding
of the substrate peptide to the active site of ERK2 and keep the substrate peptide
in close proximity to ERK2, to increase the probability of binding. The approach
required a recombinant sensor construct including ERK2, the flexible peptide linker
and an ERK2 substrate peptide sequence flanked by two fluorescent proteins suitable
for FRET. The resulting genetically encoded, intramolecular FRET-based biosensor
reports the formation of transient ES-complexes between ERK2 and the substrate
peptide upon activation of the kinase, before the phosphorylated substrate peptide
dissociates from the active site. Similar to intermolecular ES-imaging, binding of the
substrate to the enzyme changes the FRET signal obtained from the donor-acceptor
pair (Fig. 3.16A). But in contrast to intermolecular ES-imaging, this approach with its
108
Discussion
fixed stoichiometry of donor and acceptor fluorophores is designed as an intramolecular
FRET-based biosensor. Therefore, in addition to FLIM, changes in FRET efficiency
can also be detected by ratiometric FRET imaging, greatly simplifying data acquisi-
tion and analysis and increasing the signal to noise ratio (Miyawaki, 2003; Yasuda, 2006).
Screening for a functional sensor construct identified ERK Activity Sensor 4 (EAS4),
consisting of mCitrine, a spacer (SGLRSRA), rat ERK2, the long version of the flexible
linker (L(GGGGS)3AAA), amino acids 375-404 of hElk1, a spacer (ASL) and mCherry
(Fig. 3.16B), as the sensor construct with the highest dynamic range (Fig. 3.17).
Interestingly, the fluorescent donor lifetimes observed for EAS4 increased upon stim-
ulation with EGF, indicating a loss of FRET when ERK2 was activated, rather than
an increase in FRET (Fig. 3.17B). Intuitively, considering the sensor design and prin-
ciples of ES-imaging (Fig. 3.10 and 3.16), activation of ERK2 allows binding of the sub-
strate peptide, bringing the donor-acceptor pair within a distance sufficient for FRET
(Yudushkin et al., 2007). Thus, stimulation and activation of ERK2 was expected to
result in decreasing donor lifetimes indicating an increased FRET efficiency. This is in
sharp contrast to the time profile obtained from EAS4. Nevertheless, the conformational
change of the sensor protein may lead to a reorientation of the fluorophores that is un-
favorable for FRET. Indeed, the change in FRET signals from intramolecular FRET
sensors is believed to often result from reorientation of the fluorophores instead of a sig-
nificant change in distance (Giepmans et al., 2006). The true nature of the unexpected
FRET change has not been explored further. Despite that, the basic principle of EAS4
can be formulated as such: binding of the substrate peptide to the active site of ERK2
results in a decreased FRET efficiency (Fig. 4.4).
Figure 4.4: Principle of ERK2 Activity Sensor 4. Binding of the substrate peptide (blue,
phosphorylation is indicated by the orange dot) to the active site in phosphorylated ERK2 (grey)
results in a decrease of FRET from the donor to the acceptor fluorophore.
Due to the inherent characteristics of time-domain FLIM and the setup of the FLIM
microscope, it was only possible to take a few “snap-shots” of events following MAPK
activation in living cells. In consequence, the resulting low temporal resolution was
comparable to western blots. Furthermore, as the observed process is relatively fast,
relatively long intergration times for image acquisition compromise the dynamic range
of the sensor as well as spatial resolution due to an averaging effect as discussed in
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Section 4.2.2. On the other hand, sensor design predestines it to be used in ratiometric
FRET imaging. Due to its simplicity and speed (essentially only two images are required
to calculate a FRET ratio image, see Section 1.3.2), ratiometric FRET imaging can
be implemented on nearly any fluorescent microscope and provides a high temporal
resolution limited only by the speed of the instrument. The possibility to gather much
more photons per time interval than with time-domain FLIM, also offers improved
spatial resolution and signal-to-noise ratio.
Improved temporal resolution of ratiometric FRET is demonstrated by the ability
to follow translocation of EAS4 wt to the nucleus of HeLa cells after EGF stimulation
(Fig. 3.20A) in a fashion similar to fluorescently labeled ERK2 (Ando et al., 2004; Costa
et al., 2006; Cohen-Saidon et al., 2009). Whole cell FRET ratios of individual cells
reveal a sudden rise in ERK2 activity 1 - 5 min after EGF addition, with a peak after
5 - 15 min, before slowly decreasing to approximately one third of the peak value at
approximately 35 min for at least another 30 min (Fig. 3.20B). The observed dynamics
of ERK2 activity revealed by EAS4 generally resembles the characteristic translocation
of phosphorylated and thus activated ERK2 to the nucleus upon EGF treatment with
a sudden onset and a quick rise to a maximal value, followed by a slow decline (see
Fig. 3.2 and Ando et al., 2004; Burack and Shaw, 2005; Costa et al., 2006; Fujioka
et al., 2006; Cohen-Saidon et al., 2009). These characteristics of ERK2 activation in
response to EGF stimulation are widely known in the literature as assessed by the
phosphorylation state of ERK2 (Lenormand et al., 1993; Fujioka et al., 2006; Santos
et al., 2007; Nakakuki et al., 2010). Interestingly, it has been suggested, that the well
described and aforementioned, short-lived translocation of ERK1/2 to the nucleus may
be an artifact of overexpression, since ERK1/2 expressed on endogenous levels reside in
the nucleus for hours after stimulation while being quickly dephosphorylated (Volmat
et al., 2001; Lidke et al., 2010). One should therefore be careful to draw conclusions
about physiological ERK signalling simply by observing its nuclear translocation.
The observed time profile of fluorescent donor lifetime and FRET ratio changes
obtained with EAS4 wt after EGF stimulation demonstrate the reversibility of the
underlying ES-interactions. It is therefore justified to conclude, that the change in
FRET efficiency detected from EAS4 wt indeed reflects the activation state of ERK2.
However, it should be kept in mind, that the mechanism by which EAS4 functions
is not entirely clear. For example, the substrate peptide could bind to the active site
of phosphorylated ERK2 in EAS4, rapidly being phosphorylated and released. To allow
the observed detection of increasing donor lifetimes or FRET ratios, the respective phos-
phatase would have to rapidly dephosphorylate the substrate peptide as well, so that
a new cycle of binding, phosphorylation, release and dephosphorylation could begin. In
this scenario, the measured changes in FRET efficiency represent the fraction of active
ERK2 in the region of interest.
Alternatively, opening of the activation loop in phosphorylated ERK2 allows the
substrate peptide to bind in ERK2’s active site. Phosphorylated and unphosphorylated
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substrate peptide may reside in the active site independent of modification, e.g. due to
circumstances controlled by the sensor design with the close proximity of ERK2 and
the substrate peptide. Dephosphorylation of the ERK2 activation loop in EAS4 and
the subsequent conformational change of ERK2 may force the substrate peptide from
the active site and its binding pocket. In the second scenario, the observed change in
FRET efficiency upon ERK activation rather represents phosphorylation of ERK2 than
actual activity. As the binding of substrates to their enzyme is supposed to dynamic
equilibrium with a shift in the total amount substrate bound while maintaining its
binding and release, the second scenario is less likely.
Improved temporal resolution of ratiometric FRET imaging revealed that activation
of EAS4 wt actually precedes ERK2 translocation (Fig. 3.20B and Fujioka et al., 2006).
While this is expected, as the activating phosphorylation of ERK1/2 is a prerequisite
for the subsequent translocation (Fukuda et al., 1997; Adachi et al., 1999), only since
the development of fluorescent biosensors for ERK2 it has been shown in such a detail
(Fujioka et al., 2006).
Even more interestingly, EAS4 wt was able to distinguish different levels of ERK2 ac-
tivation. It has been shown, that stimulation of PC-12 cells with EGF, EGF and PMA
or PMA alone results in sustained ERK activation when treated with EGF and PMA
or PMA alone as opposed to stimulation with EGF alone. However, PMA-induced sus-
tained ERK1/2 phosphorylation was much less strong than EGF + PMA-induced ERK
response (Santos et al., 2007). A similar effect was observed in MCF-7 cells (Fig. 3.24)
and resolved by EAS4 wt, further demonstrating the potential of the sensor construct.
The specificity of the signal obtained by EAS4 was demonstrated using dominant
negative mutants of the sensor construct (see Section 3.4.3). Neither with a non-
phosphorylatable mutant of EAS4 (EAS4-TAYA) nor with an EAS4 construct including
a mutated substrate peptide (EAS4-ElkMut) exhibited significant donor lifetime changes.
In EAS4-ElkMut, the mutated substrate cannot bind to the active site. EAS4-TAYA
lacks Thr183 and Tyr185, the amino acid residues that have to be phosphorylated for
the activation loop to open and expose the active site of ERK2. Therefore, the substrate
cannot bind to ERK. In a third mutant, EAS4-K52R, ERK2’s catalytic activity was
lost (Robbins et al., 1993). Since in ERK2 K52R, Thr183 and Tyr185 can still be phos-
phorylated (Fig. 3.11 and 3.18B), the activation loop can adopt the “open” or “active”
conformation and the substrate peptide bind in the active site. However, kinase dead
ERK2 cannot modify the substrate. Therefore it was suspected that ERK2 K52R incor-
porated into EAS4 might function as a “trapping mutant” for the substrate peptide and
result in a stable donor lifetime change (see Section 3.3.1.2). Indeed, in sharp contrast
to the wildtype construct, the lifetime change observed with EAS4 K52R was stable for
times longer than 20 min after EGF stimulation, indicating prolonged enzyme substrate
interactions. These results support the hypothesis that the kinase dead mutant of ERK2
might function as a “substrate trapping” mutant.
Ratiometric FRET imaging of EAS4 TAYA further confirmed the specificity of the
signal obtained by EAS4 wt as demonstrated by the observation, that FRET ratios
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of EAS4 TAYA did not rise significantly above pre-stimulation values during the time
frame of the experiment (Fig. 3.20C).
These data show that EAS4 wt specifically reports ERK2 activity in a time-dependent
manner.
The average change in FRET ratio of EAS4 was found to be about 11 ± 1 % in HeLa
cells (Fig. 3.20C) and 13 ± 2 % in MCF-7 cells (Fig. 3.23) with changes of up to 20 %
observed in individual MCF-7 cells (data not shown). The dynamic range of EAS4 in
individual cells is therefore 3 - 4 times bigger than that of Miu2 (Fujioka et al., 2006).
It is difficult to compare the dynamic range of EAS4 with those of Erkus and EKAR.
Average FRET ratios presented for Erkus exhibit a dynamic range of 8-9 % (Sato et al.,
2007). This is an average over a number of cells and thus does not include information
about the maximally possible FRET ratio change in single cells. However, the average
FRET ratio change of EAS4 is still about 40 % bigger than that of Erkus. In contrast,
FRET ratios of EKAR show 20 % changes before and after EGF stimulation as observed
with EAS4.
Interestingly, donor fluorescent lifetimes of EKAR decreased by 70 - 80 ps in individual
cells by and 20 - 30 ps on average (Harvey et al., 2008a). In comparison, donor lifetimes
of EAS4 in single cells increased by 60 - 70 ps on average upon stimulation of cells with
EGF. The maximal lifetime change observed in indivdual cells was up to 140 ps (Fig. 3.19
and Table S.4.1). There is clearly a discrepancy between the dynamic ranges of EKAR
obtained by FLIM or ratiometric FRET imaging. However, none of the published values
for EKAR exceeds the dynamic range measured with EAS4. In fact, while ratiometric
FRET imaging of EKAR yields a similar dynamic range, FLIM measurements report a
dynamic range of EAS4 that is about a factor of two better than that of EKAR.
This demonstrates that the dynamic range of EAS4 exceeds those of previously
published FRET-based biosensors for ERK2 activity. The dynamic range of the sensor
may be improved by the use of a more optimal FRET pair as mTFP in combination with
a yellow acceptor fluorophore such as EYFP, mCitrine or Venus (Padilla-Parra et al.,
2009) or the FRET optimised FP pair CyPET and YPET (Nguyen and Daugherty,
2005). In addition, the spacer between mCitrine and ERK2 as well as hElk1(375-404)
and mCherry are potential targets for sensor optimisation.
The signal-to-noise ratio (as judged by the calibration bars and colour differences in
the pseudocolour images representing FRET ratios or fluorescent donor lifetimes before
and after cell stimulation) of Miu2, Erkus and EKAR seems to be better than that of
EAS4 (compare e.g. Fig. 3.19 and 3.22 with Fujioka et al., 2006; Sato et al., 2007; Harvey
et al., 2008a). The better the signal-to-noise ratio, the smaller is the range of different
FRET or lifetime values, that distribute around an average value. In other words, the
signal-to-noise ratio determines how well two states (e.g. high and low FRET efficiencies
displayed as high and low FRET ratios or fluorescent lifetimes) can be distinguished
when displayed as pseudocolour images. One should keep in mind though, that the
signal-to-noise ratio depends in large parts on the imaging system and is higher the
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more photons can be acquired (Pelet et al., 2006; Yasuda, 2006).
It is noteworthy that Miu2, Erkus and EKAR have been imaged using widefield fluo-
rescent microscopes (Fujioka et al., 2006; Sato et al., 2007; Harvey et al., 2008a), that
acquire more photons in a given period of time compared to confocal microscopes. In
contrast, imaging of EAS4 was performed with confocal microscopes. Ratiometric FRET
imaging was implemented on a Zeiss LSM 510 confocal laser scanning microscope be-
cause the low light sensitivity of cameras installed on accessible widefield fluorescent
microscopes required long exposure times and thereby compromised photostability of
the fluorophores (data not shown). While the pinhole of the microscope was opened
completely (to 10 µm) to allow the maximally possible number of photons to be col-
lected from the sample, the obtained image was still a (thick) section through the cell to
be imaged (data not shown). Using a true widefield microscope might therefore further
improve the signal-to-noise ratio of FRET ratio images.
The rate-limiting factor in the acquisition of time-domian FLIM images was the
sensitivity of the detector. Simply, photon counts were not allowed to exceed a certain
value per time unit for two reasons: the highly sensitive APDs could be burned with
too high light intensities and the photon-counting histogram will be biased to shorter
donor lifetimes, if the chance of photon detection after each excitation pulse is higher
than 1 % (van Munster and Gadella, 2005; Lakowicz, 2006). Thus, opening the pinhole
to acquire more photons during FLIM images acquisition is of limited use. Interestingly,
Harvey et al. (2008a) achieved high sampling rates during image acquisition using a
custom-build time-domain FLIM setup (Yasuda, 2006; Harvey et al., 2008b). It would
be highly interesting to see the performance of EAS4 in their microscope and directly
compare results.
Erkus and EKAR required specific targeting to the nucleus or cytoplasm by the
respective nuclear or cytosolic localisation sequences to differentiate ERK2 activity on
the level of subcellular compartments. In addition, both sensor constructs required
subcellular targeting to resolve the known ERK2 activity profile. Sensor proteins freely
diffusing throughout the cell only reported ERK2 activation but not inactivation (or
rather substrate phosphorylation kinetics but not substrate dephosphorylation) (Sato
et al., 2007; Harvey et al., 2008a). EAS4 wt, in contrast, includes the full ERK2 protein
and therefore behaves more or less as fluorescently labeled ERK2. In that respect,
ERK-like translocation was observed with EAS4 wt. But most importantly EAS4 wt is
able to resolve compartmentalised ERK2 signalling without specific localisation signals
(Fig. 3.5 and Fig. 3.24).
To test the potential of EAS4 in resolving spatio-temporal ERK2 activity in a real
biological context, EAS4 was used to analyse MAPK activation in response to EGF and
HRG in MCF-7 breast cancer cells.
MCF-7 is a transformed mammary epithelial cell line derived from human breast ep-
ithelial adenocarcinoma (Brooks et al., 1973; Soule et al., 1973). In MCF-7 cells, EGF
induces transient ERK1/2 activation encoding a proliferative signal, while heregulin
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(HRG) generates sustained ERK1/2 activation resulting in cell differentiation (Thot-
tassery et al., 2004; Nagashima et al., 2007).
EAS wt is indeed able to capture transient versus sustained ERK signalling in MCF-7
cells when treated with EGF or HRG, respectively (see Section 3.5). Immunoblotting
of ectopically expressed EAS4 wt in whole cell lysates (Fig. 3.21) and averaging FRET
ratios over whole cells (data not shown) purely displayed these known features of EGF
and HRG signal transduction. Surprisingly, quantification of ERK2 activity in the
cytosol versus the nucleus revealed that HRG-induced sustained ERK2 activity was
predominantly cytosolic (Fig. 3.22C), while HRG-induced nuclear ERK2 activity was
found to be transient (Fig. 3.22B). In contrast, the transient ERK2 response after EGF
treatment known from the literature in both the cytosol and nucleus (Fig. 3.22B and
C). This in agreement with a recent publication, analysing the role of dynamics of
the MAPK module on c-Fos expression in reponse to EGF and HRG stimulation in
MCF-7 cells (Nakakuki et al., 2010). However, those experiments were performed by
immunoflourescence with antibodies for phosphorylated ERK and thus a) do not report
true ERK activity and b) only offer poor temporal resolution.
As EGF versus HRG stimulation shows ERK responses in MCF-7 cells similar to EGF
and neural growth factor (NGF) stimulation in PC12 cells, it was hypothesised that the
underlying feedback mechanism observed in PC12 cells also exist in MCF-7 cells. To
approach that idea, preliminary experiments with EAS4 wt were performed.
The role of signalling upstream of ERK in the sustained ERK response to HRG
was investigated by treatment of HRG-stimulated cells with high concentrations of the
MEK inhibitor U0126. Indeed, quickly after U0126 addition, ERK2 was inactivated
showing that continuous signalling from upstream of ERK is necessary for sustained
ERK activity (Fig. 3.23).
In PC12 cells, EGF-induced transient ERK1/2 activity can be converted into a sus-
tained ERK1/2 response by introducing a PKC-mediated feedback loop in the MAPK
module via PMA stimulation (Santos et al., 2007). To test whether it is possible to induce
a similar feedback loop in MCF-7 cells and to investigate its effect on spatio-temporal
ERK signalling, MCF-7 cells were stimulated with EGF, EGF and PMA, or PMA alone.
ERK2 activation was analysed by quantitative western blotting and ratiometric FRET
imaging.
Stimulation of MCF-7 cells with EGF and PMA resulted in sustained cytosolic ERK2
activity as shown by quantitative western blotting and ratiometric FRET imaging (Fig.
3.24). Stimulation with PMA alone also resulted in sustained cytosolic ERK2 activity,
but with a markedly lower amplitude of the signal than in the cytosol of cells stimulated
with EGF and PMA. In contrast, cytosolic ERK2 activity in cells stimulated with EGF
and nuclear ERK2 activity in all cells was transient. These data hint at the existence
of PKC-mediated feedback loops in the MAPK module that may be responsible for
sustained ERK activation in MCF-7 cells.
These results show that EAS4 can indeed be used to resolve biologically meaningful
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characteristics of ERK2 activation.
In summary, a new intramolecular FRET-based fluorescent biosensor for the visuali-
sation of ERK2 activity has been developed. The sensor design principle is generic and
thus should in principle be applicable to all kinases. It is based on the reversible binding
and phosphorylation of a short substrate peptide by the kinase of interest. The peptide
is directly linked to the kinase via a flexible peptide linker. Binding of the substrate
peptide to the active site of the enzyme induces a global conformational change of
the sensor protein. Attaching a FRET pair of FPs to the sensor allows detection of
an activation-induced change in FRET signal. Therefore, it is the first FRET-based
fluorescent biosensor approach, that directly reports spatio-temporal kinase activity
by visualising transient enzyme-substrate interactions rather than the conformational
change of a kinase or binding of a phospho-protein binding domain to a phosphorylated
substrate peptide of the kinase in question.
In addition, EAS4 displays high temporal resolution, virtually only limited by the
speed of the used microscope. It also exhibits a dynamic range and spatial resolution
superior to that of previously published ERK2 biosensors. EAS4 can be used with
various techniques to assess its FRET signal, including ratiometric FRET and FLIM.
EAS4 is able to resolve actual and biological meaningful differences in ERK2 activity
upon stimulation with various growth factors.
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5 Future Perspectives and Directions
5.1 General Characteristics of MAPK Signalling
In principle, EAS4 is a useful tool to obtain information about spatio-temporal activity
of ERK2.
Using EAS4, dynamics of ERK2 activation in most experimental systems are now
accessible with precise information about the time and location of ERK activity on
single cell level (rather than population averages). Plus, EAS4 offers the possibility
to obtain these information in form of direct activity rather than phophorylation
state. Besides these advantages, it should be kept in mind, that the short-lived
nuclear translocation of ERK1/2 may be an artifact of overexpression, since ERK1/2
expressed on endogenous levels reside in the nucleus for hours after stimulation (Volmat
et al., 2001; Lidke et al., 2010). Thus, it should be considered, whether creation of
cell lines stably expressing EAS4 on levels of or close to endogenous expression levels
of ERK1/2 may help to obtain data that reflect the physiological situation in more detail.
EAS4 offers the opportunity to track features of ERK signalling in living cells that
have yet only been theoretically investigated, such as the impact of spatial gradients
of phospho-proteins on signal propagation (Brown and Kholodenko, 1999; Kholodenko,
2006; Maeder et al., 2007; Yudushkin et al., 2007). Other features of MAPK signalling
that await experimental proof include travelling waves of phospho-proteins (Markevich
et al., 2006; Kholodenko, 2006), compartmental and differential MAPK signalling
upon growth factor stimulation (Santos et al., 2007; Nakakuki et al., 2010), and the
investigation of feedback loops in the MAPK module (Kholodenko, 2006; Santos et al.,
2007; Lin et al., 2009; Smith et al., 2010). Before the development of EAS4, none
of the previously published FRET-based biosensor approaches to follow spatial and
time-resolved ERK2 activity was good enough to resolve these features. EAS4 may
also provide new insights into the relationship of endocytosis and MAPK signalling
(Di Guglielmo et al., 1994; Vieira et al., 1996; Kranenburg et al., 1999; Pierce et al.,
2000; Jiang and Sorkin, 2002; Taub et al., 2007; Uhles et al., 2007).
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5.2 Differential ERK Activation in Response to Stimulation
with Different Growth Factors
Spatio-temporal signalling of the MAPK module with its core components Raf, MEK
and ERK is critically regulated via positive or negative feedback loops (Avraham and
Yarden, 2011) by the use of additional kinases (Santos et al., 2007) phosphatases and
scaffold proteins (Pouysse´gur et al., 2002; O’Neill and Kolch, 2004; Torii et al., 2004;
Ebisuya et al., 2005).
Transient versus sustained activation of ERK1/2 in response to different stimuli is
a well-known feature of the MAPK module (Gotoh et al., 1990; Kahan et al., 1992;
Traverse et al., 1992; Costa et al., 2006; Santos et al., 2007).
In PC12 cells, cell fates are determined by the duration of ERK1/2 activation. The
response of PC12 cells to receptor tyrosine kinase (RTK) stimulation has been extensively
studied as a model system to analyse how signal transduction specificity is achieved by
different RTK that use the same downstream signalling module (Marshall, 1995). NGF
stimulation of PC12 cells results in neurite outgrowth and cell differentiation (Greene
and Tischler, 1976). In contrast, EGF treatment enhances proliferation of PC12 cells
(Huff et al., 1981). The observation, that NGF stimulation results in prolonged ERK
activation (for several hours after stimulation) while EGF-induced ERK activation is
very short, has led to the idea, that is is this transient versus sustained ERK activation
profile that determines cell fate (Fig. 5.1) (Gotoh et al., 1990; Traverse et al., 1992;
Marshall, 1995).
Cell fate decisions determined by the duration of ERK activity can be controlled on
various levels (Fig. 5.1) (Avraham and Yarden, 2011). Rapid internalisation and degra-
dation of one receptor, but not the other, eliminates its potential for prolonged signalling
and affects the duration of its signal. Indeed, the EGFR is downregulated through phos-
phorylation (Countaway et al., 1992). In additon, feedback loops in the MAPK module
have been found to control ERK activation. A negative feedback loop from ERK to Raf
inhibits further activation of ERK activators and results in transient ERK signalling. In
contrast, NGF stimulation induces a positive feedback loop in the MAPK module and
its continuous activation of ERK activators results, in combination with PKC activation
(Corbit et al., 2003; Santos et al., 2007), in sustained ERK activation.
The duration of ERK activation is sensed by a network of immediate early genes
(IEG), including the transcription factor c-Fos (Murphy et al., 2002, 2004). HRG-
mediated sustained ERK1/2 and its downstream target p90 ribosomal S6 kinase (RSK)
stimulate c-Fos transcription and stabilise the protein by multiple phosphorylation
(Chen et al., 1992; Murphy et al., 2002). Phosphorylation of c-Fos also enhances
its transcriptional activity (Pellegrino and Stork, 2006) and a differentiation-specific
gene expression program is induced. In contrast, transient ERK1/2 activation fails
to stabilise c-Fos, resulting in the induction of a different, proliferation-specific gene
expression programm. Therefore, c-Fos or its phosphorylated version may be definded
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Figure 5.1: Decision making in PC12 cells. Temporal activation profiles of ERK determine
cell fate decisions in PC12 cells stimulated with EGF or NGF (cell proliferation versus cell
differentiation). Transient (A) versus sustained (B) ERK activation profiles in response to EGF
or NGF stimulation, respectively, are shown alongside the underlying signalling mechanisms.
Aa) EGF-induced transient ERK activation is determined by rapid degradation of the EGFR.
Ab) A negative feedback loop from ERK to Raf ensures rapid signal termination. Ac) ERK
mediated induction of MKP transcription finally terminates ERK activity. Resulting transient
ERK activity leads to short-lived expression of Fos protein and culminates in a proliferation-
specific gene expression programm. Ba) NGF-induced sustained ERK activity is accompanied by
receptor recycling. Bb) A positive feedback loop from ERK to Raf results in continuous upstream
activation. Bc) Sustained Fos activity (as a result of phosphorylation-mediated stabilisation of
the Fos protein) leads to the induction of a differentiation-specific gene expression programm
(adapted from Avraham and Yarden, 2011).
as the functional ouput of the system (Murphy et al., 2002, 2004).
The duration of spatio-temporal MAPK signalling also determines cell fate in the
ErbB network as - similar to PC12 cells - different stimuli induce different activation
kinetics which result in different cell fate decisions. In MCF-7 cells, derived from
human breast cancer epithelial adenocarcinoma (Brooks et al., 1973; Soule et al.,
1973), stimulation with EGF induces transient ERK1/2 activation encoding for a
proliferative signal, while heregulin (HRG) treatment generates sustained ERK1/2
activation resulting in cell differentiation (Thottassery et al., 2004; Nagashima et al.,
2007). Indeed, HRG-induced sustained ERK activity also results in sustained RSK
activation and subsequently in ERK- and RSK-dependent c-Fos transcription and
stabilisation (Fig. 5.2) (Nagashima et al., 2007; Nakakuki et al., 2010).
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Figure 5.2: Sustained ERK activity results in increased phospho-c-Fos protein levels.
EGF and HRG stimulation in MCF-7 cells induce transient versus sustained cytosolic ERK
activity. HRG stimulation also leads to increased c-fos mRNA and phospho-c-Fos protein levels.
(adapted from Nakakuki et al., 2010).
Stabilisation of the IEG product c-Fos by phosphorylation is a hallmark for the
activation of differentiation-specific gene expression in PC-12 cells. Based on the finding
that HRG stimulation results sustained ERK activation and in a similar type of c-Fos
response, it was hypothesised, that the same feedback mechanisms underlying cell fate
decisions in PC12 cells also control the MAPK module in MCF-7 cells.
A thorough analysis of the feedback mechanisms incorporated into the MAPK module
of MCF-7 cells will be performed using modular response analysis (MRA) (Kholodenko
et al., 2002; Santos et al., 2007) and is in progress (data not shown). On the basis of the
feedback structure it should be possible to suggest experiments that would rewire the
MAPK module in MCF-7 cells in a way that would revert sustained ERK signalling into
a transient ERK response and vice-versa. While the MRA analysis can be performed
without EAS4, the new ERK2 biosensor has already proven to be an invaluable tool to
uncover previously inaccessible features of spatial ERK signalling (Fig. 3.22). Analysing
the rewiring of feedback loops in the MAPK module by EAS4 would not only be a
fast and convient appraoch, but also provide information about the spatio-temporal
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dynamics of ERK activation.
Similar to PC12 cells (Corbit et al., 2003; Santos et al., 2007), PKC activity may
be required for sustained ERK activation in response to HRG treatment in MCF-7
cells. Preliminary experiments reverting the negative feedback loop in response to EGF
stimulation into a positive one by co-activating PKC with PMA, thereby inducing a
sustained ERK response (Fig. 3.24), indicate that indeed PKC activity may be involved
in sustained ERK signalling in MCF-7 cells. Other experiments will involve the inhibition
of PKC by selective chemical inhibitors and knock-down of Raf kinase inhibitory protein
(RKIP).
5.3 The role of scaffold proteins in ERK regulation
A different but equally interesting question concerns the mechanism leading to the
purely cytosolic nature of HRG-induced sustained ERK activation. Scaffold proteins of
the Raf/MEK/ERK module offer likely candidates.
Theoretically, scaffold proteins play two - in part related - functional roles: First,
cells use scaffold proteins to maintain a high degree of specificity in signalling pathways.
This is achieved by assembling proteins of the same signalling pathway on the scaffold
so that interaction and signal propagation is facilitated. Second, scaffolds may catalyse
the activation of the pathway components, functioning as an allosteric regulator of
catalysis. Here scaffolds may present the kinases towards each other in a manner, that
directly enhances their mutual interaction. This could enhance the phosphorylation of
the downstream partner (Burack and Shaw, 2000).
One interesting candidate is the scaffold protein kinase suppressor of Ras (KSR).
KSR1 was first identified in genetic screens in Drosophila melanogaster and Caenorhab-
ditis elegans as an modulator of Ras signalling (Kornfeld et al., 1995; Sundaram and
Han, 1995; Therrien et al., 1995). KSR displays high structural similarity to proteins
of the Raf family (as reviewed in Morrison, 2001) but lacks the key residues essential
for catalytic activity of serine/threonine kinases. KSR is able to bind to all members of
the Raf/MEK/ERK module, but while a fraction of MEK is constitutively bound, ERK
seems to be recruited in a stimulus-dependent manner (Mu¨ller et al., 2000; Casar et al.,
2008). The interaction of Raf seems to require additional proteins, such as MEK, and
seems to be cell-type specific (Therrien et al., 1996; Xing et al., 1997; Nguyen et al.,
2002).
Overexpression of KSR has led to the confusing result, that KSR can both enhance
and impair Raf/MEK/ERK signalling. This is explained by the nature of scaffold
proteins outlined above. Initially, increasing scaffold concentrations enhance the acti-
vation of ERK by increasing the number signalling-competent complexes. However, at
too high concentrations of scaffold protein, every component of the MAPK module
would be bound to a separate KSR molecule and this sequestration would effectively
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abrogate activation of ERK by MEK (Burack and Shaw, 2000; Kortum and Lewis, 2004).
Based on the observation that cytosolic substrates of ERK bind in large quantities to
KSR upon EGF stimulation, but the binding sites of ERK for these substrates and KSR
are vitually identical, Casar et al. (2008) proposed that KSR serves as “dimerisation
platforms”. Upon activation, phosphorylated ERK would dimerise with ERK pre-bound
to KSR and would then bind its cytosolic substrate (Fig. 5.3). It has been further re-
ported that the formation of ERK2 dimers and their association with cytosolic scaffold
proteins is required for the activation of cytosolic targets of ERK2. At the same time,
scaffold proteins and ERK2 dimer formation were not required for activation of nuclear
ERK2 substrates (Casar et al., 2008).
Figure 5.3: A model for the role of KSR in ERK signalling. Under resting coniditons,
ERK exists in complex with MEK of KSR. Phosphorylated ERK dissociates from these complexes
and monomers may follow three different destinies: (1) ppERK could translocate to the nucleus
as a monomer to activate transcription factors. (2) ppERK may dimerise in the cytoplasm. Free
dimers could be transported to the nucleus (Khokhlatchev et al., 1998) or remain in the cytosol.
The function of free dimers is still unclear. (3) ppERK monomers could associate with ERK
monomers in complex with KSR to form a ppERK dimer. The ERK-KSR complex can then
interact with cytosolic substrates (adapted from Casar et al., 2008).
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In addition, cytosolic ERK2 signalling is essential/required for cellular proliferation
and transformation processes as its blocking is sufficient to abrogate proliferative signals,
foci formation and tumor growth (Casar et al., 2008). This only seems to contradict
earlier reports, that nuclear ERK2 activation is sufficient for cellular transformation
(Robinson et al., 1998), but it is possible that the nuclear ERK signal constitutes the
main proliferation-driving signal, while the cytosol component of ERK signalling is
required as well.
It was therefore proposed that cytosolic ERK2 scaffold proteins, namely KSR, is
the main molecular mechanism mediating HRG-induced sustained ERK2 activity
in the cytosol. Future research exploring the role of KSR in growth factor-induced
sustained ERK signalling would include to analyse the effect of KSR knock-down and/or
overexpression on ERK activity (as determined by EAS4).
Interestingly, ERK signalling in T-cells isolated from KSR knock-out mice did not
show a change in its digital or graded nature in response to superantigen-loaded
antigen-presenting cells or the chemokine SDF-1, when compared to wt mice. In
agreement with general scaffold function, only the activation threshold was increased
(Lin et al., 2009).
Another interesting candidate to mediate HRG-induced cytosolic signaling may be
phosphoprotein enriched in astrocytes (PEA15). PEA15, first isolated from astrocytes
(Araujo et al., 1993), binds ERK1/2 and prevents nuclear accumulation of ERK as
well as phosphorylation of nuclear ERK substrates. PEA15, however, does not inhibit
activation of ERK1/2, nor phosphorylation of cytosolic ERK substrates. As a result,
PEA15 blocks ERK-dependent transcription and cell proliferation (Formstecher et al.,
2001; Gaumont-Leclerc et al., 2004).
As with KSR, EAS4 would be used to analyse the effect of PEA15 knock-down
and/or overexpression on sustained cytosolic ERK activity.
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Abbreviations
aa amino acid
bp base pair
BSA bovine serum albumine
CDS coding sequence
C-terminal carboxy-terminal
Da Dalton
DMEM Dulbecco’s modified Eagle’s medium
DNA deoxyribonucleic acid
dNTP deoxynucleotide-5’-triphosphate
ddH2O double distilled water
ddNTP dideoxynucleotide-5’-triphosphate
DMSO dimethyl-sulphoxide
dsDNA double stranded DNA
E. coli Escherichia coli
EGF epidermal growth factor
(E)GFP (enhanced) green fluorescent protein
Fig. figure
for forward
g acceleration of gravity
g gram
h hour
k kilo
l litre
LB Luria Bertani
MAPKK MAPK kinase
m milli
M mol/l
min minute
mol mole
µ micro
n nano
NA numerical aperture
NES nuclear export sequence
ns nanosecond
N-terminal amino-terminal
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffered saline
143
Abbreviations
PCR polymerase chain record
PKC protein kinase C
ps picosecond
ROI region of interest
rev reverse
RT room temperature
sec second
S.E.M. standard error of the mean
SDS sodium dodecyl sulfate
TBS Tris buffered saline
TBST TBS + 0.5 % Tween-20
Tris tris-(hydroxylmethyl)aminomethane
U unit
V voltage
wt wild-type
w/v weight/volume
Ω Ohm
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S.1 A FRET-Based ERK2 Biosensor Employing ReAsH
Labeling
Table S.1.1: Template and primers used to create ERK2-ReAsH sensor constructs.
Final construct Template Forward primer Reverse primer
4C-ERK2-mCitrine ERK2-mCitrine 4C-ERK2 for 4C-ERK2 rev
ERK2-4C(9-14)-mCitrine ERK2-mCitrine 4C(9-14) for 4C(9-14) rev
ERK2-4C(30-35)-mCitrine ERK2-mCitrine 4C(30-35) for 4C(30-35) rev
ERK2-4C(171-176)-mCitrine ERK2-mCitrine 4C(171-176) for 4C(171-176) rev
ERK2-4C(172-177)-mCitrine ERK2-mCitrine 4C(172-177) for 4C(172-177) rev
ERK2-4C(173-178)-mCitrine ERK2-mCitrine 4C(173-178) for 4C(173-178) rev
ERK2-4C(174-179)-mCitrine ERK2-mCitrine 4C(174-179) for 4C(174-179) rev
ERK2-4C(175-180)-mCitrine ERK2-mCitrine 4C(175-180) for 4C(175-180) rev
ERK2-4C(176-181)-mCitrine ERK2-mCitrine 4C(176-181) for 4C(176-181) rev
ERK2-4C(327-336)-mCitrine ERK2-mCitrine 4C(327-336) for 4C(327-336) rev
mCitrine-ERK2-4C mCitrine-ERK2 ERK2-4C for ERK2-4C rev
mCitrine-ERK2-4C(9-14) mCitrine-ERK2 4C(9-14) for 4C(9-14) rev
mCitrine-ERK2-4C(171-176) mCitrine-ERK2 4C(171-176) for 4C(171-176) rev
mCitrine-ERK2-4C(172-177) mCitrine-ERK2 4C(172-177) for 4C(172-177) rev
mCitrine-ERK2-4C(173-178) mCitrine-ERK2 4C(173-178) for 4C(173-178) rev
mCitrine-ERK2-4C(174-179) mCitrine-ERK2 4C(174-179) for 4C(174-179) rev
mCitrine-ERK2-4C(175-180) mCitrine-ERK2 4C(175-180) for 4C(175-180) rev
mCitrine-ERK2-4C(176-181) mCitrine-ERK2 4C(176-181) for 4C(176-181) rev
mCitrine-ERK2-4C(327-336) mCitrine-ERK2 4C(327-336) for 4C(327-336) rev
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Figure S.1.1: Amino acid sequences of wt and recombinant rat ERK2 proteins. Do-
mains that change conformation upon activation of ERK2 are labeled in green, phosphorylatable
Thr183 and Tyr185 are highlighted in purple. The 4C motif in the ERK2 mutants is highlighted
in red.
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Table S.1.2: Single cell FLIM measurements of ERK2-mCitrine. HeLa cells co-
expressing MEK1 and ERK2-mCitrine were starved overnight and stimulated with 100 ng/ml
EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min after EGF stimulation
and are displayed as average of whole individual cells in ns (average with S.E.M.). Cells measured
were from different days and dishes.
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 3.07 3.08 3.08 3.08
2 3.05 3.05 3.05 3.07
3 3.03 3.05 3.04 3.05
4 3.01 3.02 3.02 3.02
5 3.00 3.01 3.03 3.03
6 3.00 3.00 3.00 3.01
7 3.00 3.01 3.01 3.00
8 3.00 3.01 3.02 3.00
9 3.01 3.03 3.02 3.01
10 3.02 3.02 3.02 3.03
11 2.97 3.00 3.01 3.02
12 2.98 3.02 3.04 3.04
13 3.00 3.02 3.02 3.01
14 3.01 3.02 3.03 3.00
15 2.99 3.04 3.02 3.02
16 3.01 3.01 3.03 3.01
17 3.01 3.02 3.02 3.01
18 3.02 3.01 3.03 3.02
19 3.00 3.02 3.01 3.01
20 3.01 3.01 3.02 3.03
21 3.01 3.00 3.02 3.03
22 3.00 3.00 3.03 3.02
23 2.99 3.01 3.01 3.01
24 2.99 3.01 3.02 3.02
Average 3.00 ± 0.01 3.01 ± 0.01 3.02 ± 0.01 3.02 ± 0.01
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Table S.1.3: Single cell FLIM measurements of 4C(8-358)-ERK2-mCitrine. HeLa cells
co-expressing MEK1 and 4C(8-358)-ERK2-mCitrine were starved overnight and stimulated with
100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min after EGF
stimulation and are displayed as average of whole individual cells in ns (average with S.E.M.).
Cells measured were from different days and dishes.
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.80 2.79 2.79 2.79
2 2.80 2.80 2.80 2.80
3 2.86 2.87 2.86 2.86
4 2.82 2.83 2.80 2.80
5 2.83 2.83 2.82 2.82
6 2.79 2.77 2.77 2.76
7 2.78 2.75 2.75 2.76
8 2.78 2.77 2.77 2.77
9 2.78 2.76 2.77 2.75
10 2.75 2.74 2.73 2.74
11 2.74 2.72 2.71 2.71
Average 2.79 ± 0.03 2.79 ± 0.05 2.78 ± 0.04 2.78 ± 0.04
Table S.1.4: Single cell FLIM measurements of ERK2-4C(9-14)-mCitrine. HeLa cells
co-expressing MEK1 and ERK2-4C(9-14)-mCitrine were starved overnight and stimulated with
100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min after EGF
stimulation and are displayed as average of whole individual cells in ns (average with S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.82 2.81 2.81 2.81
2 2.77 2.78 2.79 2.78
3 2.80 2.78 2.77 2.78
4 2.71 2.73 2.71 2.74
5 2.69 2.72 2.70 2.71
6 2.71 2.72 2.73 2.74
7 2.72 2.73 2.75 2.72
Average 2.75 ± 0.05 2.75 ± 0.04 2.75 ± 0.04 2.75 ± 0.04
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Table S.1.5: Single cell FLIM measurements of ERK2-4C(30-35)-mCitrine. HeLa cells
co-expressing MEK1 and ERK2-4C(30-35)-mCitrine were starved overnight and stimulated with
100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min after EGF
stimulation and are displayed as average of whole individual cells in ns (average with S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.89 2.89 2.90 2.91
2 2.89 2.89 2.88 2.87
3 2.88 2.87 2.87 2.87
4 2.88 2.86 2.86 2.84
5 2.87 2.86 2.86 2.86
6 2.91 2.92 2.91 2.91
7 2.93 2.92 2.91 2.92
8 2.91 2.92 2.92 2.92
Average 2.90 ± 0.02 2.89 ± 0.03 2.89 ± 0.02 2.89 ± 0.03
Table S.1.6: Single cell FLIM measurements of ERK2-4C(171-176)-mCitrine. HeLa
cells co-expressing MEK1 and ERK2-4C(171-176)-mCitrine were starved overnight and stimu-
lated with 100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min
after EGF stimulation and are displayed as average of whole individual cells in ns (average with
S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.87 2.84 2.85 2.85
2 2.85 2.83 2.83 2.84
3 2.88 2.88 2.89 2.88
4 2.87 2.87 2.89 2.88
5 2.80 2.81 2.81 2.80
6 2.84 2.85 2.87 2.86
7 2.83 2.85 2.86 2.86
8 2.87 2.91 2.89 2.88
9 2.83 2.84 2.84 2.84
10 2.84 2.85 2.85 2.85
Average 2.85 ± 0.03 2.85 ± 0.03 2.86 ± 0.03 2.85 ± 0.03
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Table S.1.7: Single cell FLIM measurements of ERK2-4C(172-177)-mCitrine. HeLa
cells co-expressing MEK1 and ERK2-4C(172-177)-mCitrine were starved overnight and stimu-
lated with 100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min
after EGF stimulation and are displayed as average of whole individual cells in ns (average with
S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.90 2.92 2.92 2.93
2 2.91 2.91 2.91 2.91
3 2.91 2.92 2.91 2.91
4 2.92 2.93 2.93 2.93
5 2.89 2.88 2.89 2.88
6 2.88 2.88 2.89 2.89
7 2.94 2.93 2.94 2.95
8 2.89 2.88 2.88 2.88
9 2.91 2.90 2.92 2.91
10 2.89 2.89 2.90 2.89
11 2.91 2.90 2.91 2.91
12 2.93 2.93 2.93 2.94
13 2.92 2.93 2.94 2.92
14 2.90 2.89 2.90 2.90
15 2.91 2.91 2.91 2.92
Average 2.91 ± 0.02 2.91 ± 0.02 2.91 ± 0.02 2.91 ± 0.02
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Table S.1.8: Single cell FLIM measurements of ERK2-4C(173-178)-mCitrine. HeLa
cells co-expressing MEK1 and ERK2-4C(173-178)-mCitrine were starved overnight and stimu-
lated with 100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min
after EGF stimulation and are displayed as average of whole individual cells in ns (average with
S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.80 2.84 2.83 2.83
2 2.81 2.81 2.82 2.82
3 2.80 2.80 2.82 2.79
4 2.81 2.79 2.80 2.80
5 2.82 2.81 2.80 2.83
6 2.78 2.79 2.79 2.79
7 2.80 2.79 2.78 2.79
8 2.83 2.81 2.82 2.80
9 2.82 2.780 2.77 2.77
10 2.82 2.78 2.78 2.82
11 2.70 2.71 2.70 2.71
12 2.76 2.77 2.78 2.78
13 2.67 2.72 2.73 2.74
14 2.74 2.73 2.73 2.72
15 2.79 2.77 2.80 2.79
16 2.79 2.76 2.79 2.81
Average 2.78 ± 0.05 2.78 ± 0.04 2.78 ± 0.04 2.79 ± 0.04
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Table S.1.9: Single cell FLIM measurements of ERK2-4C(174-179)-mCitrine. HeLa
cells co-expressing MEK1 and ERK2-4C(174-179)-mCitrine were starved overnight and stimu-
lated with 100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min
after EGF stimulation and are displayed as average of whole individual cells in ns (average with
S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.75 2.79 2.78 2.79
2 2.74 2.76 2.78 2.76
3 2.83 2.82 2.83 2.82
4 2.87 2.88 2.87 2.86
5 2.82 2.83 2.82 2.82
6 2.85 2.86 2.85 2.84
7 2.89 2.88 2.88 2.89
8 2.74 2.73 2.76 2.74
Average 2.81 ± 0.06 2.82 ± 0.06 2.82 ± 0.05 2.82 ± 0.05
Table S.1.10: Single cell FLIM measurements of ERK2-4C(175-180)-mCitrine. HeLa
cells co-expressing MEK1 and ERK2-4C(175-180)-mCitrine were starved overnight and stimu-
lated with 100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min
after EGF stimulation and are displayed as average of whole individual cells in ns (average with
S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.87 2.87 2.86 2.87
2 2.89 2.87 2.85 2.86
3 2.87 2.85 2.83 2.86
4 2.86 2.85 2.84 2.88
5 2.86 2.85 2.86 2.85
6 2.88 2.88 2.88 2.86
7 2.90 2.88 2.87 2.88
8 2.88 2.87 2.85 2.85
Average 2.88 ± 0.01 2.87 ± 0.01 2.86 ± 0.01 2.86 ± 0.01
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Table S.1.11: Single cell FLIM measurements of ERK2-4C(176-181)-mCitrine. HeLa
cells co-expressing MEK1 and ERK2-4C(176-181)-mCitrine were starved overnight and stimu-
lated with 100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min
after EGF stimulation and are displayed as average of whole individual cells in ns (average with
S.E.M.). Cells measured were from different days and dishes.
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.94 2.95 2.94 2.94
2 2.93 2.92 2.93 2.93
3 2.94 2.94 2.95 2.95
4 2.93 2.90 2.92 2.92
5 2.90 2.89 2.89 2.91
6 2.92 2.91 2.90 2.91
7 2.92 2.91 2.91 2.91
Average 2.93 ± 0.01 2.92 ± 0.02 2.92 ± 0.02 2.92 ± 0.02
Table S.1.12: Single cell FLIM measurements of ERK2-4C(327-336)-mCitrine. HeLa
cells co-expressing MEK1 and ERK2-4C(327-336)-mCitrine were starved overnight and stimu-
lated with 100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min
after EGF stimulation and are displayed as average of whole individual cells in ns (average with
S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.81 2.82 2.82 2.82
2 2.84 2.86 2.86 2.84
3 2.60 2.64 2.66 2.68
4 2.57 2.60 2.61 2.63
5 2.73 2.76 2.76 2.76
Average 2.71 ± 0.12 2.74 ± 0.11 2.74 ± 0.1 2.75 ± 0.90
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Table S.1.13: Single cell FLIM measurements of mCitrine-ERK2-4C. HeLa cells co-
expressing MEK1 and mCitrine-ERK2-4C were starved overnight and stimulated with 100 ng/ml
EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min after EGF stimulation
and are displayed as average of whole individual cells in ns (average with S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.83 2.82 2.82 2.83
2 2.83 2.82 2.81 2.81
3 2.76 2.75 2.77 2.76
4 2.77 2.76 2.75 2.76
5 2.74 2.69 2.67 2.67
6 2.73 2.69 2.69 2.65
7 2.63 2.60 2.61 2.59
8 2.65 2.60 2.61 2.60
Average 2.74 ± 0.07 2.72 ± 0.09 2.72 ± 0.08 2.71 ± 0.09
Table S.1.14: Single cell FLIM measurements of mCitrine-ERK2-4C(9-14). HeLa cells
co-expressing MEK1 and mCitrine-ERK2-4C(9-14) were starved overnight and stimulated with
100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min after EGF
stimulation and are displayed as average of whole individual cells in ns (average with S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.76 2.75 2.75 2.75
2 2.83 2.74 2.72 2.72
3 2.74 2.70 2.69 2.69
4 2.64 2.70 2.64 2.62
5 2.62 2.66 2.60 2.60
6 2.60 2.69 2.61 2.62
7 2.71 2.67 2.66 2.63
8 2.64 2.67 2.65 2.63
9 2.63 2.64 2.63 2.65
10 2.65 2.61 2.63 2.66
Average 2.68 ± 0.07 2.68 ± 0.04 2.66 ± 0.05 2.66 ± 0.05
154
Supplementary Material
Table S.1.15: Single cell FLIM measurements of mCitrine-ERK2-4C(171-176). HeLa
cells co-expressing MEK1 and mCitrine-ERK2-4C(171-176) were starved overnight and stimu-
lated with 100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min
after EGF stimulation and are displayed as average of whole individual cells in ns (average with
S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.76 2.82 2.80 2.81
2 2.85 2.87 2.86 2.88
3 2.85 2.89 2.89 2.89
4 2.84 2.88 2.87 2.89
5 2.86 2.90 2.86 2.85
6 2.84 2.83 2.86 2.87
7 2.88 2.87 2.87 2.90
8 2.89 2.89 2.90 2.90
9 2.88 2.85 2.88 2.90
10 2.88 2.87 2.91 2.89
11 2.87 2.86 2.87 2.89
12 2.85 2.83 2.84 2.85
13 2.85 2.85 2.85 2.86
Average 2.85 ± 0.03 2.86 ± 0.03 2.87 ± 0.03 2.88 ± 0.03
Table S.1.16: Single cell FLIM measurements of mCitrine-ERK2-4C(172-177). HeLa
cells co-expressing MEK1 and mCitrine-ERK2-4C(172-177) were starved overnight and stimu-
lated with 100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min
after EGF stimulation and are displayed as average of whole individual cells in ns (average with
S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.91 2.91 2.92 2.91
2 2.93 2.95 2.94 2.95
3 2.95 2.94 2.96 2.95
4 2.94 2.93 2.95 2.94
5 2.92 2.93 2.92 2.96
6 2.93 2.94 2.92 2.94
7 2.87 2.90 2.92 2.85
8 2.90 2.88 2.94 2.91
9 2.92 2.89 2.94 2.91
Average 2.92 ± 0.02 2.92 ± 0.03 2.94 ± 0.01 2.93 ± 0.04
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Table S.1.17: Single cell FLIM measurements of mCitrine-ERK2-4C(173-178). HeLa
cells co-expressing MEK1 and mCitrine-ERK2-4C(173-178) were starved overnight and stimu-
lated with 100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min
after EGF stimulation and are displayed as average of whole individual cells in ns (average with
S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.81 2.78 2.80 2.83
2 2.82 2.82 2.82 2.85
3 2.77 2.78 2.76 2.75
4 2.76 2.79 2.76 2.77
5 2.80 2.78 2.77 2.78
6 2.80 2.79 2.79 2.77
7 2.74 2.72 2.72 2.73
8 2.79 2.76 2.73 2.75
Average 2.79 ± 0.03 2.78 ± 0.03 2.77 ± 0.03 2.78 ± 0.04
Table S.1.18: Single cell FLIM measurements of mCitrine-ERK2-4C(174-179). HeLa
cells co-expressing MEK1 and mCitrine-ERK2-4C(174-179) were starved overnight and stimu-
lated with 100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min
after EGF stimulation and are displayed as average of whole individual cells in ns (average with
S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.66 2.71 2.71 2.71
2 2.65 2.71 2.70 2.71
3 2.63 2.70 2.71 2.74
4 2.68 2.73 2.73 2.74
5 2.64 2.69 2.69 2.71
6 2.78 2.78 2.78 2.77
7 2.78 2.79 2.79 2.78
8 2.79 2.75 2.77 2.76
9 2.70 2.70 2.72 2.70
10 2.69 2.69 2.70 2.69
Average 2.70 ± 0.06 2.72 ± 0.04 2.73 ± 0.04 2.73 ± 0.03
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Table S.1.19: Single cell FLIM measurements of mCitrine-ERK2-4C(175-180). HeLa
cells co-expressing MEK1 and mCitrine-ERK2-4C(175-180) were starved overnight and stimu-
lated with 100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min
after EGF stimulation and are displayed as average of whole individual cells in ns (average with
S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.74 2.73 2.74 2.73
2 2.75 2.76 2.75 2.76
3 2.78 2.78 2.77 2.78
4 2.77 2.76 2.75 2.75
5 2.76 2.76 2.76 2.77
6 2.78 2.75 2.79 2.77
7 2.78 2.72 2.75 2.73
8 2.72 2.69 2.72 2.69
9 2.71 2.70 2.69 2.71
10 2.75 2.70 2.71 2.75
11 2.89 2.87 2.86 2.88
12 2.87 2.88 2.85 2.89
13 2.71 2.70 2.68 2.69
Average 2.77 ± 0.06 2.75 ± 0.06 2.76 ± 0.05 2.76 ± 0.06
Table S.1.20: Single cell FLIM measurements of mCitrine-ERK2-4C(176-181). HeLa
cells co-expressing MEK1 and mCitrine-ERK2-4C(176-181) were starved overnight and stimu-
lated with 100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min
after EGF stimulation and are displayed as average of whole individual cells in ns (average with
S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 3.03 3.07 3.03 3.05
2 3.01 3.03 3.03 3.05
3 3.01 3.06 3.04 3.05
4 3.00 3.04 3.02 3.04
5 3.01 3.00 2.99 2.99
6 3.03 2.98 3.00 2.97
7 2.96 2.95 2.95 2.94
8 2.95 2.94 2.93 2.92
Average 3.00 ± 0.03 3.00 ± 0.03 3.00 ± 0.04 3.00 ± 0.05
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Table S.1.21: Single cell FLIM measurements of mCitrine-ERK2-4C(327-336). HeLa
cells co-expressing MEK1 and mCitrine-ERK2-4C(327-336) were starved overnight and stimu-
lated with 100 ng/ml EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min
after EGF stimulation and are displayed as average of whole individual cells in ns (average with
S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.96 2.97 2.95 2.95
2 2.97 2.96 2.97 2.96
3 2.94 2.95 2.91 2.95
4 2.95 2.94 2.97 2.93
5 2.93 2.92 2.93 2.95
Average 2.95 ± 0.02 2.95 ± 0.02 2.94 ± 0.03 2.95 ± 0.1
Table S.1.22: Single cell FLIM measurements of mCitrine-ERK2-4C(174-179) with-
out wash-out of ReAsH. HeLa cells co-expressing MEK1 and mCitrine-ERK2-4C(174-179)
were starved overnight, incubated with 5.0 µM ReAsH for 60 min and stimulated with 100 ng/ml
EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min after EGF stimulation
and are displayed as average of whole individual cells in ns (average with S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.58 2.58 2.58 2.54
2 2.57 2.55 2.55 2.52
3 2.63 2.63 2.63 2.64
4 2.62 2.61 2.62 2.62
5 2.65 2.65 2.65 2.66
6 2.55 2.54 2.54 2.55
7 2.58 2.61 2.55 2.55
8 2.66 2.63 2.61 2.60
9 2.65 2.62 2.61 2.61
Average 2.61 ± 0.01 2.60 ± 0.01 2.59 ± 0.01 2.59 ± 0.02
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Table S.1.23: Single cell FLIM measurements of ERK2-4C(175-180)-mCitrine) with-
out wash-out of ReAsH. HeLa cells co-expressing MEK1 and ERK2-4C(175-180)-mCitrine
were starved overnight, incubated with 5.0 µM ReAsH for 60 min and stimulated with 100 ng/ml
EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min after EGF stimulation
and are displayed as average of whole individual cells in ns (average with S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.79 2.75 2.75 2.74
2 2.84 2.81 2.80 2.80
3 2.77 2.76 2.75 2.73
4 2.72 2.67 2.65 2.62
5 2.71 2.65 2.62 2.65
6 2.84 2.83 2.83 2.83
7 2.79 2.76 2.75 2.73
8 2.81 2.78 2.78 2.75
Average 2.78 ± 0.02 2.75 ± 0.02 2.74 ± 0.03 2.73 ± 0.02
Table S.1.24: Single cell FLIM measurements of ERK2-4C(327-336)-mCitrine with-
out wash-out of ReAsH. HeLa cells co-expressing MEK1 and ERK2-4C(327-336)-mCitrine
were starved overnight, incubated with 5.0 µM ReAsH for 60 min and stimulated with 100 ng/ml
EGF. Fluorescent lifetimes were measured prior to and 5, 10 and 20 min after EGF stimulation
and are displayed as average of whole individual cells in ns (average with S.E.M.).
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.29 2.27 2.25 2.21
2 2.27 2.23 2.21 2.18
3 2.49 2.54 2.55 2.52
4 2.57 2.64 2.61 2.58
5 2.59 2.65 2.61 2.57
6 2.42 2.38 2.38 2.33
7 2.37 2.35 2.35 2.32
8 2.45 2.49 2.50 2.48
9 2.43 2.58 2.47 2.48
Average 2.43 ± 0.04 2.45 ± 0.05 2.44 ± 0.05 2.41 ± 0.05
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S.2 Visualisation of ERK2 ES-Complexes - Single Cell
Measurements
Table S.2.1: Single cell FLIM measurements of control cells. MDA cells co-expressed
MEK1, mCitrine-ERK2 and mCherry-C. Cells were starved overnight and stimulated with 100
ng/ml EGF. Fluorescent lifetimes were measured prior to and at different time points after EGF
stimulation and is displayed as average of whole individual cells in ns. Cells measured were from
different days and dishes.
Sample 0 min 2.5 min 5 min 7.5 min 10 min 12.5 min 15 min 20 min 30 min
Cell 1 3.00 2.97 2.98 2.98 2.97 3.01 3.00 2.96 2.99
Cell 2 3.06 2.97 2.97 3.02 2.99 3.04 3.02 3.00 3.00
Cell 3 3.02 3.06 3.00 3.05 2.99 2.99 3.00 3.03 2.98
Cell 4 2.97 2.97 3.00 2.97 2.98 2.97 2.98 3.03 2.98
Cell 5 3.01 2.97 2.99 2.99 3.00 2.99 3.00 2.98 3.00
Cell 6 2.97 2.91 2.95 2.96 2.95 2.94 2.95 3.01 2.95
Cell 7 2.96 2.97 2.99 2.96 2.98 2.97 2.98 2.96 2.98
Cell 8 3.08 3.10 3.13 3.11 3.13 3.12 3.16 3.16 3.15
Average 3.01 3.00 3.00 3.01 3.00 3.00 3.01 3.01 3.00
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Table S.2.2: Single cell FLIM measurements of cells expressing mCherry-hElk1(379-
403). MDA cells co-expressed MEK1, mCitrine-ERK2 and the mCherry-labeled ERK2 sub-
strate. Cells were starved overnight and stimulated with 100 ng/ml EGF. Fluorescence lifetimes
of whole individual cells was measured prior to and at different time points after EGF stimulation.
Cells measured were from different days and dishes.
Sample 0 min 2 min 5 min 7.5 min 10 min 12.5 min 15 min 20 min 30 min
Cell 1 2.98 2.89 2.88 2.85 2.91 2.81 2.89 2.87 2.89
Cell 2 3.01 2.99 2.94 2.94 2.99 2.97 2.99 2.97 2.98
Cell 3 3.09 3.08 3.03 3.05 3.05 3.07 3.04 3.03 3.04
Cell 4 3.07 3.02 3.01 3.02 3.04 3.04 3.03 3.02 3.03
Cell 5 3.08 3.07 3.04 3.09 3.08 3.09 3.02 3.03 3.02
Cell 6 3.02 2.97 2.96 2.98 3.03 3.00 3.02 2.98 3.01
Cell 7 3.07 3.06 3.08 3.07 3.08 3.08 3.06 3.12 3.17
Cell 8 3.08 3.08 3.08 3.08 3.06 3.09 3.06 3.13 3.14
Cell 9 3.04 3.03 3.07 3.03 3.05 3.08 3.06 3.08 3.12
Cell 10 3.06 3.08 3.08 3.09 3.11 3.13 3.12 3.15 3.12
Cell 11 3.05 3.06 3.11 3.10 3.14 3.16 3.13 3.12 3.17
Cell 12 3.06 3.09 3.04 3.05 3.06 3.05 3.06 3.04 3.04
Cell 13 3.05 3.09 3.05 3.06 3.05 3.05 3.05 3.05 3.04
Average 3.05 3.04 3.03 3.03 3.05 3.05 3.04 3.05 3.06
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S.3 EAS Screening - Single Cell Measurements
Table S.3.1: Single cell FLIM measurements of EAS1. HeLa cells co-expressing MEK1
and EAS1 were starved overnight and stimulated with 100 ng/ml EGF. Fluorescent lifetimes
were measured prior to and 5, 10 and 20 min after EGF stimulation and are displayed as average
of whole individual cells in ns (average with S.E.M.). Cells measured were from different days
and dishes.
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.74 2.71 2.73 2.73
2 2.74 2.69 2.74 2.74
3 2.78 2.73 2.76 2.75
4 2.75 2.74 2.75 2.75
5 2.72 2.69 2.74 2.75
6 2.78 2.76 2.77 2.78
7 2.78 2.76 2.80 2.79
8 2.77 2.76 2.77 2.78
9 2.69 2.68 2.72 2.72
10 2.71 2.69 2.74 2.69
11 2.70 2.68 2.68 2.72
12 2.69 2.68 2.69 2.69
13 2.69 2.69 2.68 2.68
Average 2.73 ± 0.01 2.71 ± 0.01 2.74 ± 0.01 2.74 ± 0.01
162
Supplementary Material
Table S.3.2: Single cell FLIM measurements of EAS2. HeLa cells co-expressing MEK1
and EAS2 were starved overnight and stimulated with 100 ng/ml EGF. Fluorescent lifetimes
were measured prior to and 5, 10 and 20 min after EGF stimulation and are displayed as average
of whole individual cells in ns (average with S.E.M.). Cells measured were from different days
and dishes.
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.82 2.78 2.83 2.81
2 2.83 2.79 2.84 2.82
3 2.85 2.81 2.82 2.82
4 2.75 2.71 2.74 2.71
5 2.75 2.75 2.74 2.71
6 2.85 2.81 2.85 2.87
7 2.77 2.71 2.69 2.76
8 2.78 2.76 2.73 2.74
9 2.77 2.75 2.67 2.70
10 2.75 2.73 2.76 2.75
11 2.76 2.75 2.77 2.77
12 2.74 2.73 2.76 2.79
Average 2.79 ± 0.01 2.76 ± 0.01 2.77 ± 0.02 2.77 ± 0.02
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Table S.3.3: Single cell FLIM measurements of EAS3. HeLa cells co-expressing MEK1
and EAS3 were starved overnight and stimulated with 100 ng/ml EGF. Fluorescent lifetimes
were measured prior to and 5, 10 and 20 min after EGF stimulation and are displayed as average
of whole individual cells in ns (average with S.E.M.). Cells measured were from different days
and dishes.
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.76 2.79 2.80 2.78
2 2.74 2.78 2.75 2.74
3 2.75 2.78 2.76 2.76
4 2.75 2.80 2.76 2.75
5 2.78 2.86 2.81 2.77
6 2.71 2.77 2.76 2.72
7 2.73 2.73 2.74 2.77
8 2.73 2.77 2.78 2.74
9 2.69 2.75 2.77 2.75
10 2.71 2.73 2.74 2.70
11 2.70 2.74 2.75 2.73
12 2.72 2.78 2.76 2.73
13 2.80 2.82 2.83 2.79
14 2.81 2.82 2.82 2.77
Average 2.74 ± 0.01 2.78 ± 0.01 2.77 ± 0.01 2.75 ± 0.01
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Table S.3.4: Single cell FLIM measurements of EAS4. HeLa cells co-expressing MEK1
and EAS4 were starved overnight and stimulated with 100 ng/ml EGF. Fluorescent lifetimes
were measured prior to and 5, 10 and 20 min after EGF stimulation and are displayed as average
of whole individual cells in ns (average with S.E.M.). Cells measured were from different days
and dishes.
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.70 2.81 2.78 2.73
2 2.73 2.85 2.82 2.80
3 2.73 2.84 2.83 2.81
4 2.76 2.78 2.79 2.78
5 2.74 2.78 2.80 2.78
6 2.70 2.74 2.75 2.73
7 2.70 2.75 2.71 2.72
8 2.72 2.86 2.78 2.69
9 2.66 2.72 2.72 2.70
10 2.82 2.85 2.82 2.82
11 2.77 2.86 2.79 2.83
12 2.81 2.85 2.86 2.79
13 2.72 2.74 2.79 2.77
14 2.71 2.73 2.79 2.75
Average 2.73 ± 0.01 2.80 ± 0.01 2.79 ± 0.01 2.76 ± 0.01
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S.4 FLIM of EAS4 Mutants - Single Cell Measurements
Table S.4.1: Single cell FLIM measurements of EAS4 wt. HeLa cells co-expressing MEK1
and EAS4 wt were starved overnight and stimulated with 100 ng/ml EGF. Fluorescent lifetimes
were measured prior to and 5, 10 and 20 min after EGF stimulation and are displayed as average
of whole individual cells in ns (average with S.E.M.). Cells measured were from different days
and dishes.
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.70 2.81 2.78 2.73
2 2.73 2.85 2.82 2.80
3 2.73 2.84 2.83 2.81
4 2.76 2.78 2.79 2.78
5 2.74 2.78 2.80 2.78
6 2.70 2.74 2.75 2.73
7 2.70 2.75 2.71 2.72
8 2.72 2.86 2.78 2.69
9 2.66 2.72 2.72 2.70
10 2.82 2.85 2.82 2.82
11 2.77 2.86 2.79 2.83
12 2.81 2.85 2.86 2.79
13 2.72 2.74 2.79 2.77
14 2.71 2.73 2.79 2.75
15 2.77 2.82 2.85 2.80
16 2.77 2.82 2.82 2.78
17 2.74 2.80 2.79 2.77
18 2.74 2.80 2.81 2.77
Average 2.74 ± 0.01 2.80 ± 0.01 2.79 ± 0.01 2.77 ± 0.01
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Table S.4.2: Single cell FLIM measurements of EAS4 K52R. HeLa cells co-expressing
MEK1 and EAS4 K52R were starved overnight and stimulated with 100 ng/ml EGF. Fluorescent
lifetimes were measured prior to and 5, 10 and 20 min after EGF stimulation and are displayed as
average of whole individual cells in ns (average with S.E.M.). Cells measured were from different
days and dishes.
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.75 2.77 2.78 2.78
2 2.76 2.79 2.77 2.79
3 2.81 2.85 2.85 2.83
4 2.79 2.82 2.81 2.84
5 2.82 2.84 2.84 2.84
6 2.81 2.84 2.85 2.84
7 2.78 2.82 2.82 2.83
8 2.78 2.81 2.81 2.81
9 2.83 2.84 2.85 2.84
10 2.80 2.84 2.83 2.84
11 2.78 2.83 2.83 2.80
12 2.78 2.88 2.81 2.80
13 2.76 2.79 2.79 2.79
14 2.75 2.80 2.80 2.80
15 2.74 2.74 2.78 2.77
16 2.72 2.74 2.77 2.76
Average 2.78 ± 0.01 2.81 ± 0.01 2.81 ± 0.01 2.81 ± 0.01
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Table S.4.3: Single cell FLIM measurements of EAS4 TAYA. HeLa cells co-expressing
MEK1 and EAS4 TAYA were starved overnight and stimulated with 100 ng/ml EGF. Fluorescent
lifetimes were measured prior to and 5, 10 and 20 min after EGF stimulation and are displayed as
average of whole individual cells in ns (average with S.E.M.). Cells measured were from different
days and dishes.
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.75 2.79 2.78 2.76
2 2.80 2.78 2.83 2.79
3 2.80 2.82 2.82 2.82
4 2.79 2.80 2.79 2.80
5 2.78 2.79 2.78 2.80
6 2.78 2.80 2.80 2.82
7 2.79 2.80 2.80 2.82
8 2.78 2.81 2.80 2.80
9 2.78 2.81 2.81 2.80
10 2.73 2.73 2.73 2.73
11 2.74 2.74 2.75 2.74
12 2.68 2.69 2.69 2.68
13 2.73 2.74 2.74 2.74
14 2.73 2.73 2.73 2.72
15 2.73 2.73 2.72 2.72
16 2.86 2.89 2.89 2.88
17 2.86 2.83 2.84 2.85
18 2.78 2.77 2.77 2.78
19 2.78 2.77 2.78 2.78
Average 2.77 ± 0.01 2.78 ± 0.01 2.78 ± 0.01 2.78 ± 0.01
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Table S.4.4: Single cell FLIM measurements of EAS4 ElkMut. HeLa cells co-expressing
MEK1 and EAS4 TAYA were starved overnight and stimulated with 100 ng/ml EGF. Fluorescent
lifetimes were measured prior to and 5, 10 and 20 min after EGF stimulation and are displayed as
average of whole individual cells in ns (average with S.E.M.). Cells measured were from different
days and dishes.
Cell
Time after EGF addition
0 min 5 min 10 min 20 min
1 2.77 2.77 2.79 2.76
2 2.73 2.74 2.73 2.73
3 2.66 2.66 2.65 2.64
4 2.75 2.75 2.75 2.74
5 2.77 2.78 2.80 2.78
6 2.77 2.79 2.78 2.82
7 2.79 2.81 2.79 2.80
8 2.74 2.74 2.75 2.74
9 2.74 2.76 2.75 2.77
10 2.80 2.80 2.80 2.78
11 2.78 2.78 2.79 2.85
12 2.78 2.79 2.79 2.80
13 2.77 2.78 2.80 2.80
14 2.76 2.78 2.77 2.77
15 2.74 2.75 2.74 2.76
16 2.81 2.81 2.81 2.81
17 2.78 2.80 2.80 2.79
18 2.78 2.79 2.81 2.82
19 2.83 2.82 2.83 2.82
20 2.76 2.78 2.78 2.77
21 2.78 2.77 2.78 2.79
22 2.80 2.81 2.80 2.80
23 2.79 2.79 2.81 2.79
24 2.79 2.79 2.79 2.79
25 2.83 2.87 2.83 2.83
26 2.77 2.77 2.78 2.77
Average 2.77 ± 0.01 2.78 ± 0.01 2.78 ± 0.01 2.78 ± 0.01
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S.5 Light-Induced Activation of ERK2
Figure S.5.1: Light-induced activation of ERK2. A) Representative confocal image se-
quence showing slow nuclear accumulation (top) following slowly increasing activity (bottom) of
ERK2 in starving cells. HeLa cells co-expressing EAS4 wt and MEK1 were starved overnight
and imaged every 60 sec without growth factor addition. Scale bar = µm. B) Average nuclear
fluorescence intensity (broken lines) and average whole cell FRET ratios obtained from HeLa cells
expressing EAS4 wt, showing slow nuclear accumulation of ERK2 and concurrent slow increase
in ERK2 activity in resting cells. Cells were treated as in A).
S.6 Primer Sequences
4C(9-14) for 5’- GGC TGC TGC CAG GTG TTC GAC GTG GGG -3’
4C(9-14) rev 5’- CGG GCA GCA GCC CGC CGC CGC CGC CGC -3’
4C(30-35) for 5’- GGC TGC TGC ATG GTT TGT TCT GCT TAT GAT
AAT CTC -3’
4C(30-35) rev 5’- CGG GCA GCA GAT GTA CGA GAG ATT AGT GTA
GC -3’
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4C(171-176) for 5’- GGC TGC TGC GAT CAT ACA GGG TTC TTG ACA
GAG -3’
4C(171-176) rev 5’- CGG GCA GCA ACG GGC AAG GCC AAA GTC ACA
G -3’
4C(172-177) for 5’- GGC TGC TGC CAT ACA GGG TTC TTG ACA GAG
-3’
4C(172-177) rev 5’- CGG GCA GCA AAC ACG GGC AAG GCC AAA GTC
AC -3’
4C(173-178) for 5’- GGC TGC TGC ACA GGG TTC TTG ACA GAG TAT
GTA GC -3’
4C(173-178) rev 5’- CGG GCA GCA TGC AAC ACG GGC AAG GCC -3’
4C(174-179) for 5’- GGC TGC TGC GGG TTC TTG ACA GAG TAT GTA
GC -3’
4C(174-179) rev 5’- CGG GCA GCA ATC TGC AAC ACG GGC AAG G -3’
4C(175-180) for 5’- GGC TGC TGC TTC TTG ACA GAG TAT GTA GC -3’
4C(175-180) rev 5’- CGG GCA GCA TGG ATC TGC AAC ACG GGC -3’
4C(176-181) for 5’- GGC TGC TGC TTG ACA GAG TAT GTA GCC ACG
-3’
4C(176-181) rev 5’- CGG GCA GCA GTC TGG ATC TGC AAC ACG GGC
-3’
4C(327-336) for 5’- GGC TGC TGC ATG GAA CCT AAG GAG AAG C -3’
4C(327-336) rev 5’- CGG GCA GCA GTT CAG AAA TGG TGC TTC AGC
-3’
4C-ERK2 for 5’- GGG CTG CTG CAT GGA ACC GGA GAT GGT CCG
CGG GCA GG -3’
4C-ERK2 rev 5’- GGG CAG CAG TTC AGA AAC ATG GTG GAG CTC
GAG ATC TGA GTC C -3’
ERK2-4C for 5’- GGG CTG CTG CAT GGA ACC GTA AGT CGA CGG
TAC CGC GG -3’
ERK2-4C rev 5’- GGG CAG CAG TTC AGA AAC ATA GAT CTG TAT
CCT GGC TGG -3’
ERK2 Stop for 5’- CCA GCC AGG ATA CAG ATC TTC GAC GGT ACC
GCG GGC CC -3’
ERK2 Stop rev 5’- GGG CCC GCG GTA CCG TCG AAG ATC TGT ATC
CTG GCT GG -3’
ERK2 substrate for 5’- GCT ACC GGT CGC CAC CAT GGT GAG C -3’
ERK2 substrate rev 5’- CTC GAG TTA GGC GCT GCC ACT GGA TGG AAA
CTG GAA GGA GAG CTT GGC CGG GCT ACG GGG
CGC AAT GGG ACT CAG GGT GCT CCA GGA TGA GTC
CGG ACT TGT ACA GCT C -3’
ERK2 +Kozak for 5’- GGA CTC AGA TCT CGA GCT CCA CCA TGG CGG
CGG CGG CGG CGG G -3’
ERK2 +Kozak rev 5’- GCC GCC GCC GCC GCC ATG GTG GAG CTC GAG
ATC TGA GTC CGG -3’
hElk1 (BspEI) for 5’- GCT CCG GAC TCA GAT CTC GAG CTA GCA TTC
ACT TCT GGA GCA CCC TG -3’
171
Supplementary Material
hElk1 (HindIII) rev 5’- CGA AGC TTG CCT GGG CGC TGC CAC TGG ATG
GAA A -3’
hElk1-linker(long) rev 5’- GGC AGC GGC GCT TCC TCC ACC GCC GCT TCC
TCC ACC GCC GCT TCC TCC ACC GCC CAG CTG GGC
GCT GCC ACT GGA TCC AAA -3’
hElk1-linker(long) rev 5’- GGC AGC GGC GCT TCC TCC ACC GCC GCT TCC
TCC ACC GCC CAG CTG GGC GCT GCC ACT GGA TCC
AAA -3’
linker-hElk1(long) for 5’- CTG GGC GGT GGA GGA AGC GGC GGT GGA GGA
AGC GGC GGT GGA GGA AGC GCC GCT GCC AGC ATT
CAC TTC TGG AGC ACC -3’
linker-hElk1(short) for 5’- CTG GGC GGT GGA GGA AGC GGC GGT GGA GGA
AGC GCC GCT GCC AGC ATT CAC TTC TGG AGC ACC
-3’
linker-MAPK1(long) for 5’- TCG GGC GGT GGA GGA AGC GGC GGT GGA GGA
AGC GGC GGT GGA GGA AGC GCC GCT GCC ATG GCG
GCG GCG GCG GCG GGC CCG -3’
linker-MAPK1(short) for 5’- TCG GGC GGT GGA GGA AGC GGC GGT GGA GGA
AGC GCC GCT GCC ATG GCG GCG GCG GCG GCG GGC
CCG -3’
M13 for 5’- GTA AAA CGA CGG CCA G -3’
M13 rev 5’- CAG GAA ACA GCT ATG A -3’
MAPK1 (BspEI) for 5’- GCT CCG GAC TCA GAT CTC GAG CTA TGG CGG
CGG CGG CGG CGG CGG GCC CG -3’
MAPK1 (HindIII) rev 5’- CGA AGC TTG CAG ATC TGT ATC CTG GCT GGA
ATC G -3’
MAPK1 K52R for 5’- CAA AGT TCG AGT TGC TAT CAG AAA AAT CAG
TCC TTT TGA GC -3’
MAPK1 K52R rev 5’- GCT CAA AAG GAC TGA TTT TTC TGA TAG CAA
CTC GAA CTT TG -3’
MAPK1 L73P for 5’- GAG AGA GAT AAA AAT CCC ACT GCG CTT CAG
ACA TG -3’
MAPK1 L73P rev 5’- CAT GTC TGA AGC GCA GTG GGA TTT TTA TCT
CTC TC -3’
MAPK1-linker(long) rev 5’- GGC AGC GGC GCT TCC TCC ACC GCC GCT TCC
TCC ACC GCC GCT TCC TCC ACC GCC CAG AGA TCT
GTA TCC TGG CTG GAA TCG -3’
MAPK1-linker(short) rev 5’- GGC AGC GGC GCT TCC TCC ACC GCC GCT TCC
TCC ACC GCC CAG AGA TCT GTA TCC TGG CTG GAA
TCG -3’
MAPK1 S151D for 5’- CGT GAC CTC AAG CCT GAC AAC CTC CTG CTG
AAC -3’
MAPK1 S151D rev 5’- GTT CAG CAG GAG GTT GTC AGG CTT GAG GTC
ACG -3’
MAPK1 Stop rev 5’- CGG TCG ACT TA GAT CTG TAT CCT GGC TGG
AAT CG -3’
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MAPK1 TAYA for 5’- CCA TGA TCA TAC AGG GTT CTT GGC AGA GGC
TGT AGC CAC GCG TTG GTA CGA AGC -3’
MAPK1 TAYA rev 5’- GCT CTG TAC CAA CGC GTG GCT ACA GCC TCT
GCC AAG AAC CCT GTA TGA TCA TGG -3’
mCherry (BamHI) rev 5’- CGG GAT CCT TAC TTG TAC AGC TCG TCC ATG
CC -3’
mCherry (HindIII) for 5’- GCA AGC TTG GTC GCC ACC ATG GTG AGC AAG
GGC -3’
MutElk1 for 5’- CAG CAT TCA CTT CTG GAG CAC CCT GAG TGC
GCT CCC CAT TCC CTT CAG CGC CTC CTC CTC CCA
GCC AAA GAG TTT TCG TCC GGG CAG CGC -3’
MutElk1 rev 5’- CCA TGG TGG CGA CCA AGC TTG CGG CGC TGC
CCG GAC GAA AAC TCT TTG GCT GGG AGG AGG AGG
CGC TGA AGG GAA TGG GGA GCG C -3’
sensor seq for1 5’- CGA GTT GCT ATC AAG AAA ATC AGT C -3’
sensor seq for2 5’- CCA TCA CAG GAA GAT CTG AAT TG -3’
sensor seq rev 5’- CAT CTT TCA TCT GCT CAA TGG TT -3’
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